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Abstract
Objectives - Gaucher disease (GD) is caused by bi-allelic mutations in the glucocerebrosidase 
gene (GBA).   GD and heterozygous carriage of GBA mutations significantly increase the risk 
of developing Parkinson's disease (PD).  Here we studied GD patients and carriers to identify 
a cohort of individuals with clinical signs of prodromal PD and generated fibroblast lines from 
them to study why GBA mutations cause PD.   
Methods -  83 patients with Type I GD and 41 of their heterozygous carrier relatives were 
recruited from  lysosomal storage disorder clinics at the Royal Free Hospital and 
Addenbrooke's Hospital Cambridge, along with 30 mutation negative matched controls.  They 
were clinically screened for hyposmia (University of Pennsylvania Smell Identification Test), 
cognitive impairment (Montreal Cognitive Assessment), autonomic dysfunction, REM sleep 
behaviour disorder and motor signs of PD.  Two hundred and thirty cases of sporadic PD 
were screened for GBA gene mutations.   Fibroblasts were generated from skin biopsies taken 
from a selection of patients.  GBA metabolism (Western blotting for protein levels,  enzyme 
activity, immunofluorescent localisation), mitochodrial metabolism, endoplasmic reticulum 
and oxidative stress markers were assayed in the cell lines.  
Results – GD patients and heterozygous carriers had significantly lower olfactory  and 
cognitive function scores than controls.  Several GD patients and carriers had motor signs of 
PD (e.g. rest tremor) while controls did not.  Thirteen PD patients with heterozygous GBA 
mutations were identified.  Their clinical phenotype was similar to mutation negative PD 
cases.   GD fibroblast lines (n=5), and lines from heterozygous GBA mutation carriers with 
(n=4) and without PD (n=2) had reduced GBA enzyme activity due to endoplasmic reticulum 
retention of GBA protein.  This was associated with upregulation of endoplasmic reticulum 
stress markers and oxidative stress (increased rate of dihydroethidium oxidation).  
Conclusions – a subset of GD patients and carriers express clinical markers of  prodromal PD. 
Study of fibroblasts from these individuals indicates that endoplasmic reticulum and oxidative 
stress may contribute to increased PD risk in these individuals.  
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Chapter I.
GENERAL INTRODUCTION.
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General Introduction 
Parkinson’s disease (PD) is the second most common neurodegenerative disease in the United 
Kingdom (U.K), with an age dependent prevalence of 1/150-1/350 (Lees et al, 2009).  PD is 
characterised by rest tremor, rigidity, bradykinesia and postural instability.  The classical motor 
syndrome of PD becomes apparent once greater than 50% of dopaminergic neurons in the 
substantia nigra pars compacta have degenerated.  Neuronal degeneration in PD is associated with 
the presence of eosinophilic inclusions in surviving neurons known as Lewy bodies.  Lewy bodies 
are composed of alpha-synuclein (SNCA), a synaptic protein of uncertain function.  Before the 
motor syndrome of PD occurs there is a long prodromal period during which non-motor signs and 
symptoms of PD predominate (Schapira & Tolosa, 2010).  Olfactory dysfunction, autonomic 
dysfunction, depression and subtle motor slowing are well recognised as clinical markers of the 
prodromal phase.  The aetiology of PD is complex; <5% of cases can be explained by monogenic 
inheritance (dominant e.g. SNCA mutations LRRK2, recessive e.g. Parkin, PINK1, DJ-1 mutations) 
with 95% of PD thought to be a complex disorder caused by interactions between genetic and 
environmental factors (Lees et al, 2009).  
Genetic causes of PD have been identified through studies of dominant and recessive PD families 
and Genome Wide Association Studies (GWAS) of many thousands of patients.  However, the 
genes identified in these studies account for only a small fraction of PD risk.  The recent 
observation that patients with Gaucher disease (GD), a recessive lysosomal storage disorder caused 
by mutations in glucocerebrosidase (GBA), and their obligate carrier relatives, are at increased risk 
of PD has provided important new insight into the causes of PD (Sidransky et al, 2009).  GD 
patients have a 9-12% chance of developing PD before age 80 (Rosenbloom et al, 2011) and 
between 5-30% of sporadic PD cases have a heterozygous mutation in the GBA gene (Sidransky et  
al, 2009). Mutations in GBA are therefore the numerically most important risk factor for PD. 
Individuals with GD or heterozygous GBA mutations represent a group at increased risk of 
developing PD.  By studying them for clinical markers of prodromal PD (e.g. olfaction, cognition, 
subtle motor signs) it should be possible to identify a cohort of individuals in the earliest stages of 
PD.  Biological samples from these individuals can then form the basis for biomarker studies to 
identify markers which may help aid early diagnosis of PD.  Fibroblast cell lines generated from 
this cohort will also form the basis of a cell biology study to define the cellular processes causing 
increased PD risk.     
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Parkinson’s disease: clinical features
The core features of the movement disorder caused by idiopathic PD are bradykinesia, rigidity, rest 
tremor and postural instability (Lees et al, 2009).  The onset of idiopathic PD is slow and insidious 
with non-specific symptoms, such as reduced manual dexterity, fatigue or stiffness, being common 
at onset (Lees et al, 2009).  Subtle early motor features will often not be noted by the patient or their 
relatives, explaining why there can be a delay of several months or even years between onset of 
symptoms and correct diagnosis of PD.   The diagnosis of PD is chiefly clinical, based upon the 
Queen Square Brain Bank criteria.  Bradykinesia refers to slowness of movements with decremental 
speed and amplitude evident with repetitive movements, and PD can not be diagnosed without the 
presence of definite bradykinesia. Bradykinesia can also manifest as reduced frequency of blinking 
and “mask like” facies.  Tremor is also a characteristic feature of PD (Lees et al, 2009).  Classically 
the tremor of PD occurs at rest, with a “pill rolling” quality and is coarse (4-6 Hz).  However, a 
faster postural and kinetic tremor, resembling essential tremor can also occur in PD (Lees et al, 
2009).  The resting tremor of PD can affect the arms, legs, head and jaw/tongue.  Rigidity, as 
assessed by passive movements of the limbs, classically has a “cog wheel” nature due to 
superimposed rest tremor.  PD has a characteristic posture with truncal flexion and festinant gait. 
Clinical features which help to support a diagnosis of PD include unilateral onset, persistent 
asymmetry, hyposmia and excellent response to L-DOPA.  Clinical features that exclude a diagnosis 
of PD include a history of repeated head injury, cerebellar signs, early severe autonomic failure and 
early severe cognitive impairment.  In the majority of cases (around 90%) a diagnosis of PD can be 
made after clinical evaluation.  
There are several parkinsonian syndromes which are distinct from idiopathic PD, so called “parkin-
sons plus syndromes” (Lees et al, 2009).  In progressive supranuclear palsy (PSP) parkinsonism is 
symmetrical, with a tendency to lean backwards accompanied by falls early in the course of the dis-
ease.  PSP also features a supranuclear gaze palsy and the underlying pathology is a tauopathy (4 re-
peat tau) not synucleinopathy.  Multiple systems atrophy (MSA) presents with atypical symmetrical 
parkinsonism with prominent cerebellar ataxia or autonomic dysfunction.  The pathology of MSA is 
oligodendroglial alpha-synuclein accumulation and MSA risk is associated with SNCA polymorph-
isms (Scholz et al, 2009) but not GBA mutations (Segarane et al, 2009).   Corticobasal syndrome is 
a rare syndrome. The classic description of corticobasal syndrome includes clumsiness/ loss of 
function of one hand due to combinations cortical sensorimotor dysfunction (Ling et al, 2010). On 
examination ideomotor and limbkinetic apraxia, cortical sensory loss leading to an alien limb, limb 
dystonia, focal action or stimulus-sensitive myoclonus may be found.  Levo-dopa responsive par-
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kinsonism may also occur.  A variety of pathologies can present with corticobasal syndrome, includ-
ing cerebrovascular disease, Alzheimer’s disease and prion disease.  Conversely corticobasal syn-
drome may be mistaken for progressive supranuclear palsy or frontotemporal dementia.  Cortico-
basal syndrome is only diagnosed correctly in life in around 25 % of cases, at post-mortem the pre-
dominant pathology is 4-repeat tau (Ling et al, 2010).  This compares to a 90% diagnostic accuracy 
for PD when Queens Square brain bank criteria are met.  Nonetheless it is usually possible to clinic-
ally differentiate between idiopathic PD and “Parkinsons plus syndromes”.
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Parkinson’s disease: epidemiology and environmental risk factors
The overall prevalence of PD in industrialised countries is reported to be 0.3% (reviewed in de Lau 
& Breteler, 2006). Studies in multiple countries have confirmed that PD is a strongly age related 
condition, being very rare under the age of 50.  Between age 60 and 70 prevalence ranges from 
0.25-1%, while by age 80 prevalence is 1-4.5 % (reviewed in de Lau & Breteler, 2006).   It is 
unclear whether ethnicity affects prevalence of PD with some studies suggesting that PD is less 
prevalent in black and asian groups than whites (van den Eeden et al, 2003; Mayeux et al, 1995). 
Idiopathic PD is more common in men than women.  Given the high prevalence of GBA mutations 
(1:10-1:18) and LRRK2 mutations in Ashkenazi Jews it might be expected that this population 
would have a significantly higher prevalence of PD than other populations.  However, there are no 
studies comparing the prevalence of PD in Ashkenazi Jews  with other ethnic groups, and further 
research might usefully adress this issue.
Less than 5% of cases of PD are monogenic with the remainder caused by interactions between 
genetic and environmental risk factors (Lees et al, 2009). Environmental risk factors will be 
discussed here and genetic factors in a later section.  A comprehensive systematic review and meta-
analysis of 173 studies investigating environmental risk factors for PD has recently been published 
(Noyce et al, 2012).    Table 1 summarises the environmental factors with a positive and negative 
association with PD risk. Several postulated environmental risk factors did not show any association 
with PD in Noyce’s analysis: oral contraceptives, statin use, diabetes, tea, paracetamol, aspirin 
(Noyce et al, 2012).  
Table 1. Environmental risk factors for PD
Positive association with PD
Pesticide exposure OR 1.78 (CI 1.5-2.10)
Head injury OR 1.58  (CI 1.3-1.91)
Rural living OR 1.43 (CI 1.13-1.81)
Beta-blockers OR 1.28 (CI 1.19-1.39)
Farming OR 1.26 (CI 1.1 – 1.44)
Well water OR 1.21 (CI 1.04.1.40)
Negative association with PD
Smoking OR 0.44 (CI 0.39-0.50)
Coffee consumption OR 0.67 (CI 0.58-0.76)
Hypertension OR 0.74 (CI 0.61-0.90)
NSAIDs OR 0.90 (CI 0.82-0.99)
Alcohol OR 0.90 (CI 0.84-0.96)
The mechanisms of effect of the above environmental factors are unclear.  The protective effect of 
coffee is stronger in men than women.  Caffeine is thought to be the active ingredient, possibly by 
inhibiting the adenosine A2 receptor, which can protect against dopaminergic neurodegeneration 
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(Kachroo et al, 2010).  Nicotine has been shown to protect against dopaminergic neurodegeneration 
in animal models by agonising nicotinic cholinergic receptors (Quik et al, 2010).    Farm work, well 
water drinking and pesticide exposure are postulated to be linked to PD by ingestion of compounds 
which induce neurodegeneration.  NSAID exposure may protect against dopaminergic 
neurodegeneration by its anti-inflammatory effects, since inflammation has been postulated as a 
pathogenic mechanism in PD.  Hypertension, alcohol and NSAID use may protect against PD by 
their association with elevated urate levels.  It should be noted that the Odds Ratios for all of these 
risk factors is low, and therefore these factors can only explain a small fraction of the aetiology of 
idiopathic PD.   
Elevated serum urate has long been associated with a reduced risk of PD.  Jain et al (2011) 
demonstrated a protective effect for raised serum urate on PD risk in men but not women.  O’Reilly 
et al (2010) confirmed that serum urate does not seem to protect women against PD. Schwarzschild 
et al (2011) demonstrated that higher serum urate levels reduced the likelihood of a dopaminergic 
neuronal loss on dopamine transporter imaging in early PD.  Higher levels of serum and 
cerebrospinal fluid urate have also been associated with slower progression of PD (Ascherio et al, 
2009). Urate is an antioxidant and has been shown to protect cultured dopmainergic neurons from 
MPP+ induced cell death (Cipriani et al, 2009). 
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Parkinson’s disease: neuropathology 
Neuropathological diagnosis of PD requires loss of dopaminergic neurons in the substantia nigra 
pars compacta and intraneuronal inclusions formed of alpha-synuclein (Lewy bodies)(Dickson 
et al, 2009). Neurodegeneration is not limited to the substantia nigra and neuronal death and 
dysfunction in other brain areas contributes to the non-motor symptoms which occur in PD and the 
clinical heterogeneity of PD.   Braak and co-workers propose that alpha-synuclein pathology begins 
in the dorsal motor nucleus of the vagus nerve and olfactory bulb (Braak et al, 2003). According to 
Braak staging pathology then spreads through the brainstem in a caudal to rostral manner (Braak 
stage 1-3) before involving cerebral neocortex and limbic system (Braak stage 4-6).  In several 
pathological studies of aged individuals who did not have known neurological disease it has been 
reported that Lewy  body pathology is largely confined to the dorsal motor nucleus of the vagus and 
olfactory bulb (van Berg et al, 2012).  This is so called incidental Lewy body disease.  This 
pathological diagnosis is proposed to be representative of the pre-motor phase of PD.  There is 
limited correlation between Braak stage and clinical stage (van Berg et al, 2003).  Braak stage does 
not correlate with disease duration or Hoehn and Yahr but the extent of cortical Lewy bodies does 
correlate with cognitive impairment.  The Braak stages of PD patients with non-tremor dominant 
disease were lower than those who had tremor predominant disease (van Berg et al, 2012).   This 
may be related to the higher prevalence of dementia in this subtype.  
While Lewy body pathology is clearly of critical importance in PD there is recent evidence that 
Lewy body deposition may not be the initial step in PD pathogenesis.  For example,  Milber et al 
(2012) demonstrate that loss of tyrosine hydroxylase staining and depletion of neurons occurs in the 
substantia nigra in the very early Braak stages (i.e. before Lewy body deposition in the nigrostriatal 
system).  In addition, Lin et al (2012) report an increase in mitochodrial DNA deletions in 
substantia nigra neurons in brain tissue from idiopathic Lewy body disease with minimal synuclein 
deposition in the nigra.  These studies highlight the contribution of factors such as oxidative stress, 
which can cause mitochondrial DNA deletions, to early PD pathogenesis.  
The pathological feature which best correlates with bradykinesia in PD patients is loss of 
dopaminergic neurons in the substantia nigra pars compacta (reviewed in Lees, 2009).  There is 
also neuronal loss in the raphe nucleus, dorsal motor nucleus of the vagus, nucleus basilis of 
Meynert and locus coeruleus.  Neuronal loss is accompanied by 3 intraneuronal inclusions: the 
Lewy body , pale body and Lewy neurite.  Lewy body and Lewy neurites are composed of 
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abnormally folded alpha-synuclein.  Lewy bodies are classified as cortical or brainstem based upon 
their morphology.  At all clinical stages of PD between 3-4 % of nigral neurons contain Lewy 
bodies, suggesting that Lewy bodies are being constantly formed and degraded.  A small number of 
cortical Lewy bodies are seen in almost  all cases of PD at autopsy, but extensive cortical Lewy 
body deposition associated with Alzheimer disease type changes are usually only observed in 
demented PD patients (Dickson et al, 2009).   
Parkinson’s disease pathogenesis: mitochondrial dysfunction
Several cellular processes have been identified as contributing to neuronal death in PD.  The 
discovery that MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a toxin which induces a 
parkinsonian syndrome (Langston et al, 1983), inhibits complex I of the respiratory chain first 
stimulated interest in the role of mitochondrial dysfunction in the neuropathogenesis of PD. 
Multiple studies have since confirmed the importance of mitochondrial dysfunction in PD.  Loss of 
mitochondrial complex I subunits has been demonstrated by immunhistochemistry in substantia 
nigra from PD patients, and reduced complex I activity demonstrated in PD brain tissue (substantia 
nigra and frontal cortex) (Schapira et al, 1990), PD platelets (Krige et al, 1992) and fibroblasts 
(Grunewald et al, 2010).  
Moreover, primary mitochondrial disorders can present with parkinsonism, especially Polymerase-
gamma (POLG) mutations (Davidzon et al, 2006).  The cause of mitochondrial dysfunction in 
sporadic PD is unclear.  However, studies of substantia nigra from aged brain and PD brain 
demonstrated clonally expanded mitochondrial DNA  (mtDNA) deletions, with associated loss of 
respiratory chain subunits and mitochondrial dysfunction (Reeve et al, 2008). There is also 
evidence implicating a role for alpha-synuclein in mitochondrial dysfunction. Mice overexpressing 
wild type or mutant alpha-synuclein develop mitochondrial fragmentation (Martin et al, 2006). 
Devi et al (2008) report that alpha-synuclein can interact directly with mitochondria in 
neuroblastoma cells and impair complex I.  There is also evidence that alpha-synuclein can impair 
mitochondrial fusion thus leading to fragmentation (Kamp et al, 2010).  Thus, though the precise 
mechanism is unclear evidence suggests that alpha-synuclein accumulating in PD can interact with 
mitochondria and influence their function in a manner which may predispose to neurodegeneration. 
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Mitochondrial dysfunction has also been reported in several types of monogenetic PD.  Fibroblasts 
from LRRK2 G2019S mutation associated PD demonstrate reduced ATP synthesis and increased 
mitochondrial proton leak due to altered expression of uncoupling proteins (Papkovskaia et al, 
2012).  Both fibroblasts carrying bi-allelic ATP13A2 mutations and neuronal cell lines with 
ATP13A2 knock down demonstrate altered mitochondrial physiology compatible with defective 
mitophagy, such as increased maximal oxygen consumption rate after treatment with mitochondrial 
depolariser and altered mitochondrial morphology (Grunewald et al, 2012).  It is postulated that 
loss of ATP13A2 function causes lysosomal dysfunction and accumulation of dysfunctional 
mitochondria (Grunewald et al, 2012).  Mitochondrial dysfunction has also been reported in models 
of Parkin and PINK1 associated PD.   Grunewald et al (2010) demonstrated reduced ATP synthesis 
and increased mitochondrial mass in fibroblasts from PD patients with bi-allelic Parkin mutations. 
Abramov et al (2012) demonstrate a number of mitochondrial abnormalities in fibroblasts from 
PINK1 patients including reduced mitochondrial membrane potential with the mitochondria 
consuming ATP via the F1F0-ATPase in order to maintain mitochondrial membrane potential.  Thus 
mitochondrial dysfunction plays a role in the pathogenesis of both sporadic and monogenetic PD.  
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Parkinson’s disease neuropathogenesis: oxidative stress 
There is much evidence that oxidative stress plays an important role in PD neuropathogenesis 
(Gandhi and Abramov, 2012).  The oxidative stress hypothesis postulates that with ageing there is 
cumulative exposure to oxidative stress, causing damage to mitochondrial DNA and mitochondrial 
membranes resulting in further oxidative stress and bioenergetic compromise which contributes to 
neurodegeneration (Gandhi and Abramov, 2012). Oxidative stress occurs when the ability of the 
cell’s anti-oxidant defences to buffer the damaging effects of reactive oxygen species (ROS) are 
overwhelmed.  ROS include superoxide (O2-), hydrogen peroxide (H2O2), and the hydroxyl radical 
(-OH).  ROS may damage several different components of the cell; causing protein, DNA or RNA 
oxidation or lipid peroxidation (Beal, 2002). The oxidation products of polyunsaturated fatty acids, 
especially arachidonic acid and docosahexanoic acid which are found at high levels in the brain, are 
malondialdehyde and 4-hydroxynonenal. ROS attacks protein, oxidising both the backbone and the 
side chain. This in turn reacts with amino acid side chains to form carbonyl groups, which can be 
detected with special Western blotting techniques (discussed in Chapter 4). ROS attack nucleic 
acids in a number of ways: causing DNA-protein crosslinks, breaks in the DNA strand, and 
modifying purine and pyridine bases resulting in DNA mutations.  In general, ROS are produced 
from a number of sources in the cell: monoamine oxidase, mitochondrial complex I and III, 
NADPH oxidase and xanthine oxidase (Gandhi and Abramov, 2012).   There are a number of 
cellular antioxidant defence systems.  These are described in detail in the introduction to Chapter 4. 
 
Several post-mortem studies of PD brain have demonstrated accumulation of products of oxidative 
damage to membranes (reduced polyunsaturated fatty acid levels, elevated 4-hydroxy nonenal) 
(Cheng et al, 2011), proteins (protein carbonyls) and DNA (8-hydroxy guanine)(Alzam et al, 1997) 
in the neurons of the substantia nigra along with loss of the antioxidant reduced glutatione.  A high 
prevalence of mitochondrial DNA deletions in substantia nigra neurons has also been described – 
which is thought to be due to oxidative damage (Bender et al, 2006). Elevated levels of oxidative 
stress markers have also been found in blood (8-OHG) and cerebrospinal fluid (4-HNE, 8-OHG) 
samples from PD patients (Abe et al, 2003).   There are several possible sources for ROS 
production in PD.  Complex I inhibition with MPTP or rotenone is associated with increased 
superoxide radical formation (Smith and Bennett, 1997).  Mutations in a number of PD genes cause 
mitochondrial dysfunction associated with oxidative stress.  The cellular pathophysiology of these 
genes is discussed  below in the section “Parkinson’s disease: neurogenetics”.  Alpha-synuclein can 
also interact with mitochondria and induce oxidative stress in some models.  Increased ROS 
 20
production by NADPH oxidase occurs in microglia in rotenone and MPTP treatment models (Gao 
et al, 2003), while PINK1 deficiency results in NADPH activation and ROS production (Gandhi et  
al, 2009).  Dopaminergic neurons are also exposed to additional oxidative stress produced by the 
metabolism of dopamine by monoamine oxidase (which generates hydrogen peroxide) and the auto-
oxidation of dopamine (which generates superoxide).  This may partly explain the selective 
vulnerability of dopaminergic substantia nigra neurons.  In turn Oxidation of alpha-synuclein 
contributes to its aggregation and Lewy body formation.  Thus there is much evidence that 
oxidative stress is a key mediator of neuronal injury and death in PD.  
Glutathione is a thiol which plays a vital role in antioxidant defence, especially in the brain 
(Johnson et al, 2012). Glutathione is synthesised intracellularly with a typical intracellular 
concentration of 0.2-10 mM. Glutathione synthesis begins with gamma-glutamylcysteine synthetase 
forming an amide bond between glutamic acid and cysteine, before glutathione synthetase adds 
glycine to complete sythesis of glutathione.  Astrocytes have higher levels of glutathione than 
neurons, and can secrete glutathione to serve as a source of glutathione precursors for neuronal 
uptake (Gegg et al, 2005).  Inside cells reduced glutathione serves as an antioxidant; acting as a 
substrate for antioxidant enzymes, inactivating electrophilic species, and restoring reduced cysteine-
thiol moieties on proteins, with the concomitant production of oxidized GSSG. Oxidised 
glutathione is recycled to reduced glutatione by glutatione reductase with NADPH as a co-factor 
(Johnson et al, 2012).  
Multiple studies have demonstrated depletion of reduced glutathione in the substantia nigra of PD 
patients (Perry et al, 1982; Sian et al, 1994). Moreover, reduced glutathione levels are also depleted 
in the substantia nigra of patients with incidental Lewy body disease; suggesting that this might be 
an early event in PD pathogenesis (Dexter et al, 1994).  There was no significant alteration of 
mitochondrial respiratory chain activity in these samples (Dexter et al, 1994). This suggests that 
oxidative stress causes glutathione depletion in PD brain, preceeding any  mitochondrial 
dysfunction in sporadic PD (Dexter et al, 1994).  Recent evidence suggests that glutathione 
depletion alone does not cause mitochondrial dysfunction (Heales et al, 2011), but it is probable that 
loss of antioxidant capacity will render mitochondria vulnerable to ROS mediated damage (Heales 
and Bolanos, 2002).  
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Parkinson’s disease neuropathogenesis: dysfunctional autophagy and ubiquitin-proteasome 
system
Impaired turnover of alpha-synuclein is of key importance in PD pathogenesis (Schapira and 
Tolosa, 2012).  Intra-cellular proteins are disposed of by 2 cellular pathways: the ubiquitin-
proteosome system (UPS) and autophagy-lysosome pathway (ALP)(Benbrook et al, 2012).  There 
is evidence that alpha-synuclein can be degraded by both of these with a complex interplay of 
physiological and pathological factors determining which is involved.  
The proteasome is a cytoplasmic organelle which degrades misfolded or unwanted proteins into 
short peptides of around 8 amino acids which can be recycled for protein synthesis (Benbrook et al, 
2012).  Proteins are tagged for degradation by the proteasome by attachment of ubiquitin molecules 
by the ubiquitin ligase system.  In addition to disposing of misfolded proteins the proteasome 
regulates the cell cycle and gene expression by degrading proteins such as transcription factors. 
The proteasome is a barrel shaped structure composed of 20S subunits and 19S regulatory subunits. 
The 19S regulatory subunit functions by restricting access of proteins to the enzymatically active 
site in the 20S subunit (Benbrook et al, 2012).  Under conditions of cellular stress the expression of 
certain Heat Shock Proteins is upregulated and these target misfolded proteins to the proteasome for 
degradation.  
Autophagy consists of 3 distinct pathways: macroautophagy, microautophagy and chaperone 
mediated autophagy (Hetz, 2012; Benbrook et al, 2012).  Macroautophagy involves formation of 
double-membraned autophagosomes, which fuse with lysosomes to deliver cytoplasmic contents 
(e.g. misfolded proteins). Microautophagy involves lysosomal pinocytosis of cytoplasmic contents 
and is involved in the turnover of long half-life cytosolic proteins. Chaperone-mediated autophagy 
is dependent on the heat shock cognate 70 (hsc70) protein and its binding to lysosomal-associated 
membrane protein 2A (LAMP2A), a lysosomal surface receptor (Alvarez et al, 2010). A highly 
specific subset of proteins containing the KFREQ motif are recognized by the hsc70 chaperone and 
internalized for degradation by LAMP2A lysosomal membrane receptors.  A further form of 
autophagy is mitophagy, which involves delivery of damage mitochondria to the lysosome for 
degradation.  
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Rott et al (2011) describe how alpha-synuclein can be targeted to either the UPS or lysosome 
(autophagy) for degradation.  Alpha-synuclein is monoubiquitinated by the enzyme SIAH.  This 
targets alpha-synuclein to the UPS for degradation.  The enzyme USP9X removes ubiquitin from 
alpha-synuclein and therefore directs it to the lysosome/macroautophagy for catabolism.  Knock 
down of USP9X leads to accumulation of monoubiquitinated alpha-synuclein.  In brain tissue from 
sporadic PD Rott et al (2011) demonstrated reduction in USP9X levels and activity and 
accumulation of USP9X in Lewy bodies (where it likely to have reduced activity due to the nature 
of the aggregated alpha-synuclein).   Thus USP9X inhibition, possibly related to age related 
changes, may predispose to reduced ubiquitination and degradation of alpha-synuclein and Lewy 
body accumulation.  
Ebrahimi-Fakhari et al (2011) used an in vivo mouse model (which involved applying UPS and 
autophagy inhibitors to mouse cortex through a cranial window) to demonstrate that the UPS 
degrades alpha-synuclein under conditions of normal, physiological turnover but that the 
autophagy-lysosome pathway is the chief route for degradation in pathological conditions.  They 
suggest that age related accumulation of alpha-synuclein in alpha-synuclein transgenic mice treated 
with proteasome inhibitor demonstrates that age related loss of UPS activity will predispose to 
alpha-synuclein accumulation.  Moreover, aged alpha-synuclein transgenic mice have significantly 
reduced UPS activity suggesting that alpha-synuclein accumulation can inhibit the UPS.  They 
report that the autophagy-lysosome system is recruited to degrade alpha-synuclein only under 
pathological conditions of pre-existing elevated alpha-synuclein levels.  For example, autophagy 
inhibitors lead to elevated alpha-synuclein levels only in mice transgenic for alpha-synuclein (which 
have high basal levels of alpha-synuclein) and not in wild type controls.  They also demonstrated 
that in alpha-synuclein transgenic mice inhibition of the UPS lead to upregulation of autophagy-
lysosome activity and vice versa.  
In addition to defects of macroautophagy, there is evidence that chaperone mediated autophagy is 
defective in sporadic PD.  Levels of HSC70 and LAMP2 are reduced in the substantia nigra of PD 
brain; suggesting a mechanism which could lead to impaired chaperone mediated autophagy 
(Alvarez et al, 2010).  Knock down of LAMP2a resulted in increased half life of alpha-synuclein 
and reduced chaperone mediated autophagy activity (Alvarez et al, 2010).  
Mutations in several genes associated with monogenetic PD result in disruption of the lysosome-
autophagy pathway.  Bi-allelic mutations in ATP13A2 cause Kufor-Rakeb syndrome (discussed 
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below).  Dehay et al (2012) show that in fibroblasts from Kufor-Rakeb syndrome patients there is 
impairment of lysosomal acidification, decreased proteolytic processing of lysosomal enzymes and 
reduced degradation of lysosomal substrates.  They also demonstrated reductions in ATP13A2 
protein levels in substantia nigra from sporadic PD brain; suggesting this protein may have a wider 
role in PD pathogenesis than simply as part of Kufor-Rakeb syndrome.  Usenovic et al (2012) 
demonstrated accumulation of alpha-synuclein in cortical neurons from ATP13A2 null mice and 
showed that silencing of alpha-synuclein in these cells ameliorated the toxicity associated with 
ATP13A2 loss of function.   Grunewald et al (2012) demonstrated deficient mitophagy in fibroblasts 
from Kufor Rakeb syndrome patients providing another mechanism by which lysosomal 
dysfunction can lead to dopaminergic cell loss.  Several studies have implicated dysfunctional 
autophagy as a mechanism by which LRRK2 mutations cause PD.  Increased basal autophagy levels 
have been demonstrated in G2019S LRRK2 mutation carrying fibroblasts, possibly relating to 
phosphorylation of MAPK/ERK kinases by LRRK2 (Bravo-San Pedro et al, 2012).   Gomez-Suaga 
et al (2011) showed that overexpression of LRRK2 in HEK293T cells causes increased autophagy 
induction through calcium dependent activation of a CaMKK/adenosine monophosphate (AMP)-
activated protein kinase (AMPK) pathway.  Pink1 and Parkin have been shown to play specific role 
in mitophagy, as discussed further in other parts of this chapter. Mutations in GBA clearly will have 
an impact on lysosomal function, though the relevance to PD is still being elucidated, and the 
biochemical effects of GBA mutation are discussed in more detail below.  
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Parkinson’s disease: neurogenetics
The genetic basis of PD has been elucidated by positional cloning studies of kindreds with 
dominant and recessive PD alongside Genome Wide Association Studies (GWAS) of thousands of 
patients with sporadic PD.  The first PD associated gene identified was alpha-synuclein (SNCA), 
cloned in a large dominant PD kindred from Southern Italy (Polymeropoulos et al, 1997).  The 
mutation in the initial report (A53T) was found on a common haplotype in families from Italy, 
Greece and North America who all had Mediterranean ancestry.  Two other SNCA point mutations 
have been identified: A30P in a German family (Kruger R et al, 1998) and E46K in Spain (Zaranz 
et al, 2004).  The importance of SNCA in PD pathogenesis has been confirmed by the discovery that 
duplications and triplications of SNCA cause dominant PD (Ibanez et al, 2004).  PD caused by 
SNCA point mutations and triplications has a very similar phenotype to sporadic late onset L-DOPA 
responsive PD, but with earlier onset (mean 12 years earlier) and possibly more severe cognitive 
impairment.  Pathologically SNCA mutation/duplication associated PD is similar to sporadic PD 
with loss of nigral neurons and LB accumulation, but with more frequent tau pathology than typical 
sporadic PD (Ikeuchi et al, 2008).  SNCA is the major component of the Lewy body and it is 
postulated that SNCA point mutations/copy number variations facilitate aggregation into Lewy 
bodies.     
The second dominant PD gene was identified at the PARK8 locus – LRRK2 (Gilks WP et al, 2005; 
Di Fonzo A et al, 2005).  LRRK2 is a large 51 exon protein with over 20 sequence changes 
identified in PD families, only six of which (R1441C, R1441G, R1441H, Y1699C, G2019S, 
I2020T) are proven to be pathogenic (Zimprich A et al, 2004).  The G2019S mutation has been 
identified in up to 7% of dominant PD families and 1-2% of sporadic PD in Caucasian populations. 
The prevalence of G2019S associated familial and sporadic PD can be 30-40% in some ethnic 
groups such as Ashkenazi jews and North African Berber Arabs.  Europe wide 1.5% of sporadic 
cases and 4% of familial cases have the LRRK2 G2019S mutation.  A large study of over 300 
LRRK2 mutation positive PD cases demonstrated that the phenotype was very similar to mutation 
negative PD, but with a wide range of age of onset from mid-20s through to 90s (Healy DG et al, 
2008).  The majority of pathological studies of LRRK2 associated PD have demonstrated typical 
Lewy body pathology, but also rare cases with pure nigral degeneration or progressive supranuclear 
palsy like tau pathology (Zimprich A et al, 2004).    
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Vacuolar sorting protein 35 (VPS35) has recently been identified as another cause of dominant PD.
Vilarino-Guell et al (2011) identified the p.Asp620Asn  VPS35 mutation in a Swiss family with 
dominant PD.  Zimprich et al (2011) identifed the same mutation in an Austrian dominant PD 
family and a second mutation p.Arg524Trp  in a sporadic PD case.  These mutations were 
associated with typical late onset, dopa responsive PD.    Sharma et al (2012) performed a large 
multi-centre study of VPS35 in PD.  Fifteen thousand PD patients from around the world were 
genotyped for VPS35 mutations; p.Asp620Asn was detected in 5 familial and 2 sporadic PD cases 
and not in healthy controls, p.Leu774Met in 6 cases and 1 control and p.Gly51Ser in 3 cases and 2 
controls. The p.Leu774Met and p.Gly51Ser mutations did not occur more frequently in PD than 
controls.  This study confirms VPS35 mutations as a cause of familial and sporadic PD, albeit a rare 
one.  The clinical characteristics of the cases were reported as being characteristic of idiopathic PD. 
The role of VPS35 in PD is unclear, but it is proposed to play a role in recycling membrane proteins 
from the endosome to the golgi.    
In 2012 Chartier-Harlin et al identified mutations in eukaryotic translation initiation factor 4-
gamma (EIF4G1) as a cause of dominant PD in a large French family.   They also identified 9 PD 
patients from amongst 4 000 sporadic PD cases screened.  Clinical features were very similar to 
sporadic PD (late onset, dopa-responsive, asymmetric onset, typical motor features of PD) and 2 
cases that came to autopsy had Lewy body pathology.  Mutant EIF4G1 protein acts in a dominant 
negative manner, binding to wild type protein and disrupting the transcription initiation complex 
(Chartier-Harlin et al, 2012) being associated with increased cellular vulnerability to oxidative 
stress.    It is clear that EIF4G1 mutations are a rare cause of sporadic PD.  In a series of Asian PD 
patients the frequency of EIF4G1 sequence variants was not different to that of controls (Zhao et al, 
2012).   Lesage et al (2012) screened 251 dominant PD cases from France; they could only confirm 
segregation of EIF4G1 mutations with PD in 1 family and concluded that this gene was not a 
common cause of dominant PD in France.     Tucci et al (2012) did not identify any EIF4G1 
pathogenic mutations in dominant PD and point out the large number of benign polymorphisms in 
this gene suggesting that one of the originally reported mutations (p.A502V) may be a 
polymorphism as it was only found in a control.  EIF4G1 mutations have been reported in 
pathologically confirmed Lewy body dementia, but it is not clear if this report represents 
coincidence and larger studies are required to examine whether or not mutations in this gene 
predispose to Lewy body dementia (Fujioka et al, 2012).  At present it is not clear if EIF4G1 
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sequence variants are benign polymorphisms co-incidentally associated with PD and Lewy body 
dementia or if they are disease causing mutations which are very rare. 
Three main genes have been identified as causing autosomal recessive Early Onset Parkinson’s 
Disease (EOPD); Parkin, PINK1 and DJ-1.  Several much rarer causes of EOPD syndromes are 
also known such as PLA2G6, FBX07, ATP13A2, SLC30A10 and spatacsin. Unlike the dominant 
causes of familial PD recessive EOPD presents with atypical parkinsonism.  The frequency of 
Parkin, PINK1 and DJ-1 mutations in EOPD varies widely depending on the study.     For example 
Lucking et al report Parkin mutations cause up to 50% of EOPD cases and 5-10 % of sporadic PD 
cases with age of onset before 50 years while other studies reported frequencies as low as 1.6% 
(Brooks et al, 2009).  A recent study comprehensively assessed mutation frequency in a UK EOPD 
population and systematically reviewed reported mutation frequencies (Kilarski et al, 2012). In 136 
UK EOPD cases 3.7% had compound heterozygous Parkin mutations, there was 1 PINK1 patient 
with bi-allelic mutations (Filipino) and no DJ-1 mutations.   They identified 1 EOPD case with the 
LRRK2 G2019S mutation.  In the systematic review encompassing 3952 unique published cases 
8.6% of EOPD cases had Parkin mutations (44% homozygous, 56% compound heterozygous). 
Mutation of PINK1 was identified in 3.7% of 2324 reported EOPD cases, 80% of PINK1 mutations 
were homozygous and PINK1 mutations were much more common in Asian patients.  Just 0.4% of 
1351 EOPD cases reported had bi-allelic DJ-1 mutations.    
The first locus for recessive EOPD was identified on chromosome 6 in 13 Japanese families, with 
several homozygous deletions in the Parkin gene then found (Hattori et al, 1998).  Subsequently a 
spectrum of mutations (including nonsense, missense and rearrangements) was identified, 
confirming that Parkin is the most common cause of EOPD (Abbas et al, 1999). EOPD due to 
Parkin mutations has a mean age of onset of 32 years, is L-DOPA responsive but with severe early 
fluctuations in response and slow progression.  Symmetry at onset and early lower limb dystonia 
distinguish this form of PD from sporadic PD.  Moreover, non-motor symptoms in Parkin 
associated PD are much less severe than sporadic PD and olfaction is normal (Kagi et al, 2010). 
The neuropathology of Parkin associated PD differs from sporadic PD in that there are often no LB, 
and a pure nigral degeneration (Sasaki et al, 2004).  Parkin is thought to function as a ubiqutin 
ligase,  and loss of its function may result in the accumulation of aberrantly folded proteins and 
damaged mitochondria (Shimura et al, 2000). 
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A second, less common gene for EOPD is Pink1 (Valente et al, 2004).  Samaranch et al (2010) 
provide a detailed clinic-pathological description of EOPD in a Spanish family with compound 
heterozygous PINK1 mutations. They report 6 affected individuals, most of whom had an 
asymmetric onset of a parkinsonian syndrome dominated by bradykinesia-rigidity with only 2 
having rest tremor.  Atypical features included anxiety, psychosis and hyporeflexia.  Lower limb 
incoordination and falls were prominent early features.  Other studies also report a high frequency 
of neuropsychiatric disorder in PINK1 EOPD (Kasten et al, 2010).  Histopathology demonstrated 
loss of neurons in the substantia nigra, and Lewy bodies in the substantia nigra and nucleus basilis 
of Meynert.  The lack of pathology in the locus coereleus is atypical however.  The authors suggest 
that sparing of this structure could account for the slow progression of PINK1 EOPD (Samaranch et  
al, 2010).      
In 2003, Bonifati and colleagues carried out homozygosity mapping and positional cloning to 
identify a homozygous deletion in PARK7 causing early onset PD in a Dutch family and a missense 
mutation in PARK7 causing disease in an Italian EOPD family (Bonifati et al, 2003). Patients have 
an age of onset in their 20s or 30s with Levodopa-responsive parkinsonism. Atypical features of dy-
stonia and neuropsychiatric manifestations have been reported. Functional imaging of the brain, 
showed significant evidence for a presynaptic dopamine deficit. Neuropathological descriptions of 
EOPD patients with bi-allelic DJ-1 mutations have not been reported.  
Bi-allelic mutations in PLA2G6, ATP13A2, FBX07 and spatacsin cause complex dystonia-parkin-
sonism syndromes which do not resemble sporadic PD (Paisan-Ruiz et al, 2010).     PLA2G6 bi-al-
lelic mutations cause L-dopa responsive dystonia-parkinsonism with an onset age ranging from 10 
to 26 (Yoshino et al, 2010; Lu et al, 2012).  The main clinical features are akinesia and rigidity, gen-
eralized dystonia and cognitive impairment.  These patients generally have no evidence of brain 
iron accumulation despite having identical mutations to that which cause infantile neuronal axonal 
dystrophy  (INAD).  Bi-allelic ATP13A2 mutations cause a pyramidal-parkinsonian syndrome with 
facio-facial-finger minimyoclonus and cognitive impairment with some cases having increased 
brain iron on MRI (Kufor-Rakeb syndrome)(Ramirez et al, 2006).  FBX07 bi-allelic mutations also 
cause a pyramidal-parkinsonian syndrome (Di Fonzo et al, 2009).  SPG11 (spatacsin) causes a spas-
tic paraparesis with thinning of the corpus callosum and a small minority of such patients also de-
velop parkinsonism (Paisan-Ruiz et al, 2010).  A further recently identified cause of dystonia-par-
kinsonism is SLC30A10 mutations, which cause dystonia-parkinsonism, manganese accumulation 
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in the basal ganglia and liver disease (Quadrie et al, 2012). This condition is potentially treatable 
with chelation using disodium calcium edetate.  
These rare recessive genes seem to play little role or no in sporadic PD/EOPD.  For example in a 
Taiwanese cohort of EOPD no homozygous ATP13A2 variants were found (Chen et al, 2011). Other 
groups have also failed to find an association between EOPD and ATP13A2 variants (Dos Santos et  
al, 2010; Fei et al, 2010). Di Fonzo et al (2007) found a single EOPD case with bi-allelic ATP13A2 
mutations and a relatively mild phenotype, ie not classical Kufor Rakeb syndrome.  Data on an as-
sociation between PLA2G6 polymorphisms and PD is inconsistent.  Lv et al (2012) could demon-
strate no association between 4 PLA2G6 SNPS and PD.  Lu et al (2012) found that bi-allelic 
PLA2G6  mutations were the second most common cause of EOPD in Taiwan after Parkin muta-
tions, but did not find any association of PLA2G6 polymorphisms with sporadic PD.     However 
these EOPD cases were highly selected and had atypical PD phenotypes.   Again in a highly selec-
ted series of Japanese EOPD cases Yoshino et al (2010) confirm that bi-allelic PLA2G6 mutations 
can cause a complicated EOPD with dopa responsive dystonia-parkinsonism, dementia and frontal 
lobe atrophy with or without evidence of brain iron accumulation on MRI.     These genes clearly 
are rare causes of EOPD and likely make little, if any, contribution to classic late onset sporadic PD. 
The reported phenotypes for these genes are clearly distinct from sporadic PD and so it would not 
be expected that a significant proportion of sporadic PD cases would have bi-allelic mutations.  
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Lysosomes and lysosomal storage disorders: general introduction
Lysosomes are small membrane bound organelles found in the cytoplasm with an acidic internal pH 
(Cox and Cachón-González, 2012).  Lysosomes contain 50-60 soluble enzymes and at least 7 
integral membrane proteins.  Lysosomal storage disorders (LSD) are caused by recessive mutations 
in lysosomal genes (apart from Fabry disease, Hunter disease and Danon disease which are X-
linked), leading to storage of undegraded substrate.  LSD are classified based upon the type of 
substrate accumulating.  LSD are also classified as infantile, juvenile and adult onset.
Lysosomes have a primary role in degradation of substrate and damaged organelles and in the 
autophagy pathway (Hetz, 2012).  The lysosomal enzymes act in concert to degrade a range of 
macromolecules which may be lipid, polysaccharide, protein or nucleic acid in nature.  These 
enzymes act in sequence, so if one is deficient then there is an interruption to the catabolic process 
and substrate accumulation occurs (Cox and Cachón-González, 2012).   As such lysosomes also 
play a key role in autophagy since they digest the contents of autophagosomes delivered to 
lysosomal lumens by autophagosomes (Hetz, 2012).  Lysosomes also play a role in apoptosis, with 
breach of the lysosomal membrane resulting in release of cathepsin proteases which trigger 
apoptotic pathways (Hetz, 2012).   
Though LSD are individually rare, between 1:5 000 and 1:7 500 live births are affected by an LSD 
(Cox and Cachón-González, 2012).  The most common LSD is GD and the epidemiology of GD is 
discussed later in this introduction.  A summary of the main LSD is presented in the table below. 
LSD can be grouped according to the material which accumulates. The mucopolysaccharidoses 
(MPS)  include Hurler-Scheie syndrome (Type I) and Hunter syndrome (Type II), the main 
sphingolipidoses are Tay-Sachs, GD and Fabry disease and the glycoproteinoses include alpha-
mannosidosis.  Other LSD feature accumulation of diverse materials, for example some of the NCL 
accumulate subunit C of the mitochondrial ATP synthetase while cathpesins accumulate in others.   
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Table 2. Summary of human lysosomal storage disorders.  
Disease Enzyme Storage material
GD Glucosylceramidase glucosylceramide
GM1-gangliosidosis Beta-galactosidase GM1
GM2-gangliosidosis Beta-hexosaminidase
A (Tay-Sachs)
B (Sandhoff disease)
GM2
MPS II (Hunter) Iduronate-2-sulfatase Dermatan/heparan sulphate
MPS IIIA Sulfaminidase Heparan sulphate
MPS IIIB N-acetyl-alpha-glucosaminidase Heparan sulphate
Morquio A N-acetylgalactosamine-6-
sulphate-sulphatase
Keratan sulphate,  chondroitin-
6-sulphate 
Morquio B Beta-galactosidase Keratan sulphate
Niemann-Pick type C NPC 1 and 2 Cholesterol and sphingolipids
NCL1 Protein palmitoyl thioesterase1 Lipidated thioesters
NCL2 Tripeptidyl amino peptidase1 Subunit C of mitochondrial 
ATP synthetase
NCL3 CLN3 protein Subunit C of mitochondrial 
ATP synthetase
NCL4B Not known Subunit C of mitochondrial 
ATP synthetase
NCL10 Cathepsin D Saposin A and D
Metachromatic leukodystrophy Arysulfatase A Sulphated glycolipids 
Beta-galactosialidosis Cathepsin A Sialyl-oligosaccharides
Multiple sulfatase deficiency Formylglycine-generating 
enzyme
Sulfatides
Niemann-Pick type B Sphingomyelinase sphingomyelin
Fabry disease Alpha-galactosidase A Gb3
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Parkinsonism in lysosomal storage disorders other than GD
The strongest association between a LSD and PD is that of Gaucher disease (GD), and heterozygous 
GBA mutations, and PD.  This is discussed later on in this general introduction.  The association 
between other LSD and PD is weaker.  This may reflect a truly weak association or may be an 
artefact due to the rarity of these conditions and difficulty of systematic study of sufficient numbers 
of cases to define an association.    Shachar et al (2011) review reports of PD in LSD.  Of 48 cases 
of adult onset GM1-gangliosidosis reported almost half had signs of akinetic-rigid parkinsonism 
(Roze et al, 2005;  Muthane et al, 2004; Yoshida et al, 1992).  In 1 case this was reported as being 
levo-dopa responsive (Shachar et al, 2011).  A few case reports of parkinsonism in GM2-
gangliosidosis exist (Tay-Sachs and Sandhoff diseases)(Inzelberg and Korczyn, 1994) and a post-
mortem on a 67 year old woman with suspected adult onset GM2-gangliosidosis demonstrated 
Lewy bodies in the substantia nigra (Suzuki et al, 2007).  Murine models of GM2-gangliosidosis 
demonstrate neuronal Lewy body accumulation (Suzuki et al, 2003).  
Niemann-Pick C disease (NPC) has been associate with Lewy body deposition in the substantia 
nigra in human brain (Shachar et al, 2011). Interestingly a single case of atypical PD has been 
reported with a heterozygous NPC mutation (Josephs et al, 2004). Parkinsonian manifestations are 
reported in patients with a variety of types of Neuronal Ceroid-lipofuscinoses (NCL)(Aberg et al, 
2001).  In both juvenile and adult onset NCLs levo-DOPA responsiveness has been reported and 
loss of uptake on dopamine transporter uptake described (Aberg et al, 2000).  Significant loss of 
neurons in the substantia nigra was reported in an adult case of NCL4 (Shachar et al, 2011).  
There is no clear link between metachromatic leukodystrophy but aryslufatase-A (the causative 
enzyme for this disease) has been reported to have reduced activity in  blood in a series of atypical 
PD cases (Martinelli et al, 1994).  Mucopysaccharidoses (MPS) are a group of LSD associated with 
glycosaminoglycan accumulation.  There are no clinical reports of convincing parkinsonism in MPS 
but brain tissue from MPSII had loss of nigral neurons and increased phosphorylation of SNCA 
(Hamano et al, 2008).  Two cases of Fabry disease with parkinsonism have been reported, but these 
were associated with extensive subcortical infarctions and may represent vascular PD rather than a 
lysosomal aetiology for PD in this LSD (Shachar et al, 2011).  The mechanisms linking these 
diverse LSD and increased PD risk remain to be completely elucidated, but may relate to increased 
propensity to accumulate alpha-synuclein in neurons.  
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Gaucher disease: epidemiology 
Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by homozygous 
or compound heterozygous mutations in the glucocerebrosidase gene (GBA) (reviewed in  Hughes 
and Pastores, 2010).  GD is most common amongst Ashkenazi jews, with a carrier frequency of 
1/10-1/14 and a disease prevalence of up to 1:855.  Prevalence is much lower in other ethnic 
groups, for example in the Netherlands prevalence is around 1:100 000.  Over 300 GBA mutations 
associated with GD have been reported, these are discussed in more detail in the introduction to 
Chapter 3 (Hruska et al, 2008).  However, 4 mutations (N370S, L444P, 84GG and IVS2+1) account 
for 90% of GBA mutations in Ashkenzi Jews and 60% of mutations in non-Jewish GD patients. 
The most common genotype causing GD is N370S either in homozygous or compound 
heterozygous form (Duran et al, 2012). Given the large number of rare mutations it is common that 
the N370S mutation is identified with the second mutation not being found.   There is a founder 
effect for mutation N370S in Ashkenzi Jews, D409H in Eastern Europeans and L444P in Swedish 
nationals.   Presentations of GD form a spectrum from a perinatal lethal variant through to 
asymptomatic disease, and the link between genotype and phenotype will be discussed in the 
introduction to Chapter 3.  Within this spectrum 3 major subtypes are recognised Type I, classically 
without primary CNS disease, and Types II and III, with primary CNS disease.  An additional rare 
form is cardiovascular GD which presents with oculomotor apraxia and calcification of mitral and 
aortic valves in the presence of homozygous D409H mutations (George et al, 2001).  
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Gaucher disease: phenotype of Type I Gaucher disease (non-neuronopathic)
Type I GD is characterised by bone disease, with between 70-100% of patients affected by clinical 
or radiological bone disease (Hughes and Pastores, 2010).  Bone disease ranges from asymptomatic 
osteopenia, to osteoporosis with pathological fractures and “bone crises” were there is deep bone 
pain with fever and leukocytosis (Khan et al, 2012).  Bone marrow infiltration with Gaucher cells 
can be extensive, leading to marrow failure.  Hepatosplenomegaly occurs due to Gaucher cell 
infiltration, splenomegaly can cause pancytopenia but liver involvement does not cause cirrhosis 
(Hughes and Pastores, 2013).  Pulmonary hypertension or interstitial lung disease are rare 
complications of Type I GD.  There is an increased incidence of peripheral neuropathy in Type I GD 
(Biegstraaten et al, 2010) and, until the association of GD with PD was discovered, Type I GD was 
not thought to involve the CNS.
The association between Type I GD and cancer remains to be completely elucidated.  Taddei et al 
(2009) studied 403 Type I GD patients retrospectively and report a relative risk of 25 (95% CI 9.17-
54.40) for multiple myeloma, a relative risk of 3.45 (95% CI 1.49-6.79) for other haematological 
malignancy and increased overall cancer risk (relative risk 1.80, 95% CI 1.32-2.40).  Landgren 
(2007) describe an increased risk of non-Hodgkin lymphoma (RR, 2.54; 95% CI, 1.32-4.88), 
malignant melanoma (RR, 3.07; 95% CI, 1.28-7.38), and pancreatic cancer (RR, 2.37; 95% CI, 
1.13-4.98) in 1500 Type I GD patients but no significant association with other solid tumours.  De 
Fost et al (2006) describe increased risk of haematological malignancy in Western European GD 
patients (relative risk 12.7 [95% CI 2.6-37.0]), they also found an increased risk of hepatocellular 
carcinoma in the absence of cirrhosis (relative risk 141.3 [95% CI 17.1-510.5]).  The mechanism for 
increased haematological malignancy risk in GD is unclear; it is postulated to be related to substrate 
accumulation and chronic inflammation and activation of immune cells.  Lo et al (2012)  describe 2 
siblings with Type I GD and acute T-cell lymphoblastic lymphoma.  These patients were shown by 
next generation sequencing to have bi-alellic MSH6 mutations, which causes DNA mismatch repair 
deficiency and increased cancer risk   It may be that genetic variation in cancer genes in GD 
patients contributes to increased cancer risk but it seems unlikely that co-inheritance of mutations in 
cancer genes will explain the increased risk of cancer for GD in general. The association between 
Type I GD and PD is discussed later in this introductory chapter.  
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Gaucher disease: phenotypes of Type II and Type III Gaucher disease (neuronopathic)
Type II GD (acute neuronopathic) is characterised by the onset of a neurological syndrome before 
the age of 2 years of age.  There is limited psychomotor development and death typically occurs by 
age 4.    Severe forms of Type II GD are associated with ichthyotic lamellar desquamation of the 
newborn (“collodion baby”), typically with bi-allelic null mutations in GBA (Lu et al, 1988). Exam-
ination of skin biopsies has confirmed that only Type II GD with null mutations is associated with 
the collodion baby phenotype and skin pathology (Sidransky et al, 1996).   Though the neurodevel-
opmental phenotype dominates the clinical picture patients with Type II GD also have visceromeg-
aly and haematological abnormalities similar to Type I.  
Individuals with Type III disease (subacute neuronopathic) have onset in later childhood or teenage 
years with a slowly progressive course with lifespan into the 20s and 30s in some cases (Benko et  
al, 2011).  Brain stem signs are common; including oculomotor apraxia, failure to initiate saccades, 
stridor and squint.  Pyramidal signs such as spasticity and opisthotonus are frequent.  Seizures, 
dementia and ataxia may occur in neuronopathic GD.  In Type III GD eye movement abnormalities 
may be the only neurological manifestation in patients with otherwise severe systemic involvement. 
Benko et al (2011) prospectively followed the neurological phenotype of 15 Type 3 GD patients 
over 4 years.  All patients studied had impaired saccadic eye movements, with horizontal movement 
more severely affected than vertical.  Only 4 of the patients had normal brainstem auditory evoked 
responses, there was a wide range of cognitive function from severe learning disability through to 
above average intellect and all had slow performance on the Purdue pegboard.  Two had evidence of 
progressive myoclonic encephalopathy of Gaucher disease.  Kraoua et al (2011) describe a French 
series of 10 Type 3 GD patients.  The most common initial neurological abnormalities were 
oculomotor with 1 patient presenting with epilepsy, though a further 3 eventually developed 
epilepsy.  Cerebellar, pyramidal and dystonic features were also common.  Six of the patients had 
neurological signs rated as stable or improved with treatment with enzyme replacement therapy or 
substrate reduction.    Tajima et al (2009) report a series of Japanese Type 3 GD patients.  Again the 
major neurological findings at diagnosis were oculomotor apraxia or seizures.  This group described 
a relatively good response to enzyme replacement therapy in GD Type 3 patients who presented 
initially with non-neurological signs and who subsequently were reclassified after developing them. 
In contrast those patients with neurological signs at the outset had a poor response to treatments.  It 
seems likely that enzyme replacement therapy is of limited efficacy for neurological manifestations 
of Type 3 GD, given that it cannot cross the blood brain barrier.  
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Gaucher disease: treatment options 
Treatment with recombinant glucocerebrosidase enzyme (ERT) has revolutionised the management 
of Type I GD (Desnick and Schuchman, 2012).  Regular intravenous infusions result in reversal of 
hepatosplenomegaly and protect against bone disease but is not associated with improved quality of 
life scores (Wyatt et al, 2012).  ERT does not appear to be affective for neurological manifestations 
of GD; Type I patients have developed PD whilst on ERT and brain stem auditory evoked responses 
have been reported to deteriorate in Type III patients on ERT (Tajima et al, 2009).  An alternative to 
ERT is substrate reduction therapy (SRT), which reduces production of  glucosylsphonigosine, 
permitting clearance by mutant glucocerebrosidase enzymes with reduced activity.  The most 
commonly used SRT is Miglustat (Venier and Igdoura, 2012), which is effective at reducing 
hepatosplenomegaly and bone disease.  Miglustat does not prevent/treat neurological manifestations 
of GD, indeed postural tremor and memory impairment have been reported as possible side effects. 
 36
Gaucher disease: biochemistry & pathogenesis
The central process in GD is failure of glucosylceramidase to hydrolyse glucosylceramide to 
glucose and ceramide.  This results in the accumulation of toxic substrates in lysosomes within 
macrophages, which are histologically identifiable as Gaucher cells.  Physical accumulation of 
Gaucher cells results in hepatomegaly and splenomegaly, characteristic features of GD.  Figure 1 
illustrates the glycosphingolipid metabolic pathway affected in GD (after Xu et al, 2010).  Enzymes 
which catalyse each reaction are in red text. 
Figure 1. Simplified outline of glycosphingolipid metabolism and disorders.
Sphinolipid metabolites re in black and the enzymes which metabilise them, and disorders 
associated with their deficiency are in red text.  
Palmitic Acid
Sphingosine
Ceramide
Cerebroside
Sulfatide
Sphingomyelin
Sphingomyelinase: 
Niemann-Pick
Beta-galactosidase:
Krabbe disease
Arylsulfatase:
Metachromatic
leukodystrophy
Glucosylcermide
  Glucosylceramidase:  
   Gaucher disease
Ganglioside
Beta-hexosaminidase:
Tay-sachs
Globoside
Alpha-galactosidase:
Fabry disease
 37
 38
Figure 2.  Sequential degradation of glycosaminoglycans which accumulate in 
mucopolysaccharidoses (from Kowalewski et al, 2012). 
The diagram to the right of the figure shows the chemical structure of glycosaminoglycans 
being sequentially degraded.  On the left of the diagram the enzyme responsible for each step 
of catabolism is given with the disorder caused by its deficiency in brackets underneath 
The development of murine GD models has proved problematic.  Germline deletion of both GBA 
genes results in perinatal lethality (Mistry et al, 2010).  Mistry and colleagues (2010) conditionally 
knocked out GBA in haematopoietic and mesenchymal lineages using the Mx1 promoter.  This 
mouse recapitulates human visceral pathology (e.g. splenomegaly), haematological dysfunction and 
osteopaenia.  In this model osteopaenia was shown to be secondary to inhibition of Protein Kinase 
C in osteoblasts.  Murine models have provided important insight into the neuropathogenesis of 
GD.  Homozygous V394L, saposin C null mice develop neurological signs (waddling gait) and die 
from progressive neurodegeneration around  1-2 months of age.  Brain tissue from this model has 
elevated glucosylceramide and glucosylsphingosine, with neuronal loss and evidence of 
inflammation (CD68 positive microglia, astrogliosis)(Sun Y et al, 2010). Other groups have 
confirmed a spatial and temporal relationship between substrate accumulation, neuroinflammation 
and neuronal loss. In the L444P/L444P mouse there is marked multi-system inflammation with 
minimal substrate accumulation, suggesting that inflammation in GD may not solely be a response 
to substrate accumulation (Mizukami et al, 2002).  Taken together these studies suggest that 
substrate accumulation, cellular responses to it and neuroinflammation play roles in neuronal death 
in neuronopathic GD.   
Gaucher disease: influence of GBA mutations on alpha-synuclein metabolism 
Neuropathological examination (immunohistochemistry) of mice homozygous for D409H or V394L 
GBA mutations with hypomorphic prosaposin alleles demonstrated intra-neuronal alpha-synuclein 
and ubiquitin accumulation in hippocampus, cortex and cerebellum coincident with neurological 
deterioration and substrate accumulation (Xu YH et al, 2011).    Cullen et al (2011) utilised enzyme 
linked immunosorbent assay (ELISA) to demonstrate increased membrane bound alpha-synuclein 
levels in forebrain, hippocampi and brainstem from 6 and 12 month old D409V/D409V knock in 
mice without neurological deficits.  Immunohistochemical analysis of the same mice did not 
demonstrate elevated neuronal alpha-synuclein.  Recently, Mazzulli and colleagues (2011) 
demonstrated that alpha-synuclein accumulates in human neuronal cell lines with GBA knocked 
down and in induced Pluripotent Stem Cells (iPS) differentiated into dopaminergic neurons.  They 
also demonstrated that glucosylceramide accumulating in these cells facilitates formation of toxic 
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alpha-synuclein aggregates.    These studies provide evidence that dementia and PD occurring in 
GD may be related to aberrant processing of alpha-synuclein, but it must be noted that the murine 
models utilised GBA mutations typically associated with neuronopathic GD rather than mutations 
frequently found in association with Type I GD or PD such as N370S.     The clinical presentations 
of neuronopathic GD and of PD associated with GD differ significantly and it is unclear to what 
extent the underlying pathological mechanisms overlap. 
The mechanisms by which heterozygous GBA mutations lead to synucleinopathy are unclear.  Aged 
heterozygous D409V mice do not have neurological deficits or elevated alpha-synuclein levels as 
assessed by ELISA (Cullen et al, 2011).  However, transfection of MES23.5 cells (a rodent 
midbrain cell line) and PC12 cells with mutant GBA alleles results in significant elevation of alpha-
synuclein levels as detected by ELISA.  This elevation of alpha-synuclein correlated with levels of 
mutant GBA protein expressed but not levels of GBA enzyme activity (Cullen et al, 2011). 
Treatment of these cell lines with Rapamycin significantly reduced alpha-synuclein levels in the 
transfected cells. This suggests that dysfunctional autophagy may be associated with GBA mutations 
and lead to alpha-synuclein accumulation, and that loss of GBA enzyme activity is less relevant to 
neurological disease in heterozygous carriers. However, Mazzulli and colleagues (2011) have 
demonstrated that alpha-synuclein aggregates can inhibit lysosomal GBA activity in neuronal 
cultures and in post-mortem sporadic PD brain higher levels of alpha-synuclein are associated with 
lower GCase activity.  Thus loss of lysosomal GCase activity may occur secondary to alpha-
synuclein accumulation in PD and produce a positive feedback effect by further inhibiting alpha-
synuclein degradation. Heterozygous GBA mutation carriers would theoretically be much more 
susceptible to such an effect.           
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Gaucher disease: effects of glucosylceramidase inhibition on cellular metabolism 
In preliminary work from our lab, Cleeter et al (2012) treated neuroblastoma cell lines with 
conduritol-b-epoxide, a specific inhibitor of GCase, and demonstrated inhibition of mitochondrial 
function.  Complex I-linked ADP phosphorylation with glutamate/malate as substrate was 
significantly decreased by 47% at 20 days (p < 0.01) and by 33% at 30 days (p < 0.05). Complex 
II/III-linked ADP phosphorylation using succinate as substrate was significantly reduced by 30% at 
20 days (p < 0.05) and 26% at 30 days (p < 0.05). There was no significant change in complex IV-
linked ADP phosphorylation.  This was associated with loss of mitochondrial membrane potential 
as assessed by TMRM fluorescence.  There was no reduction in individual respiratory chain enzyme 
activities, but mitochondrial fragmentation was observed after 30 days of treatment.  There was a 
significant increase in rate of dihydroethidium oxidation by 52% at 20 days (p < 0.01) and 71% at 
30 days (p < 0.01). Treatment with conduritol-b-epoxide also caused a significant increase in alpha-
synuclein accumulation, which was not related to lysosomal dysfunction or impaired autophagy. 
Clearly mitochondrial dysfunction, oxidative stress and alpha-synuclein accumulation are key 
processes in PD neuropathogenesis and this work illustrates that loss of GCase activity can trigger 
metabolic changes that might be associated with, and predispose to, neurodegeneration.    
The Parkinson’s disease prodrome 
The classical motor syndrome of PD occurs when greater than 50% of the dopaminergic neurons in 
the substantia nigra pars compacta have degenerated (Lees et al, 2009).  However, the process of 
neuronal dysfunction and degeneration leading up to this is believed to last up to 20 years (Schapira 
& Tolosa, 2010).  During this period it is the non-motor symptoms and signs of PD which 
predominate (Schapira & Tolosa, 2010).  As discussed above, one model of PD neuropathogenesis 
postulates that alpha-synuclein accumulation and neuronal dysfunction begins in brainstem areas 
outside the substantia nigra, which can explain why some of the prodromal features of PD occur 
prior to the onset of the motor syndrome of PD.  
Symptoms of autonomic dysfunction are common in PD.  Constipation (defined as <1 bowel 
motion per day) is the best characterised of these and has been shown to precede the development 
of motor symptoms of PD (Savica et al, 2009). In the Honolulu ageing study the mean interval from 
administration of the bowel motion questionnaire to diagnosis of PD was 12 years for men, while in 
the Olmsted County case-control study constipation preceded onset of PD by 20 years or more in 
women (Savica et al, 2009).  In the Honolulu aging study men 25 % of men with constipation had 
incidental lewy body disease (compared with 6.5% of controls) (Abbott et al, 2007) and constipated 
men who died without PD had a significantly lower density of substantia nigra neurons than non-
constipated men (Petrovich  et al, 2009).  
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REM sleep behaviour disorder (RBD), is characterised by loss of the normal muscular atonia seen 
during REM sleep, with the result that the individual acts out their dreams and complains of non-
refreshing sleep.  RBD has been associated with lewy body pathology in the brain at autopsy.      In 
a prospective study RBD was found to precede development of PD by 12 years (Postuma et al, 
2009).  
Olfactory dysfunction occurs in up to 90% of cases of PD and is one of the best characterised 
clinical markers of prodromal PD (Schapira & Tolosa, 2010).  In the Honolulu ageing study 
olfactory dysfunction was associated with an odds ratio of developing PD of 5.2 for the lowest 
quartile of olfactory function scores compared with the highest quartile of scores (Ross GW et al, 
2008).  This increased risk only applied for the first 4 years after testing however.  In the Honolulu 
cohort olfactory dysfunction predicted the presence of lewy body pathology in those who died free 
from PD (Ross GW et al, 2006).  The role of olfactory dysfunction in predicting PD risk was 
reinforced by a study demonstrating that 5 years after testing 12.5% of hyposmic individuals with a 
first degree relative with PD develop the disorder (Berendse & Ponsen, 2009).  Hyposmia is 
associated with loss of dopaminergic neurons as assessed by DAT-scan in first degree relatives of 
PD patients who subsequently develop PD; suggesting that this clinical sign is a sensitive marker of 
the early stages of dopaminergic neuronal loss in PD before the motor syndrome becomes clinically 
apparent (Berendse & Ponsen, 2009).    
Subtle bradykinesia may also occur in the years before the motor syndrome of PD becomes fully 
manifest (Schapira & Tolosa, 2010). This can be assessed by simple clinical evaluations known as 
“timed motor tests” (Haaxma et al, 2008).  For the upper limbs one of the best characterised tests is 
the Purdue pegboard. This requires the participant to place as many pegs as they can into a row of 
holes in 30 seconds.  Using their dominant then their non-dominant hand and then both hands 
simultaneously.  For the lower limbs a timed 3-metre walk is commonly used.  In this the 
participant sits in a chair, stands, walks 3 metres then turns and returns to sit.  The number of pegs 
placed in the pegboard and the time taken to walk 3m have been shown to discriminate patients 
with PD from age matched controls (Haaxma et al, 2010).  Moreover, when hemi-parkinsonian 
patients were assessed it has been shown that the number of pegs placed is lower for the unaffected 
limb than for normal controls, suggesting that a reduced number of pegs placed may detect PD 
before the full motor syndrome develops (Haaxma et al, 2010).  To further support the contention 
that the peg board can detect bradykinesia in pre-motor PD there is evidence that a reduced number 
of pegs placed correlates with loss of dopaminergic neurons on DAT-scan (Bohnen et al, 2007) and 
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at post-mortem (Alder et al, 2002).  In established PD the peg board score and 3m walk speed 
correlates with the UPDRS score, at baseline and disease progression, suggesting that these markers 
are sensitive to clinical progression in PD (Haaxma et al, 2008).  
In our clinical study we will use validated clinical rating scales to assess for the presence of these 
prodromal markers of PD in a cohort of GD patients and their obligate carrier relatives.  For 
example, we will use the commercially available British version of the University of Pennsylvania 
Smell Identification Test to screen for hyposmia.  
The role of glucocerebrosidase mutations in Parkinson’s disease
The association between PD and glucocerebrosidase mutations was first noted by clinicians who 
recognised an increased frequency of PD amongst GD patients, and subsequently their obligate 
carrier relatives (Goker-Alpan et al, 2004).  Two large cohort studies have estimated the risk of PD 
in patients with Type I GD.  Bultron and colleagues (2010) identified 11 cases of PD amongst 444 
Type I GD patients seen at a New York clinic and calculated a lifetime risk for PD in Type I GD of 
21-24 times that of the general population.  The study of Rosenbloom et al (2011) calculated a 4% 
risk of developing PD at age 70 and a risk of 8-12% by age 80 for Type I GD patients.  The 
association of heterozygous GBA mutations with increased PD risk has been confirmed in multiple 
studies.  The meta-analysis of Sidransky et al (2009), which included almost 6 000 PD patients, 
found an Odds Ratio of 5 for the presence of a heterozygous GBA mutation in a case of sporadic PD 
compared with a control.  Increased frequencies of GBA mutations have been found in clinical 
cohorts of sporadic PD from several regions, including North America (Eblan, Walker & Sidransky, 
2005), Japan (Sidransky et al, 2009), Greece (Kalinderi et al, 2009)  and North Africa (Lessage et  
al, 2011).  As expected, the highest frequency of GBA mutations is seen in Ashkenazi Jewish 
populations, with some studies from Israel detecting heterozygous GBA mutations in almost 1/3 
cases of sporadic PD (Aharon-Peretz et al, 2005).  In the Sidransky meta-analysis (2009) the most 
common mutations in Ashkenazi PD patients were N370S (72%), followed by 84GG (11%) and 
R496H (6%).  In non-Ashkenazi patients L444P (35%) and N370S (18%) were the most common 
alleles.  Importantly, G2019S LRRK2 mutations are not found in association with GBA mutations in 
cases of PD with heterozygous GBA mutations (Eblan et al, 2006). The lifetime risk of developing 
PD for a heterozygous GBA mutation carrier is not known.  
PD associated with heterozygous GBA mutations (PD-GBA) has a younger age of onset than 
sporadic PD (mean age of onset 5 years younger) (Sidransky et al, 2009), with cases of PD with an 
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age of onset under 50 years old significantly more likely to have a GBA mutation and some studies 
suggesting that severe GBA mutations (e.g. L444P) have a younger age of onset than mild 
mutations (e.g. N370S) (Gan-Or et al, 2008).  The phenotype of PD associated with GBA mutations 
is very similar to that of sporadic PD.  In the study of Saunders-Pullman et al (2010) a series of 250 
Ashkenazi patients with typical PD were screened for GBA mutations.  Four individuals with bi-
allelic GBA mutations were identified who had a phenotype of typical PD.  This vividly illustrates 
that the movement disorder associated with GD can be indistinguishable from sporadic PD.  Several 
case series of PD patients with heterozygous GBA mutations describe patients with  dopamine 
responsive parkinsonism, more often akinetic rigid than tremulous, which is associated with the 
development of cognitive impairment later in disease.  The Sidransky meta-analysis suggested that 
compared to sporadic PD, PD-GBA may be symmetrical at onset and more frequently associated 
with cognitive impairment. Crucially, pathological studies of brain tissue from sporadic PD patients 
with heterozygous GBA mutations display Lewy bodies and other neuropathological features 
characteristic of sporadic PD (Neumann et al, 2009).  A case report has described loss of 
dopaminergic neurons on DAT scan in a GD patient with PD and his heterozygous parent with PD 
(Kono et al, 2007).  Thus there is strong evidence that GBA mutations predispose to a parkinsonian 
disorder indistinguishable from sporadic PD which implies that studying PD-GBA will provide 
insights into the pathogenesis of sporadic PD.                
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The role of fibroblasts in studying human neurological disease 
Despite fibroblasts being non-neuronal cells they are widely used as patient derived cell lines in the 
study of neurological disorders and have provided many useful insights into the pathogenesis of 
various diseases.  Fibroblasts lack many of the specialised features of neurons (e.g. 
neurotransmitters) but contain the cellular machinery relevant to PD and GD pathogenesis such as 
the glucocerebrosidase enzyme, lysosomes, endoplasmic reticulum, mitochondria et al.  In addition 
patient derived fibroblasts carry mutations associated with the genetic disease being studied.  This 
permits more authentic modelling of recessive disorders than the alternative model of knocking 
down mRNA and protein expression, since many recessive mutations do not completely inhibit the 
gene and its protein’s function.  Moreover it is possible to model heterozygous mutations in this 
way. It is very difficult to do this in other models, for example transfecting in a plasmid containing a 
mutant allele will result in a tri-allelic cell with 2 wild type alleles and one mutant allele which does 
not recapitulate the human disease.  Using fibroblasts also avoids confounding by factors such as 
genes being disrupted during “Knock out” and “Knock in” procedures in mice.  
Abnormalities occurring in these organelles due to mutations in GBA  are likely to be present in all 
the cells of the body of a GD patient or carrier, even if some cell types, such as bone marrow stem 
cells, are more prone to manifest pathology than others, such as neurons.  In this project fibroblasts 
from GD patients, heterozygous carriers of GBA mutations without PD and PD patients with 
heterozygous GBA mutations will be studied to identify cellular changes which may explain why 
GBA mutations increase risk of developing PD.  Moreover, fibroblasts do have some relevance to 
GD as the skin is damaged in severe early onset Type II GD associated with null mutations in GBA. 
Published studies demonstrating oxidative stress in fibroblasts from Type II and Type III GD 
patients provides evidence to support the use of fibroblasts in studying the basis of neurological 
abnormalities in Type I GD (De Gunato, 2007).  Fibroblasts have also been used to study several 
genetic types of PD.   Fibroblasts from patients with the LRRK2 G2019S mutation have been 
reported to show defects in autophagy (Bravo-San Pedro et al, 2012) and increased mitochondrial 
uncoupling (Papovskia et al, 2012).  Fibroblasts with bi-allelic Parkin mutations have features 
compatible with impaired mitophagy – loss of mitochondrial branching, elevated mitochondrial 
mass, impaired mitochondrial energy generation and elevated mitochondrial mass (Grunewald et al, 
2009).  Thus it is feasible that studying patient derived fibroblasts will provide useful insight into 
both the pathogenesis of GD and PD associated with GBA mutations. 
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Hypotheses to be tested and initial research plan
Hypothesis 1: A subset of GD patients and GBA mutation carriers will express clinical markers of  
prodromal PD.
GD patients and heterozygous GBA mutation carriers will be recruited from the Royal Free Hospital 
Lysosomal Storage Disorders clinic.  Research participants will be screened for prodromal markers 
of PD using well validated tools such as the University of Pennsylvania Smell Identification Test 
(British version).   The individuals recruited to the study will be invited to undergo skin biopsy to 
generate fibroblasts for use in addressing hypothesis 4 (see below). 
Hypothesis 2: Age related risk of  PD will be elevated in heterozygous GBA mutation carriers.
The age related risk of PD in heterozygous GBA mutation carriers (i.e. parents of GD patients) will 
be determined from family history studies of GD patients.
Hypothesis 3: the clinical phenotype of PD associated with GBA mutations will be very similar to  
that of sporadic PD.
PD patients with heterozygous GBA mutations will be phenotyped using standard rating scales of 
motor and non-motor symptoms.   
Hypothesis 4: fibroblasts from GD patients and heterozygous GBA mutation carriers will manifest  
biochemical defects known to be associated with PD.
Fibroblasts will be generated from partial thickness punch biopsies of skin.  These will be assayed 
for defects of lysosomal metabolism and mitochondrial function.  Evidence of oxidative stress will 
be sought.  A variety of methodologies including Western blotting, polymerase chain reaction based 
techniques, measurement of enzymatic activity and single cell imaging will be used as appropriate.  
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Chapter II. 
A CLINICAL STUDY OF PRODROMAL MARKERS OF 
PARKINSON’S DISEASE IN GAUCHER DISEASE PATIENTS 
AND HETEROZYGOUS CARRIERS OF 
GLUCOCEREBROSIDASE MUTATIONS
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Ia. Introduction 
Clinical markers of prodromal Parkinson’s disease 
The classical motor syndrome of PD occurs when greater than 50% of the dopaminergic neurons 
in the substantia nigra pars compacta have degenerated (Lees et al, 2009).  However, the 
process of neuronal dysfunction and degeneration leading up to this is believed to last up to 20 
years (Schapira & Tolosa, 2010), a phase referred to as the Parkinson’s disease prodrome. 
During this period it is the non-motor symptoms and signs of PD which predominate (Schapira 
& Tolosa, 2010), these are termed prodromal markers of PD.  As discussed in the general 
introduction, one model of PD neuropathogenesis postulates that SNCA accumulation and 
neuronal dysfunction begins in brainstem areas outside the substantia nigra, which can explain 
why some of the prodromal features of PD occur prior to the onset of the motor syndrome of PD. 
Symptoms of autonomic dysfunction are common in both the prodromal and clinical phase of 
PD.  Constipation (defined as <1 bowel motion per day) is the best characterised of these and has 
been shown to precede the development of motor symptoms of PD (Savica et al, 2010). In the 
Honolulu ageing study the mean interval from administration of the bowel motion questionnaire 
to diagnosis of PD was 12 years for men, while in the Olmsted County case-control study 
constipation preceded onset of PD by 20 years or more in women (Savica et al, 2009).  In the 
Honolulu aging study 25 % of men with constipation had incidental lewy body disease 
(compared with 6.5% of controls) (Abbott et al, 2007) and constipated men who died without PD 
had a significantly lower density of substantia nigra neurons than non-constipated men 
(Petrovich  et al, 2009). The mechanism of constipation in prodromal PD is unclear.  However, 
recent studies have demonstrated alpha-synuclein accumulation in the enteric nervous system in 
colonic biopsies taken from PD patients 2-5 years before onset of the motor syndrome (i.e. in the 
prodromal phase).  SNCA accumulation was mainly localised to substance-P positive neurons 
(Shannon et al, 2012).  This suggests that Lewy body formation/SNCA accumulation in the 
enteric nervous system in the prodromal phase of PD may be causally related to the occurrence 
of constipation.  In addition to constipation other autonomic symptoms are associated with PD. 
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However, in the majority of cases urinary and erectile dysfunction develop after the onset of 
motor Parkinsonism (reviewed in Sakakibara et al, 2011).  In 1 study only 60% of PD patients 
had orthostatic hypotension as an early feature (reviewed in Goldstein et al, 2011).  All of these 
autonomic symptoms have low sensitivity and specificity for prodromal PD and are more 
commonly associated with motor PD.  There are several screening tools to detect the presence 
and severity of autonomic symptoms in PD.  However, most of these are very detailed and  time 
consuming to administer.  In the context of this study of a range of prodromal markers of PD the 
autonomic component questionnaire of the Unified Multiple Systems Atrophy Rating Scale 
(UMSARS) was selected as a screening tool as it is easy to administer and validated for the 
detection of the 4 main autonomic symptoms (constipation, urinary dysfunction, orthostatic 
hypotension, erectile dysfunction)(Wenning et al, 2004).   
        
Rapid eye movement (REM) sleep behaviour disorder (RBD) is a parasomnia and movement 
disorder described by Schenck in 1986 (reviewed in Arnulf, 2012).  RBD is associated with loss 
of normal muscle atonia during REM sleep, leading to dreams being acted out.  It is thought to 
be related to lesions of the REM sleep atonia centre in the pontomedullary brain stem.  Patients 
with RBD classically experience violent/distressing dreams which are combined with purposeful 
limb movements and vocalisations during sleep (reviewed in Arnulf, 2012).  Probable RBD is 
diagnosed based upon clinical screening, which can be done using validated questionnaires, with 
confirmation by formal sleep studies (video-polysomnography during sleep).  RBD is present in 
up to 60% of PD patients and 80-100% of patients with Lewy body dementia.  Interestingly 50-
80 % of patients with RBD develop PD, LBD or MSA within 5-15 years (Schenck et al, 1996; 
Postuma et al, 2009).  RBD is the most sensitive and specific marker of prodromal PD and RBD 
patients represent an important at risk cohort for studying the earliest phases of PD (see below). 
Several questionnaires have been developed to screen for RBD.  The screening questionnaire 
designed by Stiasny-Kolster et al (2012) was chosen to screen for RBD  as it was developed in a 
European population and validated in a large cohort of RBD patients with diagnosis confirmed 
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by sleep studies.  Other RBD questionnaires available were not utilized as they had been 
validated in non-European populations or were general screening tools for sleep disorders in PD. 
Olfactory dysfunction (hyposmia) occurs in up to 90% of cases of PD and is one of the best 
characterised clinical markers of prodromal PD (Schapira & Tolosa, 2010).  It should be noted 
that hyposmia is not unique to PD and can be observed in other neurodegenerative conditions 
such as Alzheimer’s disease.  Hyposmia occurs in Progressive supranuclear palsy, MSA, CBD 
and essential tremor but to a lesser degree than in PD (Doty RL, 2012).  The pathological 
substrate of hyposmia in PD is Lewy body deposition in the olfactory bulb, anterior olfactory 
nucleus and olfactory cortices (Ubeda-Banon et al, 2012).    In the Honolulu ageing study 
olfactory dysfunction was associated with an odds ratio of developing PD of 5.2 for the lowest 
quartile of olfactory function scores compared with the highest quartile of scores (Ross GW et al, 
2008).  This increased risk only applied for the first 4 years after testing however.  In the 
Honolulu cohort olfactory dysfunction predicted the presence of central nervous system Lewy 
body pathology in those who died free from PD (Ross GW et al, 2006).  The role of olfactory 
dysfunction  in predicting PD risk was reinforced by a study demonstrating that 5 years after 
testing 12.5% of hyposmic individuals with a first degree relative with PD develop the disorder 
(Ponsen et al, 2009).  Hyposmia is associated with loss of dopaminergic neurons as assessed by 
dopamine transporter imaging in first degree relatives of PD patients who subsequently develop 
PD themselves; suggesting that this clinical sign is a sensitive marker of the early stages of 
dopaminergic neuronal loss in PD before the motor syndrome becomes clinically apparent 
(Berendse & Ponsen, 2009).  Several aspects of olfaction are abnormal in PD; including odour 
identification, discrimination and olfactory threshold (reviewed in Doty RL, 2012).  In clinical 
practice the most commonly used tests of olfactory function are based upon odour identification, 
as these have been shown to be the most reliable and reproducible (Doty RL, 2012).  One of the 
most extensively studied tests of olfactory function is the University of Pennsylvania Smell 
Identification Test (UPSIT).  This features 40 odours contained in a microencapsulated form on a 
card.  The card is scratched to release the odour and the study participant selects from 4 choices 
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to identify the odour.  There is extensive age and sex adjusted normative data for the UPSIT to 
enable identification of hyposmic individuals.  The UPSIT was selected as a screening tool for 
hyposmia as it has been used extensively in publications, is easy to administer, is portable and is 
available in a British format.
Subtle bradykinesia may also occur in the years before the motor syndrome of PD becomes fully 
manifest (Schapira & Tolosa, 2010). This can be assessed by simple clinical evaluations known 
as “timed motor tests” (Haaxma et al, 2008).  For the upper limbs one of the best characterised 
tests is the Purdue pegboard, which is commercially available. This requires the participant to 
place as many pegs as they can into a row of holes in 30 seconds.  Using their dominant hand, 
then their non-dominant hand and then both hands simultaneously.  For the lower limbs a timed 
3-metre walk is commonly used.  In this the participant sits in a chair, stands, walks 3 metres 
then turns and returns to sit.  The number of pegs placed in the pegboard and the time taken to 
walk 3m have been shown to discriminate patients with PD from age matched controls (Haaxma 
et al, 2010).  Moreover, when hemi-parkinsonian patients were assessed it has been shown that 
the number of pegs placed is lower for the unaffected limb than for normal controls, suggesting 
that a reduced number of pegs placed may detect PD before the full motor syndrome develops 
(Haaxma et al, 2010).  To further support the contention that the peg board can detect 
bradykinesia in pre-motor PD there is evidence that a reduced number of pegs placed correlates 
with loss of dopaminergic neurons on dopamine transporter imaging  (Bohnen et al, 2007) and at 
post-mortem (Adler et al, 2002).  In established PD the peg board score and 3m walk speed 
correlates with the UPDRS score, at baseline and disease progression, suggesting that these 
markers are sensitive to clinical progression in PD (Haaxma et al, 2008).   The Purdue pegboard 
and 3m timed walk are well validated in the literature and easy to administer, therefore they were 
selected as screening tools to identify individuals with subtle bradykinesia.   
Cognitive dysfunction (both Mild Cognitive Impairment, MCI, and dementia) has recently been 
recognised as being highly prevalent in incident, untreated PD.  Reported rates of cognitive dys-
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function in newly diagnosed PD range from 20-35% (Foltynie et al, 2004).  Most commonly 
cognitive deficits are either frontostriatal or temporal lobe in nature (Foltynie et al, 2004).  Func-
tional imaging with 18F-fluorodeoxyglucose (FDG) and PET (FDG-PET) demonstrated posteri-
or cortical hypometabolism in patients with early PD and MCI.  There are no studies demonstrat-
ing that MCI is a prodromal marker of PD, but given the evidence from incident PD cohorts it 
seems probable that MCI occurs in prodromal PD.  The Montreal Cognitive Assessment (MoCA) 
is a well validated bedside screening tool for detection of cognitive impairment.  The MoCA has 
been shown to be significantly more sensitive in detection of cognitive impairment in PD than 
the more commonly used Mini Mental State Examination (MMSE)(Dalrymple-Alford et al, 
2010; Hoops et al, 2009).  The MoCA is simple to use and quick and does not require specialized 
equipment making it suitable for clinical screening studies of prodromal PD. 
Physiology of the human olfactory system and anatomical basis of hyposmia
The major anatomical components of the human olfactory system are described here to provide a 
context for the discussion of causes of hyposmia later in this chapter (Gottfried and Zald, 2005). 
Odor-evoked responses are conducted from the first order neurons in the olfactory mucosa to 
synapse in the second order neurons (mitral and tufted cells) in the olfactory bulb.  The axons of 
the mitral and tufted cells then form the olfactory tracts ipsilateral to the olfactory bulb.  The ol-
factory tract lies in the olfactory sulcus of the basal forebrain and conveys olfactory stimuli to a 
variety of brain structures (Gottfried and Zald, 2005).  These projection sites are collectively 
called the “primary olfactory cortex” and include the anterior olfactory nucleus, anterior and pos-
terior piriform cortex, amygdala and rostral entorhinal cortex.   The piriform cortex is the largest 
area receiving olfactory projections and is often used synonymously with primary olfactory cor-
tex.  Higher order projections from these primary olfactory areas converge on secondary olfact-
ory cortical regions in the orbitofrontal cortex, agranular insula, hypothalamus, thalamus and 
hippocampus (Gottfried and Zald, 2005).  This complex network of cortical regions forms the 
basis for odour guided regulation of behaviour, autonomic function, feeding and memory.  
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Functional neuroimaging studies demonstrate that distinct cortical networks underly different as-
pects of odour perception (Reviewed in Savic, 2002).  In the majority of studies, the piriform 
cortex, amygdala, thalamus, right orbitofrontal cortex, insula and cingulum are activated in all 
types of olfactory task.  However, when comparing the intesity of different odours the left insular 
cortex and right cerebellum are activated in addition.  In discriminating the quality of different 
odours the right prefrontal cortex, bilateral frontal operculum and brainstem areas are activated. 
While odour recognition/memory tasks involve the right temporal neocortex.  
Clearly the human olfactory system is vulnerable to damage at a number of anatomical locations.
Damage to the olfactory bulb is associated with hyposmia after head injury while sinonasal dis-
ease (e.g. polyps) can damage the sensory nerves in the nasal mucosa.  Several different central 
nervous system diseases are associated with hyposmia as discussed elsewhere in this chapter 
(Doty, 2012).  Thus when hyposmia is identified in a  particular neurological disease further 
characterisation, e.g. with functional neuroimaging is required to identify the cortical structures 
involved in the pathogenesis of hyposmia.    
Retinal thinning as an ocular manifestation of early Parkinson’s disease
A variety of ocular features have been reported in Parkinson’s disease.  Visual symptoms range 
from dry eyes, through to perceptual abnormalities and complex visual hallucinations (reviewed 
in Archibald, 2011).  The retina contains dopaminergic cells in the form of amacrine cells which 
are found in the inner nuclear layer and to a lesser extent the retinal ganglion cell layer (reviewed 
in Archibald, 2011).  The main physiological role of dopamine in the retina is to facilitate light 
adaptation.  Loss of dopaminergic cells in the retina of PD patients has been demonstrated at post 
mortem and this is proposed to explain the loss of contrast and colour sensitivity displayed by 
PD patients.  
Optical coherence tomography (OCT) is a non-invasive technique which utilises reflected light 
to measure retinal nerve layer thickness with a resolution of 3-5 micrometres.  Several OCT 
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studies have demonstrated retinal nerve fiber loss in PD patients.  Hajee et al (2009) reported 
reduced retinal nerve fiber layer thickness in early PD. La Morgia et al (2012) demonstrated loss 
of temporal retinal nerve fiber layer thickness in PD patients compared to controls; they point out 
that a similar pattern is observed in mitochondrial disease.   Aaker et al (2010) describe loss of 
macular thickness in PD but normal retinal nerve fiber layer thickness.   However, Archibald et  
al (2011) could not demonstrate retinal pathology using OCT in sporadic PD.  Some of the 
variability of studies of OCT in PD reflects the different OCT techniques used and the 
heterogeneity of PD patients.  Nonetheless, it seems that OCT can demonstrate retinal nerve fiber 
loss as a biomarker of both early and established PD.
There are no studies of OCT in GD.  However, the retina is involved in GD with reports of pre-
retinal white spots (probable retinal Gaucher cells) described in GD patients before the advent of 
ERT (Wollstein et al, 1999; Cogan et al 1980).  Seidova et al (2009) describe reduced 
electroretinogram responses in a GD patient. The retina is involved in other LSDs, for example, 
the cherry red spot in Tay-Sach’s disease.  Given that OCT can detect subtle retinal degeneration 
in both early and advanced PD and that the retina is likely to be involved in GD it was decided to 
investigate the ability of OCT to detect retinal degeneration in GD patients.
The role of dopamine transporter imaging in diagnosis of Parkinson’s disease
Parkinson’s disease is clinically diagnosed based upon the Queen Square Brain Bank criteria 
(Hughes et al, 1992).  In the majority of cases diagnosis is straightforward with no need for 
ancillary tests.  However, in certain circumstances imaging of the dopaminergic nigrostriatal 
system is required to aid diagnosis.  For example, in cases where there is monosymptomatic 
tremor to help differentiate essential or dystonic tremor from PD (Kagi et al, 2010a).  In clinical 
practice dopaminergic nigrostriatal imaging is performed using radioligands which bind the 
dopamine transporter [DAT, 123I-FP-CIT, 123I-beta-CIT or 99m-TRODAT-1], or less commonly 
18-F-dopa [an analogue of L-DOPA which is taken into dopaminergic neurons], and visualising 
uptake with positron emission tomography (PET) or single photon emission computed 
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tomography (SPECT)(Kagi et al, 2010a).   At the Institute of Neurology 123I-FP-CIT SPECT 
[DaTSCAN] is utilised to image the nigrostriatal dopaminergic system; compared to other 
radioligands it is taken up rapidly permitting imaging 3-6 hours after injection and binds 
exclusively to DAT on dopamine synthesising neurons.  Factors such as age, gender and smoking 
which can theoretically influence DAT density are of limited impact on DaTSCAN use in clinical 
practice (Kagi et al, 2010a).  It should be noted that several drugs can influence DAT availability 
and should be stopped at an appropriate time before DaTSCAN. For example, cocaine, selective 
serotonin uptake inhibitors and modafinil (Kagi et al, 2010a).    
The primary use of DaTSCAN in clinical practice is to assess patients with early or clinically 
uncertain PD.  In a small minority of cases with clinically probable PD (6.7-14.7%) DaTSCAN 
is normal.  However, detailed clinical analysis of patients with so called “SWEDDs” (scans 
without evidence of dopaminergic dysfunction in patients with signs of PD) demonstrated that 
the majority have subtle clinical signs which point to a diagnosis other than PD (e.g. evidence of 
dystonic tremor).  Most authors conclude that DaTSCAN is unlikely to be normal in bona fide 
cases of early PD, and that a normal DaTSCAN should prompt consideration of another 
diagnosis in patients with clinically uncertain PD.  In this regard it is of note that DAT ligand 
binding intensity correlates with bradykinesia and not tremor in PD (kagi et al, 2010a). 
DaTSCAN is of limited value in distinguishing PD from Parkinson’s plus syndromes such as 
Multiple Systems Atrophy and Progressive Supranuclear Palsy (Kagi et al, 2010a). However, 
DaTSCAN is normal in essential or dystonic tremor, vascular Parkinsonism and psychogenic 
PD.   In PD DAT ligand binding is characteristically reduced in an asymmetric pattern, with 
greatest reduction contralateral to the affected side, and with relative sparing of the caudate early 
in disease (Kagi et al, 2010).
    
DaTSCAN has also been used to demonstrate dopaminergic nigrostriatal dysfunction in 
conditions which are associated with a high risk of developing PD.  For example, DaTSCAN 
studies of REM sleep behaviour disorder have revealed loss of dopaminergic nigrostriatal 
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neurons (Iranzo et al, 2011), which could be taken as evidence of pre-motor substantia nigra 
dysfunction.  In support of this, DAT ligand binding decreases over time in RBD patients and in 
one study baseline reduction in DaTSCAN ligand binding predicted development of clinical PD 
over a 2.5 year period (Iranzo et al, 2011).  DaTSCAN ligand binding is also reported as being 
reduced in patients with hyposmia and in the contralateral basal ganglia in hemi-parkinsonian 
patients. This suggests that DaTSCAN imaging may be of use in tracking progression from pre-
motor to motor PD in individuals who are in populations at increased risk of developing PD (e.g. 
GBA mutation carriers).  
There are relatively few studies of DaTSCAN or 18-F-DOPA –PET in monogenetic PD (Guo et  
al, 2011).  In PD with bi-allelic Parkin mutations there is, compared to sporadic PD, a more 
symmetrical and generalised loss of DAT ligand binding, with a slower rate of loss of DAT 
ligand binding over time than in sporadic PD (Ribeiro et al, 2009).  Likewise, in PD patients 
with bi-allelic PINK1 mutations reduction in DAT-ligand binding is more symmetrical than in 
sporadic PD, though some patients have an asymmetrical pattern similar to sporadic PD 
(Samaranch et al, 2010).  DAT-SPECT in SNCA mutation associated PD is similar to sporadic 
PD but reported as being more symmetrical (Bostantjopoulou et al, 2008; Sammi et al, 1999; 
Ahn et al, 2008; Nishioka et al, 2006)   while in LRRK2 G2019S mutation associated PD the 
pattern is asymmetrical and identical to sporadic PD (Isaias et al 2006).  DaTSCAN imaging has 
been reported in 2 GD patients with PD and 1 heterozygous GBA mutation carrier with PD, 
documenting DAT-ligand binding loss similar to sporadic PD but not reporting region of interest 
analysis of DAT-ligand binding intensity with comparison to sporadic PD (Kono et al, 2007; 
Sunwoo et al, 2011).  Thus, to provide a description of DaTSCAN imaging in PD-GBA we 
performed a retrospective analysis of  DaTSCANs from cases of PD-GBA and other 
monogenetic PD cases.  
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Studies of prodromal markers of PD in “at risk” cohorts  
There are a number of clinical cohorts who can be considered to be at increased risk of 
developing PD.  The most obvious of these are individuals who carry pathogenic mutations in 
PD associated genes (e.g. LRRK2) but who have not developed PD.  As discussed above 
individuals with RBD are also at significantly increased risk of developing PD.  Several studies 
have investigated clinical markers of prodromal PD in these “at risk” cohorts.  
Asymptomatic carriers of the LRRK2 G2019S mutation have been extensively studied. 
Saunders-Pullman et al (2011) demonstrated  hyposmia in a subset of non-manifesting carriers of 
the LRRK2 G2019S mutation suggesting it to be a prodromal marker of PD in these subjects. 
Marras et al (2011) identified a higher prevalence of constipation, postural tremor and reduced 
colour discrimination in asymptomatic LRRK2 G2019S carriers.    
Several clinical markers of prodromal PD have been identified in patients with RBD (Postuma et 
al, 2009).  Including hyposmia,  orthostatic hypotension and mild cognitive impairment. A subset 
of individuals with RBD have depletion of dopaminergic neurons on dopamine transporter 
imaging.  Longitudinal studies of RBD have demonstrated that this loss of dopaminergic neurons 
is progressive and that individuals with prodromal markers can convert to overt motor PD 
(Iranzo et al, 2011).       
These studies clearly demonstrate that clinical markers of the PD prodrome can be identified in 
“at risk” cohorts and that these markers can identify individuals who subsequently go on to 
develop PD.  It is more efficient to identify at risk individuals carrying PD associated mutations 
rather than those who have RBD, given that accurate diagnosis of RBD requires cumbersome 
sleep studies.  These points indicate that our study of clinical markers of prodromal PD in 
Gaucher disease patients and heterozygous GBA mutation carriers is feasible, with the potential 
to efficiently identify a cohort of individuals in the prodromal phase of  PD. 
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Phenotypic variability of sporadic and genetic PD
Both sporadic and genetic PD show considerable variability in the motor and non-motor 
phenotype (reviewed in Kasten et al, 2010; Chaudhuri et al, 2011).  The major motor phenotypic 
groups in sporadic PD are tremor predominant and postural instability-gait disorder.  In addition 
rare genetic forms of PD have unusual motor features.  For example, in Kufor-Rakeb syndrome 
facio-facual-finger minimyoclonus is a characteristic feature (Santoro et al, 2011) whilst lower 
limb dystonia is common in Parkin mutation associated PD (Kagi et al, 2010b).  In the rare 
pallido-pyramidal syndromes (e.g. FBX07 mutations) parkinsonism  is accompanied by upper 
motor neuron signs.  
The heterogeneity is even more apparent in the non-motor phenotype of PD  (reviewed in Kasten 
et al, 2010; Chaudhuri et al, 2011).  The proportion of PD patients who develop PD-dementia 
varies, but longitudinal studies indicate that up to 85% of PD patients will eventually develop 
dementia (Foltynie et al, 2004).  Neuropsychiatric features such as anxiety and depression are 
also common in sporadic PD, but by no means uniform.  Symptoms of autonomic dysfunction 
are prevalent in sporadic PD affecting a variable proportion of patients (Sakakibara et al, 2011). 
Constipation affects the majority of PD patients (circa 60%), and many develop urinary and 
erectile dysfunction.  Orthostatic hypotension  is a feature of sporadic PD, often occurring late in 
the disease course.  
The explanation for the phenotypic heterogeneity in PD is unclear.  The study of monogenetic 
PD has shown that genotype plays a clear role (reviewed in Kasten et al, 2010).  For example, 
cognitive dysfunction has been shown to be more frequent and more severe in PD associated 
with GBA or SNCA mutations (Kasten et al, 2010).  Neuropsychiatric problems may occur more 
frequently in PINK1 associated PD.  Interestingly, PD with recessive Parkin mutations has a very 
mild non-motor symptom profile (Kagi et al, 2010b).  Given the evidence that mutations in PD 
associated genes can influence the phenotype of PD it was decided to undertake a detailed 
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phenotypic study of PD patients with GBA mutations in order to examine the hypothesis that 
GBA mutations can influence the phenotype of PD.             
Ib. Methods
Patient Cohort
Consecutive patients with GD, without a previous diagnosis of PD or dementia, from the Royal 
Free Hospital Lysosomal Storage Disorders unit (LSDU) and Lysosomal Disorders clinic at 
Addenbrookes hospital, Cambridge, were invited to participate in the clinical study.  The GD 
patients had been previously diagnosed with Type I disease by the Consultant Haematologists of 
the LSDU (Prof A Mehta & Dr D Hughes [Royal Free], Dr P Deegan & Prof TM Cox 
[Addenbrookes Hospital]) on the basis of their clinical features, molecular genetics and blood 
biochemistry.  A detailed family history was taken from each proband to identify relatives who 
were either obligate carriers of heterozygous GBA mutations (parents of probands) or at risk of 
carriage (uncles, aunts, siblings).  Each proband was also asked about a family history of 
dementia or movement disorders.  Relatives were then contacted by letter and invited to 
participate in the study with the proband’s permission.  GBA mutation status was confirmed in 
probands and carriers by direct sequencing of the GBA gene (see below).  
To identify a cohort of PD patients with GBA mutations 220 patients with typical PD were 
selected from the Royal Free Hospital Movement Disorders database, which is a prospective 
collection of DNA and clinical data from movement disorders patients seen at the Royal Free 
Hospital.  The DNA from these individuals was sequenced to detect mutations in exons 1-11 of 
the GBA gene (sequenced by Rob Baker and Dr Raquel Duran-Ogalla).  Controls who were age, 
sex and ethnicity matched to the Gaucher disease patient and carrier groups were recruited from 
relatives of the GD patients and PD patients.  Absence of a pathogenic GBA mutation was 
confirmed by gene sequencing.  A cohort of PD patients who did not carry a GBA mutation nor 
the G2019S LRRK2 mutation (n=20) was recruited from the Royal Free Hospital movement 
disorders database to act as a mutation negative PD control group.  All PD patients in the 
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Movement Disorders DNA database had previously had the LRRK2 G2019S mutation sequenced 
by a previous research fellow.  
The project has been granted ethical approval by the North West London Research Ethics 
Committee (REC number 10/H0720/21) and hospital Research and Development approval 
granted by the Royal Free Hospital (project ID 7995, CSP 42224) and Cambridge University 
Hospitals NHS Trusts.  
Glucocerebrosidase gene sequencing
Sequencing of  exons 1 – 11 of the GBA gene was performed by Rob Baker  in the Molecular 
Haematology laboratory of the Royal Free Hospital, where diagnostic sequencing of the GBA 
gene is performed as an NHS service, and Dr Raquel Duran PhD of the Molecular Neuroscience 
group, UCL Institute of Neurology.  GBA sequencing was performed with a previously reported 
protocol (Neumann et al, 2009) using polymerase chain reaction (PCR) primers designed 
exclusively for regions of the GBA gene not found in the pseudogene.  After amplification by 
PCR the product was run on a 1% agarose gel with ethidium bromide and size checked to ensure 
it was not the pseudogene.  Sanger sequencing was performed for each exon and flanking 
intronic sequences using the Dye Terminator Sequencing Kit (Applied Biosystems) and run on 
an ABI 3700xl genetic analyzer.  All identified mutations were confirmed by a second reaction 
and by checking the forward and reverse sequences
Assessment of Clinical Markers Of Prodromal Parkinson’s Disease
All testing procedures were performed identically in GD patients, carriers, PD patients and 
controls.  It was not possible to blind as to the disease or mutation status of the participants. 
Olfactory function was assessed using the British version of the University of Pennsylvania 
Smell Identification Test (SIT), which has been used to assess olfaction in several published U.K 
cohorts.  The test was administered using the manufacturer’s protocol, both nostrils were used 
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for olfactory function testing.  Individuals with an upper respiratory tract infection (URTI) or 
who had an anatomical lesion of their upper airways known to cause hyposmia were excluded as 
were current smokers.  The SIT has 40 items, for each item the participant is asked to scratch a 
pad, which releases an odour and select from a choice of 4 what the odour is.  If the individual 
cannot recognise the smell then they are instructed to make a best guess, as the SIT is a “forced 
choice” test.  Hyposmia was defined as a score lower than the 15th centile for age and sex.   It 
should be noted that none of the odours tested activate the trigeminal nerve, i.e. this is truly a test 
of olfactory nerve and olfactory system function.  Training in administration of the UPSIT was 
provided by the outpatient department of the Royal National Ear, Nose and Throat hospital 
(UCL).
Cognitive function was assessed with 2 well recognised questionnaires, the Mini Mental State 
Examination (MMSE) and the Montreal Cognitive Assessment (MoCA).  Each questionnaire 
was administered according to the author’s protocols.   Mild cognitive impairment on the MoCA 
was a score less than 26 while dementia was taken as a score less than 24, as recommended by 
the authors of the test.  Dementia on the MMSE was taken as a score less than 24, as 
recommended by the original authors of the test. 
 
Each participant was assessed for features of parkinsonism by a structured physical examination 
using the Movement Disorders Society-Unified Parkinson’s Disease Rating Scale (MDS-
UPDRS).  The participants’ facial expression, speech and general movements are assessed for 
parkinsonian features such as bradykinesia.  The participant is asked to make a series of 
repetitive movements of their arms and legs to assess for bradykinesia (slowed movements, 
interrupted movements, decremental amplitude).  The limbs are assessed for rest, postural and 
kinetic tremor.  Posture, gait and balance are rated.  Each item is scored from 0 (normal) – 4 
(most severely affected).  Individuals found to have signs of PD then had a complete 
neurological examination (including reflexes, cerebellar signs, cranial nerves et al).  In addition 
the presence of isolated motor signs which did not meet the full diagnostic criteria for 
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Parkinson’s disease were noted: for example isolated rest tremor, isolated rigidity or clear 
gait/postural disturbances.  Training on administration of the UPDRS was obtained by viewing 
the training videos on the Movement Disorders Society website 
(http://www.movementdisorders.org/).
Subtle motor dysfunction was assessed using 2 timed motor tests.  For the upper limbs the 
Purdue pegboard was used.  This requires the participant to place as many pegs as they can into a 
row of holes in 30 seconds.  Using their dominant hand then their non-dominant hand and then 
both hands simultaneously.  This was performed with the participants seated comfortably in front 
of a desk.  For the lower limbs a timed 3-metre walk was used.  In this the participant sits in a 
chair, stands, walks 3 metres then turns and returns to sit.  The participant is instructed to walk at 
a normal brisk pace for them. Patients with painful bone or joint disease inhibiting movement 
were excluded from the timed motor tests.    
Symptoms of autonomic dysfunction were screened for using the autonomic subscale of the 
Unified Multiple Systems Atrophy Rating Scale (UMSARS).  This asks about the presence of 
constipation, urinary dysfunction, erectile dysfunction and orthostatic symptoms. The REM 
Sleep Behaviour (RBD) questionnaire was administered to detect symptoms of RBD in the study 
cohort. 
Determination of age related risk of Parkinson’s disease in heterozygous GBA mutation 
carriers
Family history data on the health status and current age or age and cause of death was obtained 
for parents of patients with Type I GD using standard clinical family history technique.  A 
Kaplan-Meier analysis was performed using PASW (version 20.1, IBM) to define the age related 
risk of PD in these obligate carriers.  
Clinical phenotyping of PD cases with GBA mutations 
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Study participants with PD who did or did not carry a heterozygous GBA mutation were assessed 
identically. All had a full neurological history and neurological examination to assess age of 
onset and clinical features of the Parkinsonian syndrome affecting them.  The full UPDRS, 
UPSIT, MoCA, RBD questionnaire and the non-motor symptoms scale were applied to assess 
the motor and non-motor phenotype of these individuals in detail.  
Optical Coherence Tomography
OCT was performed by Dr Gloria Roberti and Dr Gerassimos Lascaratos (under Prof Garraway-
Heath) at Moorfields Eye Hospital. OCT was performed using Fourier domain OCT (RTVue-
100, Optovue Inc, Fremont, CA). OCT was performed with dilated pupils in both eyes, after en-
suring that intra-ocular pressure was normal and visual fields were full. The ganglion cell com-
plex thickness (GCC), which extends from the internal limiting membrane to the inner nuclear 
layer, and retinal nerve fiber layer (RNFL) thickness were measured as markers of retinal degen-
eration. Exclusion criteria were intraocular pressure ≥ 22 mmHg in either eye; evidence of a re-
producible visual field defect in either eye; a myopic refractive error exceeding -8.00 D; in-
traocular surgery in the study eye; history of ocular trauma in the study eye. Mean GCC and 
RNFL thickness were compared between groups using a student’s t-test (IBM, PASW version 
20.0). Both eyes from each individual were included in the analysis.
DaTSCAN imaging in monogenetic PD
We formed a consortium of Movement Disorders and Neurogenetics centres from Western 
Europe, South America and Asia to identify a large series of monogenetic PD cases.  Mutations 
in GBA, SNCA, LRRK2, Parkin, or PINK1 were identified by molecular genetic sequencing 
according to standard clinical protocols.  From amongst such patients individuals who had been 
imaged with DaTSCAN as part of their initial clinical evaluation were identified by retrospective 
chart review.    
A region of interest (ROI) analysis was performed using Image J (NIH, Bethesda, MD). Four 
ROIs were anatomically defined: right and left caudate, right and left putamen. To permit 
calculation of background signal a region of occipital cortex was designated as a 5th ROI.  The 
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outcome measure was the specific-to-nondisplaceable binding ratio V3” (ROIstriatum – 
ROIoccipital/ROIoccipital).  For each ROI, 4 transaxial slices were analysed. Four slices 
showing the most intense radiotracer uptake were selected for analysis from each case.   For each 
case the right:left asymmetry index (ASI, most severely affected ROI V3”/least severely affected 
ROI V3”) was calculated.  The whole striatal asymmetry index was also calculated (SASI: 
(ipsilateral-contralateral striatum V3”)/((ipsilateral+contralateral striatumV3”)/2)*100%) 
Images were analysed blind to the genetic diagnosis by a single investigator (AM), apart from 
the SNCA scans which were reported by SB.  Ethical approval was granted by the relevant bodies 
from each participating centre.  Written informed consent was taken from each participant.      
Statistical analysis was performed with PASW 20.1 (version 20, IBM).  Differences in ASI 
between genotypes were sought using the Mann-Whitney U-test. Significance was taken at the 
5% level (p=0.05), with bonferroni correction (i.e. p=0.05/n where n=number of comparisons). 
The SASI was compared between genotypes with a linear regression analysis. Correlations 
between disease duration and with SASI were sought using Spearman's correlation.       
   
General statistical analysis of prodromal markers
All analysis were performed using PASW (SPSS version 20.1, IBM). Statistical advice was 
provided by Dr Fox, Education Unit UCL Institute of Neurology.  
UPSIT, MoCA, MMSE, UPDRS, RBD and UMSARS scores are not normally distributed. 
Differences between groups in the assessed marker were tested for with a Kruskall-Wallis test 
(the non-parametric equivalent of ANOVA).  Post-hoc testing with a Mann-Whitney U-test was 
then performed.  Since multiple comparisons were made Bonferroni correction was applied, 
being 0.05/n (where n is the number of comparisons made). Two comparisons were made for 
each null hypothesis tested (controls versus GD and controls versus carriers) so significance at 
the 5% level was taken as a p value of 0.025.  
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Categorical variables were compared using the chi-squared test. Bivariate correlations between 
prodromal markers were investigated using Spearman's test.  Bonferroni correction was not 
applied to chi-squared or correlation statistics.  All results are quoted as mean +/- 1 SD or median 
and interquartile range.  
Ic. Results
Demographic, Clinical & Molecular Genetic Characteristics Of Patient Cohort
A total of 83 previously diagnosed GD Type I patients (female 37: male 46, mean age 49.1 +/- 
15 years, range 18-89 years) were initially recruited. Of these the following 6 individuals were 
excluded from the study of prodromal markers: GD7 and GD9 were both recent immigrants from 
Eastern Europe and so not familiar with the U.K SIT and there was a prohibitive language 
barrier, GD15 and GD43 were brothers and excluded as they had the R262G/R262G genotype 
not typical of Type I GD,  GD43 as he had L444P/L444P genotype typical of Type II GD and 
GD26 as he was under the age of 18 years.  Additionally 2 GD patients gave family history data 
and blood but refused the phenotyping study.  The GD patients with atypical genotypes were 
enrolled in the family history study as they could provide family history data and had parents 
who were willing to participate as obligate carriers.     
Thus for the study of prodromal markers 75 patients with Type I GD were enrolled (female 40: 
male 35, mean age 50.9 +/-14 years, range 22-89 years) and  41 carriers (female 24: male 17, 
mean age 61 +/- SD 11.9 years, range 40-81 years).  The mean age of the carriers was 
significantly older than that of the GD patients (students t-test, P<0.0001), as expected given that 
the carriers were the parents of the GD patients. Thirty four age/sex matched controls (male 16 : 
female 18, mean age 56.6 +/- 14 years, range  23 – 88 years) were recruited.  The controls were 
age matched to the GD cases (students t-test, p=0.062) and carriers (students t-test, p=0.1).  The 
controls were sex matched to both the GD cases and controls.  None of the study cohort or 
controls had been previously diagnosed with PD or dementia.  The controls were free of any 
neurological or systemic disease which might impair cognitive or motor function. Controls were 
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recruited from the following sources: non-carrier relatives of GD patients (7/34, 20%), relatives 
of PD patients (10/34, 29%), non-carrier members of the U.K. Gaucher Disease association 
(2/34, 5.8%) and volunteers from laboratory and office staff at the Department of Clinical 
Neurosciences, UCL (15/34, 44%).   Of the GD patients 17/83 (20%) were of Ashkenazi Jewish 
descent, 5/83 (6.25%) were Eastern European, 2/83 (2.5%) South African, 1/83 (1.25%) Afro-
Carribean, 1/83 (1.25%) Sri Lankan and the remainder white UK born who had no recorded 
Ashkenazi heritage (55/83, 68.75%).   Among carriers 6/41 (17%) were Ashkenzi Jewish, 1 
Eastern European and 1 Afro-Carribean with the remainder (33/41, 75%) white UK born 
individuals with no recorded Ashkenazi heritage.  Among controls 7/34 (20%) were Ashkenazi 
Jewish while the remainder where White, UK citizens with no reported Jewish ancestry.  The 
controls were matched by ethnicity to both the GD cases and carriers.      
For GD patients the majority (65/83, 78%) had at least one N370S allele, with the most common 
genotype being N370S/L444P (17/83, 20.5%) followed by N370S/N370S (14/83, 16.8%).  The 
remainder were compound heterozygous for N370S and a rare point mutation on the second 
allele. In addition 5 patients carried novel GBA mutations with the following genotypes: 
N370S/IVS9+1, R262G/L444P,  N370S/A341V,  N370S/V447E, N370S/G250V.  None of the 
GD patients had clinical features of Type III disease such as generalised seizures or progressive 
myoclonic epilepsy, but formal oculomotor testing was not available. Table 2 summarises the 
clinical and molecular genetic features of the GD patients.  For carriers the most common 
genotype was  N370S (15/41,   36%).   Clinical and molecular genetic data for the carriers are 
summarised in table 3. The presence of a GBA mutation in carriers and absence of a GBA 
mutation in control subjects was confirmed by sequencing of the GBA gene.  
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Table 3. Clinical, demographic and genetic characteristics of GD patient cohort.
Case Age, 
sex
Age 
onset
Family 
History
Genotype Splenectomy Bone 
disease
Rx
GD01 30, M 5 D (f) N370S/c1226A>G No No ERT
GD02 49, M 37 N370S/c1263del55 No Yes ERT
GD03 25, M 20 N370S/R496H No No ERT
GD04 56, F 24 N370S/N370S No Yes ERT
GD05 66, M 47 PD (gf) N370S/N370S Yes Yes ERT
GD06 69, F 16 N370S/L444P Yes Yes ERT
GD07^ 19, F 5 N370S/D409H Yes Yes ERT
GD08 56, F 16 N370S/84GG Yes Yes ERT
GD09^ 21, M 5 N370S/D409H No Yes ERT
GD10 49, F 5 N370S/N370S No Yes SRT
GD11 53, F N370S/? Yes Yes ERT
GD12 49, M 10 D (f) N370S/N370S No Yes ERT
GD13 56, F 29 L444P/F216Y Yes Yes ERT
GD14 76, M 10 N30S/N370S No Yes ERT
GD15* 50, M 48 PD (m) L444P/R262G No Yes ERT
GD16 88, F 87 N370S/ins intron 6 No Yes Nil
GD17 25, M 24 N370S/RecNil Yes No ERT
GD18 88, F 73 N370S/N370S No Yes ERT
GD19 58, F 50 N370S/M123T No Yes ERT
GD20 50, M 5 PD(gm) R463C/RecNil Yes Yes ERT
GD21 25, F 14 PD(gf) N370S/A341V No Yes ERT
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GD22 20, F 20 W184R/W184R No Yes ERT
GD23 54, F 6 N370S/V447E Yes No SRT
GD24 71, M N370S/N370S No Yes ERT
GD25 56, F 30 D (f) N370S/L444P No Yes ERT
GD26# 16, M 5 N370S/R120Q No Yes ERT
GD27 67, F 51 L444P/R463C Yes Yes ERT
GD28* 23, M 10 L444P/L444P No Yes ERT
GD29 41, F 41 R469H/R359X No No ERT
GD30 61, F 5 N370S/N370S Yes Yes ERT
GD31 46, M 27 N370S/L444P No Yes ERT
GD32 48, M 27 N370S/L444P Yes Yes ERT
GD33 51, F 38 N370S/? No Yes Nil
GD34 47, M 45 R463C/596delCT No Yes Nil
GD35 81, M 5 N370S/L444P No Yes ERT
GD36 84, F 80 N370S/N370S No No ERT
GD37 35, M 13 N370S/L444P No Yes ERT
GD38 45, F 37 PD (f) N370S/L444P No Yes ERT
GD39 52, M 50 D (f) N370S/L444P No Yes ERT
GD40 43, F 38 N370S/L444P No Yes ERT
GD41 49, M 11 N370S/R463C Yes Yes ERT
GD42 58, M 40 N370S/N370S No Yes ER
GD43* 47, M 45 PD (m) L444P/R262G No Yes ERT
GD44 56, F N370S/L444P No Yes ERT
GD45 41, M 30 N370S/L444P No Yes ERT
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GD46 53, F 34 N370S/N370S No Yes SRT
GD47 38, M 5 N370S/D409H No Yes ERT
GD48 43, F N370S/? No Yes Nil
GD49 62, M 8 N370S/? Yes Yes Nil
GD50 47, F 30 N370S/G250V No Yes ERT
GD51 47, M 39 N370S/inversion Yes Yes ERT
GD52 49, M 55 N370S/L444P No Yes ERT
GD53 44, M 28 N370S/L444P No Yes ERT
GD54 43, M 28 N370S/RecNil No Yes ERT
GD55 56, M 37 PD(gm) N370S/? No Yes ERT
GD56 60, M 44 203InsC/N370S No Yes ERT
GD57 32, M 10 N370S/D380A No Yes No
GD58 35, M 10 N370S/N370S No Yes Yes
GD59 30, F 5 N370S/D409H No Yes Nil
GD60 34, M 30 N370S/N370S No No Yes
GD61 53, M N370S/84GG No Yes ERT
GD62 48, M N370S/N370S No Yes ERT
GD63 58, M N370S/P182T No Yes ERT
GD64 52, F N370S/L444P No Yes ERT
GD65 73, F N370S/D380N No Yes ERT
GD66 66, M PD(s) N370S/L444P No Yes ERT
GD67 56, F R496H/G202R No Yes ERT
GD68 48, F N370S/L444P No Yes ERT
GD69 57, F N370S/IVS9+1 No Yes ERT
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GD70 57, F N370S/L444P No Yes ERT
GD71 59, M N370S/L444P No Yes ERT
GD72 52, F N370S/84GG No Yes ERT
GD73 44, F N370S/R120W No Yes ERT
GD74 42, M P305R/L444P No Yes ERT
GD75 52, M N370S/L444P No Yes
GD76 67, M N370S/A318D
GD77 44, F N370S/?
GD78 50, M PD(f) N370S/RecNcil Fhx only
GD79 30, M c.154insACAGCT/?
GD80 70, F N370S/N370S
GD81 56, M N370S/c.329delCAGA
GD82 45, F R463C/RecNcil
GD83 44, M PD(m) R463C/IVS2+1G>A Fhx only
Key: PD = Parkinson’s disease, D=dementia, (f) = father, (m)=mother, (gf)=grandfather, 
(gm)=grandmother, (s)=sibling. *=excluded as genotype not typical for Type I GD, 
^=excluded as language barrier prohibited assessment, #=excluded as aged under 18 years. 
Fhx = family history only and no phenotyping performed.  
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Table 4. Clinical, demographic and genetic characteristics of carriers
Age, sex Ethnicity Mutation
C1 50, F White Splice site intron 9
C2 66, F Ashkenazi N370S
C3 58, F White N370S
C4 77, M White Splice site intron 2
C5 56, M Ashkenazi N370S
C6 56, F White W184R
C7 56, M White W184R
C8 58, F White N370S
C9 79, F White W184R
C10 57, F White N370S
C11 74, F Ashkenazi V394L
C12 56, F Ashkenazi V394L
C13 54, M White N370S
C14 69, F White N370S
C15 60, M White N370S
C16 69, M White R463C
C17 68, F White 595delC
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C18 69, F White N370S
C19 72, M White L444P
C20 72, F White N370S
C21 65, F White N370S
C22 65, M White L444P
C23 62, M White N370S
C24 53, F White RecNil
C25 66, M White RecNil
C26 64, F White N370S
C27 74, F White G250V
C28 74, M White N370S
C29 74, F Ashkenazi N370S
C30 62, M White L444P
C31 41, F Ashkenazi N370S
C32 42, F White L444P
C33 61, M White N370S
C34 52, F White RecNcil
C35 65, M N370S RecNcil
C36 64, F White N370S
C37 73, F White G250V
C38 73, M White N370S
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C39 78, F White N370S
C40 73, F Ashkenazi N370S
C41 60, M White L444P
Prodromal markers of Parkinson's disease in GD patients compared to controls
Results are summarised in figures 2-4. Compared with controls GD patients demonstrated an 
impairment of olfaction (control median 35.1 [interquartile range 34-37] vs GD median 31.5 
[interquartile range 30 – 36] Mann-Whitney U-test, P=0.004).  Three GD patients were excluded 
from the smell identification test as they were current smokers.  The median MoCA score was 
lower in GD patients versus controls (GD median 27 [IQR 24.5-28] vs control median 28 IQR 
[26.75-28.7], p=0.022). There was no difference in MMSE scores (GD median 30 [IQR 29-30] 
vs control median 29 [IQR 29 – 30], P=0.251).  
Four GD patients had signs compatible with early parkinsonism upon clinical examination. 
GD18 had bilateral rigidity with activation manoeuvre, postural tremor and gait impairment. 
GD35 had an asymptomatic left upper limb rest tremor and bilateral upper limb rigidity with 
activation manoeuvre.    GD52 had a flexed posture, bilateral rigidity, and a postural and kinetic 
tremor of the upper limbs. GD76 had asymmetrical rigidity of the upper limbs with activation 
manoeuvre and dragged the left leg when walking.  In addition the UPDRS part III (P=0.006) 
scores were significantly higher in GD patients (median 0 [IQR 0 – 2.75]) than age matched 
controls (median 0 [IQR 0-0]).  There was no difference in the UPDRS Part II scores (GD 
median 0 [IQR 0-0] vs control median 0 [IQR 0-0], P=0.035).
There was no difference on the score from the RBD questionnaire (GD median 0 [IQR 0 – 0] vs 
control median 0 [IQR 0 – 0], P=0.45) nor the UMSARS score between GD cases and controls 
(GD median 0 [IQR 0 – 0.5] vs control median 0 [IQR 0 - 0], P=.059).   Five GD patients gave a 
89
positive response to the RBD questionnaire using a cut off score of 5, which is suggestive of 
possible RBD, compared with none of the control group.  This was not significant on the chi-
squared test.   
Prodromal markers of Parkinson's disease in heterozygous carriers compared to controls 
Results are summarised in figures 2-4.  Compared with controls heterozygous GBA mutation 
carriers demonstrated an impairment of olfaction (carrier median 32 [IQR 27 - 35] vs control 
median 35.1 [IQR 34 - 37], P<0.001).  One Eastern European carrier was excluded from the 
smell identification test as he was not sufficiently familiar with the odours used for UK 
populations, 2 were excluded due to coryzal illness, 1 excluded as they were blind and unable to 
read the test card.  The MoCA demonstrated impaired cognition in carriers versus controls 
(carrier median 26 [IQR 24 - 27] vs control median 28 IQR [26 - 28.7], P=0.004), but  there was 
no overall difference in MMSE scores (carrier median 29.5 [IQR 28.75 – 30] vs control median 
29 [IQR 29 – 30], P=0.60).  One carrier was excluded from cognitive function testing due to 
blindness. 
Two carriers had physical signs compatible with early parkinsonism. C23 had bilateral rigidity, 
mask like facies and slow movements without decremental amplitude while C34 had minimal 
masked facies, bilateral rigidity with activation manoeuvre, left arm kinetic tremor and flexed 
posture. The UPDRS part III score was significantly higher in carriers than controls (carrier 
median 0 [IQR 0 – 2] vs control median 0 [IQR 0-0], P=0.004). There were no significant 
differences in the UPDRS part II (carrier median 0 [IQR 0 – 0] versus control median 0 [0-0], 
P=0.1), the UMSARS  (carrier median 0 [IQR 0 – 0] vs control median 0 [IQR 0 – 0], P=0.1) or 
the RBD questionnaire scores (carrier median 0 [IQR 0 – 0] vs control median 0 [IQR 0 – 0], 
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P=0.57) between carriers and controls.    No carrier gave a positive response to the RBD 
questionnaire using 5 as the cut off score.  
Timed motor tests in GD patients and carriers 
The average number of pegs placed in the Purdue pegboard in 30 seconds (number of pegs 
placed with right hand plus number placed with left hand divided by 2) differed significantly 
between controls, carriers and GD patients (Kruskal-Wallis, p=0.01).  Post-hoc testing 
demonstrated a trend for GD patients to place fewer pegs than controls (GD patients median 
13.74 [IQR 13 – 15] vs control median 14.5 [IQR 13.4 – 15.5], Mann-Whitney, p=0.047) while 
carriers placed significantly fewer pegs than controls (carrier median  13 [IQR 11.5 – 14.5] vs 
control median 14.5 [IQR 13.4 – 15.5]  Mann-Whitney, p=0.001). 
The time taken to complete the 3-metre walk test differed significantly between the control, 
carrier and GD groups (Kruskal-Wallis, p=0.001).  Post-hoc testing revealed that it took 
signifcantly longer for carriers (median 8 seconds [IQR 7 – 8 seconds, Mann-Whitney, p<0.001) 
and GD patients (median 8 seconds [IQR 7-8], Mann-Whitney, p<0.0001) to complete the 3-
metre walk than controls (median 6 seconds [IQR 6 - 7]). 
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Figure 3.  Box plot of UPSIT scores in Gaucher disease patients and carriers versus 
controls.
GD patients (median 31.5, IQR 30-36) and heterozygous mutation carriers (median 32, 
IQR 27-35) demonstrated a significan impairment of olfaction compared to controls 
(median 35.1, IQR 34-37).
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Figure 4. Box plot of UPDRS Part III score in Gaucher disease patients and carriers versus 
controls.
GD patients (median 0, IQR 0-2.75) and heterozygous carriers (median 0, IQR 0-2) had 
significantly higher UPDRS part III scores than controls (median 0, IQR 0-0)
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Figure 5. Box plot of MoCA scores in Gaucher disease patients and carriers versus control. 
GD patients (median 27, IQR 24.5-28) and heterozygous carriers (median 26, IQR 24-27) 
scored significantly less on the MoCA than controls (median 28, IQR 26.75-28.8). 
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Comparison of Montreal cognitive assessment domains between GD, carriers and controls
The MoCA subscale scores (given as median and IQR) for GD patients and carriers compared to 
control are given in Table 4.   Differences in subscale scores were examined using the Mann-
Whitney U-test.  Significant differences are highlighted in bold.  
Table 5. Montreal cognitive assessment subscale scores. 
Control GD Carrier
Executive 5, 4-5 5, 4-5, P=0.159 5, 3-5, P=0.129
Memory 3, 3-3 3, 3-3, P=0.558 3, 3-3, P=0.236
Naming 3, 2-4 3, 1-4, P=0.304 3, 1-4, P=0.409
Attention 6, 6-6 6, 5-6, P=0.004 6, 5-6, P=0.007
Language 3, 3-3 3, 2-3, P=0.029 3, 2-3, P=0.042
Abstraction 2, 2-2 2, 2-2, P= 0.879 2, 1-2, P=0.016
Orientation 6, 6-6 6, 6-6, p=0.32 6, 6-6, P=0.236
Correlations between olfactory, cognitive and motor function in GD patients and carriers
Several GD patients and carriers had more than one clinical marker of neurodegeneration, 
statistical associations were therefore sought between them.  Statistically the UPSIT score was 
correlated negatively with UPDRS part III  in GD patients (Spearman's rho -0.46, p<0.001) and 
carriers (Spearman's rho -0.41, p=0.011), ie lower olfactory function scores were associated with 
higher UPDRS part III scores.  The UPSIT and MoCA were positively correlated in GD patients 
(rho=0.257, p=0.034) and the correlation approached significance in carriers (rho=0.326, 
p=0.052).  
In GD the number of pegs placed in the purdue pegboard was negatively correlated with the 
UPDRS III score (Spearman's rho -0.44, P<0.001) and approached a significant negative 
correlation in carriers (Spearman's rho = -0.339, P=0.058).  The  number of pegs placed 
correlated positively with UPSIT scores in GD (rho = 0.288, P=0.03)  and carriers (rho = 0.549, 
P=0.002).   
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The time taken for the 3 minute walk correlated positively with UPDRS III scores in GD (rho = 
0.434, P=0.004) and carriers (rho = 0.381, P=0.024).  There was no correlation of the 3 minute 
walk time with UPSIT scores in GD (rho= -0.37, p=0.8) or carriers (rho =-0.179, p=0.3). The 3-
minute walk  was correlated negatively with the pegboard score in GD (rho =-0.478, p=0.002) 
but there was no correlation in carriers (rho = -0.21, p=0.234).  
Table 5 describes the numbers of individuals who expressed one prodromal marker in isolation 
or who manifested combinations of markers.  Hyposmia was defined as an UPSIT score less than 
the 15th centile expected for age and sex and dementia as a score <24/30 on the MoCA.  No 
controls scored in the hyposmia or dementia range. 
Table 6. Summary of prodromal markers of Parkinson’s disease occurring in isolation and 
combination. 
GD Carrier
Isolated hyposmia 
(score <15th centile for 
age/sex)
5/75 (6.6%) 5/41 (12%)
Isolated dementia
(score <24/40 on MoCA)
4/75 (5.3%) 2/41 (4.8%)
Isolated clear motor sign
(e.g. rest tremor)
2/75 (2.6%) 1/41 (2.4%)
Hyposmia &  cognitive 
impairment
1/75 (1.3%) 2/41 (4.8%)
Hyposmia  & clear motor sign 1/75 (1.3%) 0/41
Hyposmia, cognitive 
impairment and clear motor 
sign
1/75 (1.3%) 0/41
Cognitive impairment & clear 
motor sign
1/75 (1.3%) 1/41 (2.4%)
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Correlations between age and neurodegenerative markers in Gaucher disease
Since Parkinson's disease is strongly age related, correlations between age of GD patients and 
abnormalities in neurodegenerative markers were sought. UPSIT scores demonstrated a 
significant negative correlation  with age in GD patients (rho = -0.269, P=0.030).  Higher 
UPDRS part III scores were strongly correlated with increasing age in GD patients (rho = 0.50, 
P=<0.001) while MoCA scores had a significant negative correlation with age (rho = -0.44, P 
<0.001).  The UPSIT scores in carriers had a significant negative correlation with age (rho = 
-0.43, p=0.009).  Neither the UPDRS part III score (rho = 0.251, p=0.124) nor the MoCA score 
correlated with age (rho = -0.25, p=0.124) in carriers.  The UPSIT score did not correlate with 
age in controls (rho = 0.15, p=0.4), neither did UPDRS III (rho =0.07, p=0.7) score or the MoCA 
score (rho =0.04, p=0.8).  
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Optical coherence tomography in Gaucher disease patients
Eleven GD (5 female, mean age 63.7 years, range 45-89 years, 6/11 N370S/N370S genotype and 
remainder N370S/L444P) and 7 healthy controls with no history of neurological disease matched
for age (mean age 67, range 51-85, p=0.9 vs GD) and sex (4 female) were studied. None had
ocular pathology. Four of the GD patients had clinical markers of prodromal PD; 1 with
hyposmia, 1 with cognitive impairment, 1 with hyposmia and cognitive impairment, 1 with
rigidity, flexed posture and postural tremor. None of the participants met diagnostic
criteria for PD. 
The mean GCC thickness for all GD patients (mean 92 +/- 7 uM) did not differ
from controls (mean 93.4 +/- 8 uM, p=0.6). Mean GCC thickness for GD patients with
neurological signs (86+/-7 uM) was significantly less than that of controls (p=0.044) or GD
patients without neurological signs (93.6+/-5 uM, p=0.024) (figure 5). Mean RNFL thickness
was significantly less in GD patients with a prodromal sign (91.28 +/-6.5uM, p=0.03) than
controls (mean 105+/-16 uM) but not GD patients without a sign (100+/-8 uM, p=0.3). The
difference in the mean GCC and RNFL thickness remained significant after correcting for the
participants’ refractive error.
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Figure 6. Mean Ganglion Complex Thickness in GD compared to control.
Bars represent mean and 95% confidence intervals.  Note decreased mean ganglion 
complex thickness in GD patients with a prodromal sign of PD compared to both controls 
and GD patients without a sign.  
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Demographic, Clinical & Molecular Genetic Features of Parkinson's disease patients with 
GBA mutations
Sequencing of the GBA gene in 220 cases of typical PD from the Royal Free Hospital Movement 
Disorders database identified 12  PD patients with a heterozygous GBA mutation (designated 
PD-GBA) of whom 9 were available for enrolment into this study.  Three parents of GD patients 
were identified who had PD. Giving a cohort of 12 PD-GBA for phenotyping (5/12 female, mean 
age 65 (range 49-81 years), 1/12 (8%) Ashkenazi Jewish, mean disease duration 8 years (range 
2-15). Twenty of the 208 GBA mutation negative PD cases were selected as controls (7/20 fe-
male, mean age 65 (range 50-83), 2/12 (10%) Ashkenazi Jewish, mean disease duration 9 years 
(range 2-20years), designated as sporadic PD (PD-S). All PD cases in the Royal Free Hospital 
Movement Disorders database had previously had the G2019S LRRK2 mutation excluded by dir-
ect sequencing.   Table 6 summarises the characteristics of the PD-GBA cases.  Mutations in the 
PD-GBA group who underwent clinical phenotyping were: N370S (5/12, 42%), L444P (2/12, 
16%), recombinant alleles (2/12, 16%), R496H (1/ 12, 8.3%), V460L (1/12, 8.3%) and IVS2+1 
(1/12, 8.3%).  
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Table 7. Clinical and genetic characteristics of PD-GBA and PD-S patients
PD-GBA (n=12) PD-S (n=20) Significance
Sex 5F:7M 7F:13M P=0.067
GBA Mutation (number) N370S (5)
L444P (2)
Recombinant (2)
IVS2+1 (1)
V460L (1)
R496H (1)
None
Age (mean, range) 65, 49-81 65, 50-83 P=0.90
Family history (%) 2/12, 16% 2/20, 10% P=0.06
Disease duration 8, 2-15 9, 2-20 P=1.0
UPDRS Part I score
(median, interquartile range)
8, 5-14 9, 5-14 P=0.95
UPDRS Part II score
(median, interquartile range)
17, 9-24 18, 9-20 P=0.67
UPDRS part III score
(median, interquartile range)
33, 26-35 34, 30-46 P=0.13
UPDRS Part IV score
(median, interquartile range)
1, 0-5 0, 0-1 P=0.135
On L-dopa treatment 8/12, 75% 12/20, 60% P=0.067
On dopamine agonist
SIT score
(median, interquartile range)
16 15 P=0.50
MoCA  score
(proportion <26/30)
7/12, 58% 5/20, 25% P=0.0014*
NMSS score
(median, interquartile range)
104, 69-134 38.5, 16.25-60 P=0.002*
RBDQ score
(proportion score >6/10)
7/12, 58% 1/20, 5% P=0.0016*
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All PD patients enrolled had a classical phenotype of idiopathic PD which met Queen Square 
Brain Bank criteria (Hughes et al, 1992). Two of the PD-GBA patients had an autosomal domin-
ant family history of PD.  All PD patients were assessed in the “on” state. The motor phenotype 
of these individuals was very similar to sporadic PD, and none had features of a “Parkinson’s 
plus” syndrome.  None had cranial nerve palsies, pyramidal signs or clinical evidence of peri-
pheral neuropathy.  Seven of the 10 PD-GBA patients had a tremor predominant phenotype while 
3/10 had a predominant bradykinetic-rigid phenotype.  Of the 7 tremulous patients 4 had typical 
rest tremor of the upper limbs while 3 had action tremor of the upper limbs.  The PD-GBA and 
PD-S cases were matched for use of levo-dopa (75% vs 60%, p=0.067) and UPDRS parts I (PD-
GBA median 8 vs PD-S 9, p=0.95), II (17 vs 18, p=0.067), III (33 vs 34, p=0.13) and IV scores 
(1 vs 0, p=0.13). No patient had deep brain stimulation but two PD-GBA patients were on select-
ive serotonin reuptake inhibitors for depression. The degree of hyposmia in the PD-GBA and 
PD-S cases was identical (UPSIT score median 16/40 vs 15/40, Mann-Whitney U-test p=0.503). 
Using a cut off score of 26/30 on the MoCA, significantly more PD-GBA had cognitive impair-
ment than PD-S (7/12 [58%] vs 5/20 [25%], chi-squared test p = 0.014).  PD-GBA scores for ab-
straction (p=0.034) and orientation (p=0.022) were significantly lower.  The overall NMSS score 
was higher for PD-GBA than PD-S (median 104 [interquartile range 69-134] vs 38 [16-60], p = 
0.002).  PD-GBA reported more symptoms per participant than PD-S (median 13 [range 1-19] 
versus median 7 [range1-14], p=0.0012). The following were more common in PD-GBA: falls 
with loss of consciousness (25% vs 0%, p=0.04), fatigue (92% vs 30%, p=0.001), unexplained 
pain (58% vs 10%, p=0.005), loss of interest in life (66% vs 5%, p=0.0004), anxiety (66% vs 
20%, p=0.02), apathy (50% vs 10%, p=0.03).  Using the recommended cut off score of 5/10, 
more PD-GBA participants screened positive for REM sleep disorder than PD-S (7/12 [58%] vs 
1/20 [5%], p= 0.0016).  
The MoCA subscale scores were compared between PD-GBA and PD-S in table 7.  Results are 
given as median with IQR. Differences in MoCA subscale scores were examined with the Mann-
Whitney U-test.  
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Table 8. Montreal cognitive assessment subscale scores in PD-GBA compared to PD-S
Control PD-S Controls PD-GBA Significance GBA vs 
sporadic PD
Executive 5, 4-5 4, 3.75 – 4.25 3.5, 2-5 P=0.59
Memory 3, 3-3 2.5, 2-4 3, 2-3 P=0.89
Naming 3, 2-4 3, 3-3 3, 3-3 P=1.0
Attention 6, 6-6 6, 5-6 5, 4-6 P=0.2
Language 3, 3-3 3, 3-3 3, 3-3 P=0.58
Abstraction 2, 2-2 2, 2-2 3, 2-3 P=0.034
Orientation 6, 6-6 6, 6-6 5, 4-6 P=0.022
Determination of age related risk of Parkinson’s disease in carriers of heterozygous GBA 
mutations 
Data on 166 parents of Type I GD patients was available (17/83 [20%] families Ashkenazi 
Jewish, 5/83 [6%] Eastern European and the remainder White UK citizens, no consanguineous 
families).  Eighty-three families were enrolled in the family history study as 2 GD probands 
consented to give family history but not to other parts of the study.  A PD case was defined by 
the proband reporting a definite medical diagnosis in their parents.  Ten cases of PD were 
identified in obligate carriers, 3 were examined in person to confirm diagnosis (these are 
included in the cohort of 12 PD-GBA described above).  Of the 10 cases of PD in relatives 5 
were male (50%), and mean age of onset was 67 (standard deviation 8.6 years). Figure 6 shows a 
kaplan-Meier analysis for developing PD for men and women combined.  Age related risk of PD 
peaked at age 80 (15%). Based on the London population (5) 0.33 cases of PD would be 
expected in our cohort of 166 (derived from lifetime prevalence of      2/1 000 for men and 
women).  This gave a life time relative risk of 30 (95 % CI 7-122).
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Figure 7.  Kaplan-Meier analysis of age related risk of developing Parkinson’s disease. 
Risk is derived from family history data on 166 obligate carriers of glucocerebrosidase 
mutations (parents of Type I Gaucher disease patients), combined for men and women. 
Overall lifetime RR of Parkinson’s disease was 30 (95% CI  7 to 122) in carriers compared 
to the London population.
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DaTSCAN imaging in monogenetic PD
Clinical and genetic characteristics of the 36 monogenetic PD patients enrolled are given in 
Table 8.    Control DaTSCAN images were available from 12 individuals without neurological 
disease from the European Nuclear Medicine Consortium (provided by Dr John Dickson, 
Nuclear Medicine Department University College London Hospital). All scans were performed 
according to standard clinical protocols.   All of the DaTSCANS utilised in the current study had 
previously been reported as showing reduction of radioligand binding compatible with PD. 
Ethical approvals were obtained at each centre and written informed consent taken as required. 
The PINK1 (Samaranch et al, 2010), heterozygous GBA mutation associated PD (McNeill et al, 
2012b), Brazilian Parkin and LRRK2 patients (Barsottini et al, 2009), SNCA cases 
(Bostantjopoulou et al, 2008) and Italian Parkin cases (Varrone et al, 2004) have been reported 
previously.  
The age at assessment of the GBA group (50+/-13 years) was not significantly older than the 
Parkin group (44+/-14, p=0.14), PINK1 (42+/-17, p=0.07), LRRK2  (40+/-7, p=0.40) or SNCA 
(47 +/-7, p=0.58) groups.  The proportion of men in the GBA mutation group (7/7, 100%) did not 
differ from that of the  Parkin (9/12, 75%), PINK1 (5/7, 71%, p>0.05), LRRK2 (2/2, 100%, 
p>0.5) or SNCA (5/8, 62.5%)  groups.   The disease duration did not differ between groups (one 
way ANOVA, F=2.3, p=0.076). The UPDRS part III scores for the PINK1 group were 
significantly lower than the other genetic subgroups (p<0.05 for all comparisons with Bonferroni 
correction).     There was no difference between the proportion of patients in each genetic 
subgroup taking levo-dopa.  The control group were all of Western European ancestry but were 
matched to the PD group for age (52+/-12 years, p>0.05) and sex (7/12 male, chi-squared test 
p>0.05).
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A comparison of  right:left asymmetry index (ASI) and whole striatal asymmetry index (SASI) 
between genotypes was performed.  Table 9, figure 7 and figure 8 describe the ASI  for putamen 
and caudate and SASI  for each group.  Figure 9 shows representative DaTSCANS from 
monogenetic PD cases. 
The caudate ASI for the PD cases with GBA mutations (Mann-Whitney U-test, median ASI  0.42 
[0.33-0.56], p<0.001)  or LRRK2 G2019S mutations (0.75 [0.59-0.86], p=0.005) was 
significantly different to the control value of 0.92 (interquartile range 0.89-0.92). The caudate 
asymmetry indices for PD with bi-allelic Parkin (median 0.88 [0.72-0.93]. p=0.098), PINK-1 
(median 1.0 [0.9-1.13], p=0.065) or SNCA (median 1.02 [0.9-1.13], p=0.91) did not differ from 
the control value. This indicates an asymmetric reduction of radioligand uptake in the caudate of 
PD associated with GBA and LRRK2  mutations with a relatively symmetrical reduction in ligand 
uptake in the caudate of PINK1, Parkin and SNCA mutation associated PD.  
The putamen ASI for PD cases with GBA mutations (median 0.18 [0.08-0.33], p<0.001) and 
LRRK2  (median 0.49 [0.13-0.5], p=0.01) differed significantly from the control value (median 
0.89 [0.82-0.96]).  The putamen ASI for bi-allelic Parkin  (median 0.6 [0.1-1.0], p=0.68), 
PINK1 (median 1.05 [0.9-1.4], p=0.14) and SNCA (median 1.05 [0.92-1.22], p=0.30) mutation 
associated PD did not differ from control values (median 0.89 [0.82-0.86]).  This indicates an 
asymmetric reduction of radioligand uptake in the putamen of PD associated with GBA and 
LRRK2  mutations with a relatively symmetrical reduction in ligand uptake in the putamen of 
PINK1, Parkin and SNCA mutation associated PD.  
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To further explore these findings, the whole striatum asymmetry index (SASI) was calculated. 
A linear regression analysis demonstrated a significant difference in the SASI between genotypes 
(r-squared = 0.233, p<0.001).     The highest SASI value was for PD-GBA (mean 80.5+/-5.1), 
followed by LRRK2 G2019S (44.6+/-5.3), Parkin (32.7+/-5.6), PINK1 (13.16+/-4.4), SNCA 
(13.4+/-3.9) and controls (8.3+/-2.7).  This supports the results from the caudate and putamen 
ASI which demonstrate that loss of radioligand uptake is relatively asymmetrical in PD 
associated with GBA and LRRK2 G2019S mutations and relatively symmetrical in Parkin, 
PINK1 and SNCA.    
To investigate clinical variables which may confound the relationship between genotype and 
dopaminergic neuronal imaging symmetry, correlations between SASI and patient characteristics 
were sought.  There was no correlation between disease duration (Spearmans rho 0.09, p=0.60) 
or patient age at evaluation (Spearmans rho 0.15, p=0.2)  and SASI.    
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Table 9. Clinical, demographic & genetic characteristics of Parkinson’s disease patients 
who underwent DaTSCAN. 
GBA PARKIN PINK1 LRRK2 SNCA
Male 7/7(100%) 9/12 (75%) 5/7(55%) ½  (50%)
 
5/8 (62.5 %)
Age at scan 50+/-13 years 44+/-14 years 42+/- 17 years 32 and 53 47.1+/-7.5
Disease 
duration 
7+/- 4 years 14.5+/-10 12.3+/- 11 years 5 and 11 7.4+/-2  years
Mutations N370S/L444P 
(1/7),
N370S (1/7),
L444P (1/7),
IVS2+1G>A(1/7),
E326K(1/7),
T369M (1/7),
R496H (1/7).
Del exon 3/del exon 3 
(1/12)
Del exon 3-4/del exon 
3-4
(1/12)
Del exon 3/del exon 2-3
(1/12)
Del exon 2/del exon 2-4
(1/12)
C820T/del exon 2 
(1/12)
G96C/C1305T (1/12)
R42P/R42P (3/12)
G429EfsX5/G429EfsX5 
(3/12)
1573insTTAG/1573insTTAG (1/7)
1488 + 1G>A/1488 + 1G>A (1/7)
1488+1G>A/1252_1488del (5/7)
G2019S (2/2) G209A (8/8)
L-DOPA 
use
4/7 (57%) 8/12 (66%) 5/9 (55%) 2/2 (100%) 8/8 (100%)
UPDRS III 13.7 +/-2 28.2+/-12.7 12.8 +/- 6 41 and 43 36.2+/-14
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Table 10. Summary of asymmetry index results for monogenetic Parkinson’s disease cases. 
GBA Parkin PINK1 SNCA LRRK2 Control 
CASI 0.42* 
[0.33-0.56]
0.88 [0.72-
0.93]
1.0 [0.9-1.13] 1.02 [0.9-1.13] 0.75* [0.59-
0.86]
0.92 [0.89-0.92]
PASI 0.18* 
[0.08-0.33]
0.6 [0.1-1.0] 1.05 [0.9-1.4] 1.05 [0.92-1.2] 0.49* [0.13-0.5] 0.89 [0.82-0.96]
SASI 80+/-5.1 32.7+/-5.6 13.1+/-4.4 13.4 +/-3.9 44.6+/-5.3 8.3+/-2.7
Key: CASI, PASI = right/left asymmetry index quoted as median and interquartile range 
for caudate and putamen, SASI = striatal asymmetry index quoted as mean and standard 
error. *= significantly different than ASI from control population (Mann-Whitney u-test, 
p<0.001). 
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Figure 8. Box plots of right:left asymmetry indices by genotype.
Top panel. Median right:left asymmetry indices for caudate nucleus for each genotype.    
Lower panel. Median  right:left asymmetry indices for the putamen for each genotype.  The 
caudate and putamen values for GBA and LRRK2  were significantly different to the 
control value (p<0.001).  
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Figure 9. Striatal Asymmetry index by genotype.
Striatal asymmetry index reported as mean +/- standard error.  The higher the index the 
greater the degree of asymmetry between right and left striatum.  A linear regression 
analysis demonstrated a significant effect of genotype on SASI (p<0.001). As can be seen 
from the graph GBA and LRRK2 genotypes have the highest SASI and so the greatest 
asymmetry of radioligand uptake.  
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Figure 10.  Representative DaTSCANS from monogenetic PD cases.
10a.  DaTSCAN from 50 year old man with PD-GBA, note marked loss of tracer uptake in 
right striatum.
10b. DaTSCAN from 67 year old woman with PINK1 mutation associated PD, note 
bilateral absence of tracer uptake in the putmanina and symmetric reduction in the 
caudate heads.
10a 10b
10c 10d
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10c. DaTSCAN from a 45 year old man with Parkin mutation associated PD, not 
symmetrical reduction of tracer uptake in caudate heads.
10d. DaTSCAN from a 32 year old man with LRRK2 G2019S mutation associated PD, note 
loss of tracer uptake in left caudate compared to right.
Id. Discussion
Discusion of significance of clinical markers of prodromal PD detected in GD patients and 
heterozygous GBA mutation carriers
Here  neurological features relevant to increased risk of developing a neurodegenerative disorder 
such as PD were studied in the largest cohort of GD patients and heterozygous GBA mutation 
carriers yet reported (McNeill et al, 2012a).  We demonstrate that hyposmia, cognitive 
dysfunction and parkinsonian motor signs are more frequent amongst GD patients and 
heterozygous GBA mutation carriers than age matched controls.  Both GD patients and carriers 
also performed significantly more slowly on the timed motor tests than control individuals. 
These clinical markers of prodromal PD were heterogeneously distributed, with a subset 
expressing more than one and the majority of individuals having no abnormalities on clinical 
testing. This may reflect a mixed population, with some individuals being in the early stages of a 
neurodegenerative disorder and others not.  
The potential markers of neurodegeneration studied have diverse aetiologies and a poor ability to 
predict development of PD. Therefore, only a minority of study participants with abnormal 
markers will be in the prodrome of a neurodegenerative disorder.  Hyposmia has been described 
in GD patients with PD (Saunders-Pullman et al, 2010), but there are no reports of hyposmia in 
non-parkinsonian GD patients or as a side effect of GD treatment. Only a minority of individuals 
with idiopathic hyposmia go on to develop a neurodegenerative condition.  In the Honolulu 
ageing study 10/549 hyposmic individuals developed PD (Ross et al, 2008)  while Ponsen et al  
(2004) found 10% of hyposmic first degree relatives of PD patients developed PD themselves. 
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Thus only a fraction of hyposmic GD patients and heterozygous carriers will have hyposmia due 
to a neurodegenerative prodrome.  
The cause, or causes, of hyposmia in the GD patients and heterozygous GBA mutation carriers 
could not be elucidated in the current study. However, current smokers and those with 
symptomatic disease of their upper respiratory tracts were excluded, thus minimising these 
potential confounding variables and there is no reported association between GD and upper 
respiratory tract pathology.  Obviously, there is an association between impaired cognition and 
impaired odour indentification.  While there was a correlation between UPSIT and MoCA score 
in our cohort, the fact that several GD patients and heterozygous GBA mutation carriers had 
isolated hyposmia demonstrates that hyposmia in our cohort was not solely due to cognitive 
impairment. In theory pathology involving any part of the olfactory tract from olfactory bulb to 
olfactory cortical areas could contribute to hyposmia.  Alpha-synuclein pathology in the 
olfactory bulb has been suggested as a cause of hyposmia in PD and it is possible that this 
process also occurs in GD and heterozygous GBA mutation carriers, since increased neuronal 
alpha-synuclein accumulation has been described in association with GBA mutations (Gegg et al, 
2012).  It is also interesting that in 2 GD mouse models infiltration of the olfactory bulb with 
activated microglia/macrophages is clearly described (Cabrera-Salazar et al, 2012;  Farfel-
Becker et al, 2011). Suggesting that the primary pathological process of GD might contribute to 
hyposmia in GD in addition to/instead of alpha-synuclein deposition.  However, this would not 
explain hyposmia in the heterozygous GBA mutation carriers.  Pathology involving olfactory 
cortical areas might also occur in GD and heterozygous GBA mutation carriers.  Clearly in the 
context of the current study, the most attractive hypothesis is that olfactory cortical areas become 
affected by alpha-synuclein pathology in GD patients and heterozygous mutation carriers.  In 
support of this, patients with Lewy-body dementia have been shown to develop hyposmia which 
is more marked than that observed in Alzheimer's disease, indepent from naming defects 
associated with cognitive impairment (Williams et al, 2009).  Moreover, alpha-synuclein/Lewy 
body accumulation and neuronal loss has been described in the hippocampus and temporal lobe 
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of GD patients (Wong et al, 2004).  The pathological basis of hyposmia in GD and heterozygous 
GBA mutation carriers remains to be defined.  This issue could be resolved by histopathological 
examination of olfactory bulb, olfactory tract and olfactory cortex tissue from GD patients and 
heterozygous GBA  mutation carriers.  However a lack of appropriate post-mortem tissue is likely 
to be a barrier to this.  Functional neuroimaging studies of cortical responses to olfactory stimuli 
could help detect olfactory cortex pathology/dysfunction contributing to hyposmia, but such 
studies are complex to perform and interpret.  In any event, the pathology causing hyposmia in 
GD and  heterozygous GBA mutation carriers is perhaps of less interest than the issue of whether 
hyposmia identifies individuals at increased risk of developing PD in the future.            
Cognitive dysfunction had not been reported in Type I GD at the time of this study but substrate 
reduction therapy (SRT) has been reported to induce memory problems (Hollak et al, 2009). 
However, only 2 GD patients were receiving SRT when assessed. Neither of whom had cognitive 
impairment.  Multiple studies have demonstrated that PD patients with heterozygous GBA 
mutations have a greater prevalence and severity of cognitive dysfunction than PD patients 
without mutations. For example Brockmann et al (2012) conducted a study of 20 PD  patients 
carrying the N370S or L444P mutation found cognitive impairment by MoCA and other 
neuropsychiatric features to be more common than in PD patients without GBA mutations, but 
they did not provide details of  performance on the individual domains of the MoCA.  Alcalay et  
al (2012) detail the cognitive profile of PD-GBA compared to PD-S.  They describe defects of 
non-verbal memory and visuo-spatial function using the Wechsler memory scale-revised and 
Benton Visual Retention Test in PD-GBA compared to PD-S.  Our findings on the non-motor 
manifestations of PD-GBA are broadly in agreement in that we identified more frequent 
cognitive impairment in PD-GBA using the MoCA (McNeill et al, 2012b).  However, we did not 
identify specific defects in non-verbal memory and visuo-spatial function; this probably reflects 
both the small sample size of our study and the non-sensitivity of the MoCA for certain types of 
cognitive dysfunction.  There are no reports of cognitive dysfunction in non-manifesting carriers 
of heterozygous GBA mutations. However, given the association of PD-GBA with marked 
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cognitive dysfunction it seems reasonable to suggest that cognitive dysfunction may occur in the 
pre-motor stages of PD associated with GBA mutation carriage. In support of this it is interesting 
to note that in our cohort both non-manifesting GBA carriers and PD-GBA participants had lower 
scores on the abstraction domains of the MoCA compared to controls.  This broad similarity in 
cognitive deficits suggests that the cognitive impairment present in non-manifesting carriers may 
be a non-motor feature of individuals who are in the prodromal phase of  PD-GBA.  The 
cognitive deficits identified in the GD patients and non-manifesting GBA carriers may thus 
represent a feature of neurological disease associated with GBA mutations rather than solely 
being part of the neurodegenerative process of Parkinson’s disease.   
           
It is well recognised that the UPDRS part III differentiates poorly between subtle parkinsonian 
signs and non-specific motor features occurring as part of normal ageing.  Amongst study 
participants who scored 0-10 on the UPDRS part III there was a mixture of individuals with 
signs which were highly likely to reflect early motor features of PD (e.g. rigidity with activation 
manoeuvre) and those whose motor features overlapped with normal physiology (e.g. bilateral 
postural tremor) or might reflect bone disease in GD (e.g. postural abnormalities). Despite this, 
there were 4 GD patients and 2 carriers with UPDRS part III scores >10 with motor phenotypes 
falling short of diagnostic criteria for PD (e.g. rest tremor with asymmetric rigidity but no 
bradykinesia) but clearly distinct from normal. We do not propose that all subjects with elevated 
UPDRS part III scores will develop PD but hypothesise that those with clear motor abnormalities 
(e.g. rest tremor) are more likely to be in the prodromal phase of PD.  In addition, the correlation 
between the timed motor test results and the UPDRS part III scores supports the contention that 
GD patients and heterozygous GBA mutation carriers with elevated UPDRS part III scores may 
be in the early phases of PD (Haaxma et al, 2008).  In both GD patients and carriers higher 
UPDRS Part III scores were associated with slower performance on the timed motor tests 
(Purdue pegboard and 3m walk).  Moreover, 3 of the 4 PD patients with an isolated motor sign of 
PD had the lowest 3 pegboard scores of all GD patients, whilst the 4th had a score in the bottom 
quartile of GD patients. The score on the Purdue pegboard has been shown to correlate with 
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density of ligand binding on dopamine transporter imaging (Bohnen et al, 2007; Troiano et al, 
2010).  This relationship between decline in ligand binding on dopamine transporter imaging and 
pegboard performance occurs in both PD and normal ageing, but with greater severity in PD. 
Moreover, slower performance on the Purdue pegboard in normal elderly individuals has been 
associated with development of clinically probable PD over a 4 year period, though the 
sensitivity and specificity were poor (Adler CH, 2002).  This correlation between poor 
performance on the timed motor tests (which is associated with dopaminergic neuronal loss and 
increased risk of developing PD) and higher UPDRS part III scores thus implies that the isolated 
motor signs identified in the GD patients and non-manifesting carriers may reflect prodromal PD 
in this cohort.      
The motor syndrome of PD is associated with cognitive dysfunction and hyposmia (Schapira & 
Tolosa, 2010).  Thus it is expected that those individuals with combinations of prodromal 
markers will be most likely to be in the prodromal phase of PD. The fact that higher UPDRS part 
III scores are statistically associated with lower MoCA and UPSIT scores demonstrates that a 
there is a subset of GD patients and carriers manifesting multiple prodromal markers who are 
most likely to be in the prodromal phase of PD (see table 5).    
We did not identify an increased frequency of symptoms of autonomic dysfunction in the GD 
patients and carriers, and whilst more GD patients gave a positive response to the REM sleep 
behaviour disorder questionnaire than controls this did not reach significance.  This does not 
undermine our contention that we identified early markers of neurodegeneration in this cohort. In 
the majority of cases urinary and erectile dysfunction develop after onset of motor PD (Goldstien 
et al, 2011). In one study of PD patients with autonomic dysfunction, orthostatic hypotension 
was only present in 60 %  as an early feature (Goldstien et al, 2011).  Constipation is well 
recognised as a marker of increased PD risk, but it has low specificity (Petrovich et al, 2009). 
Thus,  autonomic symptoms are often more associated with clinical PD than the prodromal phase 
and their absence does not preclude increased risk of neurodegeneration.  REM behaviour 
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disorder correlates with risk of developing neurodegeneration (Postuma et al, 2009). There is 
evidence REM sleep behaviour disorder may define an endophenotype of PD,   with 25 – 50 % 
of PD patients having clinical features of the disorder (Arnulf, 2012).  Thus, since not all PD 
patients have this disorder, it is logical that not all individuals in the prodrome of 
neurodegeneration will have REM sleep behaviour disorder and so its absence does not indicate 
a low risk of neurodegeneration. Moreover, the screening tools used to identify autonomic 
dysfunction and RBD are not “gold standard” tests and have suboptimal sensitivity and 
specificity.  Thus some individuals with these prodromal markers will not have been identified 
by the screening tools.  This is especially true of REM sleep behaviour disorder in which the 
research participant’s bed partner was usually not present to help answer the questionnaire.   
Both bi-allelic and heterozygous GBA mutations predispose to PD and Lewy body dementia 
(LBD) (Sidransky et al, 2009).  The olfactory deficits, cognitive dysfunction and parkinsonian 
signs in our cohort may thus represent the prodrome of one of these disorders.  Olfactory 
dysfunction is well recognised in established and prodromal PD.  In the Honolulu Ageing study, 
hyposmia (lowest quartile of odour identification scores) gave an OR of 5.2 for the development 
of PD over a 4 year period and correlated with idiopathic Lewy body pathology at autopsy (Ross 
et al, 2008; Ross et al, 2006). Hyposmia also occurs in LBD, distinct from odour 
identification/naming difficulties associated with dementia (Williams et al, 2009).  Olfactory 
dysfunction in PD and LBD is associated with Lewy body deposition in the olfactory bulb, 
nucleus and cortex but not the olfactory mucosa.   Several GD patients and carriers had isolated 
cognitive impairment (dementia), defined by the MoCA (score of  <24/30).  Mild cognitive 
impairment is common in newly diagnosed PD (18 – 30%). A distinct MCI phenotype is 
proposed as a prodrome to LBD.  Cortical Lewy body pathology is associated with cognitive 
impairment in PD and LBD.  Poor performance on the Purdue pegboard has been correlated with 
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loss of dopaminergic neurons at autopsy and dopamine transporter imaging.  Thus a subset of the 
GD patients and carriers have clinical signs associated with Lewy body deposition or neuronal 
loss which have been linked to future development of PD or LBD.  However, it needs to be 
recognised that there are multiple neurological causes for the clinical signs we have identified, 
including Alzheimer’s disease and cerebrovascular disease.  We did not perform diagnostic tests 
such as brain MRI to rule these pathologies out, but as there is no known association between 
GBA mutations and these pathologies it seems less likely that they are responsible for our 
findings.  
Discussion of optical coherence tomography findings in GD patients at risk of PD
Given the lack of sensitivity and specificity of the clinical markers of prodromal PD it was 
decided to examine  GD patients with  OCT.  Retinal nerve fibre loss as demonstrated by OCT 
has been shown in early and advanced PD  (Hajee et al, 2009; Garcia-Martin et al, 2012).   We 
utilised OCT to measure GCC and retinal nerve fibre layer thickness in GD patients  in order to 
examine the hypothesis that clinical markers of prodromal PD in this cohort would be associated 
with loss of retinal thickness. This would support the contention that the clinical markers of 
prodromal PD were associated with underlying neurodegeneration.  There was no significant 
difference in the mean GCC or RNFL thickness of GD patients compared to controls.  However, 
the mean GCC and RNFL thickness of GD patients who expressed at least one prodromal marker 
of PD was significantly lower than that of both the control group and the GD patients without 
prodromal markers.  The OCT data from GD patients suggests that the clinical markers of 
prodromal PD reflect underlying neurodegeneration and may help to stratify Type I GD patients 
at high and low risk of developing PD or another neurodegenerative condition.  The study group 
of GD patients utilised in this part of the project was by necessity small given the time 
consuming nature of OCT.  Our results suggest that the clinical markers of prodromal PD 
detected in our cohort are associated with the presence of underlying neurodegeneration.  This 
preliminary study indicates that OCT may be clinically useful in stratifying GD patients into 
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those at high and low risk of neurodegeneration.  This requires confirmation in larger study 
cohorts with longitudinal follow up.    
The main cells found in the GCC are ganglion cells and dopaminergic amacrine cells.  The cells 
of the GCC have been shown, in cell culture models, to be sensitive to mitochondrial toxins and 
oxidative stress (Almasieh et al, 2012).  Thus it might be that the loss of GCC thickness in our 
cohort reflects metabolic derangements in the central nervous system associated with the 
presence of GBA mutations.  In chapters 3 and 4 the cell biology of GD and the heterozygous 
carrier state is described in detail using fibroblasts as a model.  Fibroblasts derived from GD 
patients and heterozygous GBA mutation carriers both with and without PD have evidence of 
oxidative stress (McNeill et al, in preparation).  Thus chronic oxidative stress in these individuals 
may contribute to degeneration of cells in the GCC.   Moreover, in a mouse model of the 
lysosomal storage disorder Niemann-Pick Type C there is retinal ganglion cell death associated 
with markers of dysfunctional autophagy (Claudepierre et al, 2010). Thus, the  retina is clearly 
vulnerable to the pathological process associated with bi-allelic carriage of GBA mutations. 
Future studies might profitably focus on examining the cell biology of retinal ganglion cells 
derived from murine models of GD held at University College London or studying the effect of 
GCase inhibition or knockdown in cultured retinal ganglion cells in order  to understand the 
mechanisms underlying retinal degeneration in GD and carriers.              
Discussion of GBA mutation spectrum detected in the Royal Free-Addenbrookes GD 
Cohort
All of the GD patients included in the phenotyping study had a typical Type I GD phenotype and 
genotypes.  Two Type I GD patients with the R262G/RecNcil genotype were excluded from 
phenotyping as their genotype was more commonly associated with  early onset neuronopathic 
GD.  Our Type I GD cohort was multi-ethnic. Most of the families were of white UK extraction 
with only 20% having Ashkenazi Jewish heritage.  The literature suggests that greater than 75% 
of GBA mutations in Type I GD should be N370S (Duran-Ogalla et al, 2012). The fact that 78% 
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of alleles in our GD patients were N370S  is thus entirely congruent with this.  The presence of 
clinical markers of prodromal PD was not restricted to GD patients of Ashkenazi origin and our 
data indicates that these clinical features are not due to genetic background restricted to any one 
particular ethnic group.   The function consequences of the novel mutations were studied using 
in silico prediction tools (Duran-Ogalla et al, 2012). The A341V mutation was predicted to 
destabilize the GBA-substrate binding site and so disrupt GBA catalytic activity.  The V447E 
mutation was predicted to disrupt the binding site for the GBA activator protein saposin C.  The 
R262G change results in loss of a positively charged residue with potential destabilisation of 
GBA structure,   an R262H mutation which affects the same site has been linked with PD. 
G250V was not predicted to affect GBA function, however the heterozygous carrier it was found 
in had prodromal markers of PD suggesting it may be pathogenic and it was present with N370S 
in a GD patient.  The mutation IVS9+1G>A was strongly predicted by HSF finder to destroy the 
canonical donor splice site at +1 position of intron 9. This was likely to affect splicing and 
produce aberrant transcripts and a non functional GBA protein.     
Discussion of the non-motor phenotype of PD in heterozygous GBA mutation carriers 
The motor phenotype of PD-GBA is very similar to that of PD-S, but the non-motor phenotype is 
less well studied (Sidransky et al, 2009).  We identified that the degree of hyposmia in PD-GBA 
and PD-S is not significantly different.  This suggests that the neuropathology in PD-GBA 
involves olfactory pathways to a similar degree to that seen in PD-S.  This is interesting as 
olfactory dysfunction in LRRK2 and Parkin associated PD is reported to be less severe than PD-
S, suggesting that the neuropathological process in these genotypes may involve olfactory 
pathways to a lesser degree than in PD-S.  Using the non-motor symptoms scale we also 
identified a greater number and severity of non-motor symptoms in PD-GBA than PD-S.  This is 
in keeping with other studies which utilised different clinical screening tools to study the 
phenotype of PD-GBA.  Brockmann et al (2011) used the Neuropsychiatric inventory to show 
that PD-GBA patients have a greater prevalence and severity of depression and anxiety, which 
agrees with our findings from the non-motor symptoms scale.  As discussed above several 
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groups have found more severe cognitive impairment in PD-GBA, as did we with the MoCA. 
However, we did not identify more severe autonomic symptoms in our PD-GBA cohort; but this 
may reflect the relatively small size of our study.  The more severe non-motor symptom profile 
of PD-GBA has been suggested to be due to more widespread Lewy body pathology in PD-GBA, 
this has been confirmed by some neuropathological studies but not by all (Parkkinen et al, 2011). 
Interestingly we found that more PD-GBA than PD-S patients had possible REM sleep behaviour 
disorder as classified by the REM sleep behaviour disorder questionnaire. This has not been 
previously reported in PD-GBA and needs confirmation with formal sleep studies, but correlates 
with the observation that reduced echogenicity of the brainstem raphe on transcranial sonography 
occurs more frequently in PD-GBA  than PD-S (Brockmann et al, 2011).  This area is potentially 
involved in sleep regulation and so this observation could be of mechanistic relevance to our 
findings.  Our study of PD-GBA further supports the notion that genotype influences the non-
motor phenotype of PD and that genetics may explain part of the phenotypic heterogeneity in 
PD.  
Despite these differences in non-motor phenotype between PD-GBA and PD-S the motor 
phenotype appears identical on clinical examination. PD-GBA patients manifest the same 
spectrum of both motor and non-motor features reported in PD-S.  But in general PD-GBA 
patients report a greater number and severity of non-motor symptoms.  This is in contrast to 
other genetic forms of PD which less closely resemble PD-S.  For example, Parkin mutation 
associated PD presents with very mild non-motor manifestations and normal olfaction (Kagi et  
al, 2010b).  While the motor phenotype of ATP13A2 and FBX07 mutations is very different to 
that of PD-S. Based on our detailed clinical phenotyping, and the reports of typical Lewy body 
pathology in PD-GBA, PD-GBA sufficiently resembles PD-S to represent a good genetic model 
to study the aetiology of PD.            
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Discussion of age related risk of PD in heterozygous GBA mutation carriers
Data on the age related risk of PD in GD and heterozygous GBA mutation carriers is clearly of 
interest to both clinicians and patients.  Bultron et al (2010) demonstrated that Type I GD 
patients have a lifetime relative risk of PD of around 20 fold greater than control populations. 
Rosenbloom et al (2010) studied the registry of the International Gaucher Disease Collaboration 
to define age related incidence of PD in GD.  For men at age 80 the incidence of PD was 12% 
while for women it was 9%.   This risk is very similar to the age related risk of PD we defined in 
the heterozygous GBA mutation carriers in our study.   
In heterozygous mutation carriers from families with autosomal dominant PD associated with 
GBA mutations Anheim et al (2012) described an age related risk of PD of 7.6% at 50 years and 
29.7% at 80 years.  This is significantly greater than the age related risk we identified amongst 
parents of Type I GD patients (the parents are obligate heterozygotes), in whom there is a risk of 
PD of 5% at age 60 and 15% at age 80 years.  It is also greater than the risk of PD calculated by 
Rana et al (2012), who found  risk of PD in obligate GBA mutation carriers to be  2.2%  at age 
65 years and 10.9% at 85 years. A family history of PD is associated with an elevated risk of the 
disorder in first degree relatives, thus other genetic and environmental factors present in PD 
families may account for the increased risk of PD in heterozygous carriers reported by Anheim 
et al (2012).  There may also be ascertainment bias when studying age related PD risk in families 
in which the index case has PD.  Thus it is likely that our estimate of age related PD risk in the 
obligate carriers from Type I GD families is more accurate given the absence of confounding 
factors relating to an autosomal dominant family history of PD.    
Discussion of DaTSCAN features of monogenetic PD
Here we report the DaTSCAN features of a large set of cases of monogenetic PD.  Our key 
finding is an asymmetric pattern of loss of striatal dopaminergic neurons in PD with GBA or 
LRRK2  mutations as assessed by both the ASI and SASI.  However, by comparison, the pattern 
of dopaminergic neuronal loss in PD with SNCA mutations or bi-allelic Parkin or PINK1 
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mutations was relatively symmetrical.  There was no correlation between measures of asymmetry 
and disease duration or patient age at examination.  Indicating that the differences in symmetry 
of dopaminergic neuronal loss are related to genotype and not differences in disease stage 
between groups.
The results of our comparison of dopaminergic neuronal imaging features are in keeping with 
previous reports of imaging of single PD genotypes.  There are 2 reports of DaTSCAN in 
Gaucher disease patients with PD or PD patients with heterozygous GBA mutations (Sunwoo et  
al, 2011; Kono et al, 2007) .  Though not formally quantified, inspection of the published images 
reveals obvious asymmetry of radioligand uptake affecting the caudate and striatum.   Here we 
confirm asymmetric loss of dopaminergic neurons in sporadic PD associated with heterozygous 
GBA mutations.   Multiple studies of Parkin mutation associated PD using both DAT-SPECT and 
18-F-DOPA-PET clearly describe a symmetrical reduction in striatal radioligand uptake (Varrone 
et al, 2004; Ribeiro MJ et al, 2009; Khan et al, 2002).  The DAT-SPECT  features of PD patients 
with bi-allelic Parkin mutations reported herein is entirely in keeping with this.  DAT-SPECT in 
PINK1 linked PD is usually described as symmetrical but some reports state that it is 
asymmetrical in a pattern reminiscent of sporadic PD (Samaranch et al, 2010).   As previously 
described we found that the LRRK2  mutation carriers with PD had asymmetric loss of 
radioligand uptake on DAT-SPECT (Isaias et al, 2006).  The SNCA mutation PD cases reported 
here had symmetric reduction of ligand binding. This is in keeping with reports of 18F-DOPA in 
PD with the A53T mutation which demonstrated relatively symmetrical loss of radioligand 
uptake, however, reports of SNCA multiplication and A30P mutation associated PD describe an 
asymmetrical pattern of reduced tracer uptake (Kruger et al, 2001; Ahn et al, 2008; Nishioka et  
al, 2002).     
The currently available data on the pathological mechanisms underlying monogenetic PD help to 
explain the differences in symmetry of radioligand uptake between genotypes (Schapira and 
Tolosa, 2010).  PINK1 and Parkin mutations are generally associated with early onset, relatively 
124
symmetrical parkinsonism (reviewed in Lees et al, 2009).  Both PINK1 and Parkin proteins are 
proposed to play a role in clearing damaged mitochondria, and there is evidence that loss of 
function of these proteins is associated with mitochondrial dysfunction (de Vries et al, 2012; 
Abramov et al, 2012).  The diffuse and symmetrical loss of dopaminergic neurons reported by 
us, and many others, may reflect widespread dysfunction and degeneration of striatal 
dopaminergic neurons due to a general predisposition to neuronal mitochondrial dysfunction in 
PINK1 and Parkin mutation associated PD.  SNCA mutations are proposed to act chiefly by 
facilitating Lewy body formation (Ahmad et al, 2012).  The symmetrical loss of dopaminergic 
neurons on DAT-SPECT reported herein may thus reflect a generalised, homogeneous increase in 
Lewy body formation in the striatum since the mutation is present in every cell.   By contrast, 
GBA and LRRK2 mutations are most commonly associated with a phenotype which closely 
resembles late onset sporadic PD.  This suggests that these mutant proteins may interact with 
additional pathological process, either genetic or environmental, predisposing to age related PD 
and explaining the low penetrance of these genotypes.  For example in PD with mono- or bi-
allelic GBA mutations there is reduction or loss of glucocerebrosidase enzyme activity in the 
brain, associated with elevated alpha-synuclein deposition as measured by Western blot (Gegg et  
al, 2012; Mazzulli et al, 2011).  Both cell biology and mouse studies indicate that inhibition of 
glucocerebrosidase activity is associated with elevated alpha-synuclein accumulation.  The 
asymmetric loss of dopaminergic neurons observed in PD with GBA mutations may thus reflect a 
stochastic element whereby there is a focal loss of glucocerebrosidase activity below a critical 
level eventually resulting in an initially focal accumulation of alpha-synuclein and Lewy body 
formation.  There is evidence from human brain and cell models that alpha-synuclein 
accumulation results in inhibition of glucocerebrosidase, thus causing a “feed forward” 
mechanism which could contribute to the spread of pathology and neurodegeneration (Gegg et  
al, 2012).  Recently it has been shown that loss of glucocerebrosidase activity associated with 
alpha-synuclein accumulation in brain tissue from PD without GBA mutations (Gegg et al, 
2012).  This suggests that a similar mechanism may operate in sporadic PD and may account 
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partly for the similarities in dopaminergic neuronal imaging and clinical phenotype between 
sporadic PD and PD associated with GBA mutations.  
Studies have shown that dopaminergic neuronal imaging improves accuracy of diagnosis in 
sporadic PD.  Here we provide data suggesting that DAT-SPECT and 18-F-DOPA PET also have 
potential clinical utility in genetic PD.  Recessive forms of genetic PD (Parkin, PINK1) generally 
demonstrate relatively symmetric loss of radioligand uptake in the striatum.  This symmetrical 
pattern is also evident in reports of multisystemic neurogenetic syndromes in which 
parkinsonism is found alongside other signs (e.g. Kufor-Rakeb syndrome).  PD associated with 
heterozygous mutations in GBA or LRRK2 G2019S, which can present with dominant or 
apparently sporadic PD, produces an asymmetric pattern of loss of radioligand uptake.  Here we 
found that the SNCA G209A  mutation is associated with symmetrical loss of dopaminergic 
neurons on DAT-SPECT, but others have reported asymmetric loss of uptake especially with 
SNCA multiplication.   In clinical practice asymmetric loss of radioligand binding should not 
exclude a genetic aetiology for PD while relatively symmetric decrease should raise suspicion of 
a monogenetic form of PD.  The asymmetric loss of dopaminergic neurons in GBA and LRRK2 
associated PD supports the hypothesis of secondary interactions with genetic or environmental 
factors leading to neurodegeneration in these genotypes.    
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Concluding remarks
Here,  the presence of clinical markers of prodromal Parkinson's disease in a cohort of Type I GD 
patients and heterozygous carriers of GBA mutations is described (McNeill et al, 2012a). 
Hyposmia, cognitive impairment and parkinsonian motor signs were more common in these 
individuals than in controls.  There was a statistical correlation between the severity of each of 
these clinical markers of prodromal Parkinson's disease.  This is expected since patients with 
Parkinson's disease manifest a range of motor and non-motor problems and individuals in the 
prodromal phase are likely to have these to a lesser degree than in clinically manifest disease 
(Schapira and Tolosa, 2010).  Additionally, the frequency and severity of the scores on the 
clinical ratings scales used for these prodromal markers worsened with increasing age in the GD 
and carrier groups, but not in controls.  This fits with the proposal that they reflect underlying 
neurodegeneration since Parkinson's disease is strongly age related.  The thickness of the retinal 
ganglion cell complex and retinal nerve fiber layer, measured by OCT, was thinner in GD 
patients with prodromal markers of Parkinson's disease than in controls but not in GD patients 
without prodromal markers.   This provides objective evidence of neurodegeneration in this 
cohort suggesting that the prodromal markers we identified are indeed associated with the 
prodromal phase of Parkinson's disease.  
It is clear that only a minority of GD patients and heterozygous GBA  mutation carriers develop 
PD.   The reasons for this are unclear; but may relate to genetic or environmental factors.  Co-
inheritance of mutations in other PD causing genes seems unlikely given the rarity of LRRK2 and 
VPS35 in sporadic PD. All of our PD-GBA cases had sequencing of LRRK2 G2019S performed 
by a previous research fellow, no cases had a pathogenic GBA mutation with LRRK2 G2019S as 
well. This is in agreement with a previous study (Eblan et al, 2006).  In addition the phenotype 
of PD-GBA with severe hyposmia and non-motor symptoms is distinct from that of Parkin 
mutation associated PD (Kagi et al, 2010b).  It is very unlikely that mutations in rare PD genes 
such as PINK1, ATP13A2, DJ-1 would explain the occurrence of PD in GD and heterozygous 
GBA mutation carriers.  Several environmental factors such as smoking and coffee consumption 
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are known to protect against PD (Lees et al, 2009).  Given the weak associations between PD 
and environmental factors it seems less likely that one of these would explain why a subset of 
GD/mutation carriers develop PD.  Our study was not designed or powered to detect associations 
between environmental factors and risk of PD in GD patients and mutation carriers.  This is 
however an important issue which would require a multi-centre international collaboration to 
address. 
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Chapter III. 
ENDOPLASMIC RETICULUM RETENTION OF 
GLUCOSYLCERAMIDASE IN FIBROBLASTS FROM 
GAUCHER DISEASE PATIENTS AND PARKINSON’S DISEASE 
PATIENTS WITH HETEROZYGOUS GLUCOCEREBROSIDASE 
MUTATIONS
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IIIa. Introduction 
The biosynthetic pathway of glycosylceramidase
The glucosylceramidase (GCase) protein is synthesised as a 56kDa polypeptide on endoplasmic 
reticulum (ER) bound  polyribosomes and translocated across the ER membrane with cleavage 
of the leader sequence and glycosylation on 4 asparagine residues (Ron and Horowitz, 2005). 
GCase then passes through the golgi body and through the endosomal pathway to reach the 
lysosome via a mannose-6-phosphate receptor-independent pathway, where it expresses its 
enzymatic function as a 59-63 kDa mature glycoprotein. As GCase passes through the golgi, 
Golgi mannosidase II removes 2 mannose residues from GCase to form the mature glycoprotein. 
The steps in GCase biosynthesis are discussed in more detail below.  
As GCase passes through the ER it interacts with a variety of protein chaperones and undergoes 
folding into its active structure.  Depletion of ER calcium levels in GD has been associated with 
reduced folding of the mutant GCase; several studies with calcium channel blockers which raise 
ER calcium levels have demonstrated that raising ER calcium results in improved GCase protein 
folding (Ong et al, 2010; Wang et al, 2011). The LIMP-2 (SCARB2) protein is an important 
chaperone for GCase. It has been shown that LIMP-2 binds to GCase in the ER and ensures it is 
correctly targeted to the lysosome, at the acid pH of the lysosome LIMP-2 and GCase dissociate 
(Blanz et al, 2010).  The physiological importance of LIMP-2 has been emphasised by the 
identification of bi-allelic mutations in SCARB2  as causing Action Myoclonus Renal Failure 
syndrome (AMRFS), a storage disorder in which GCase processing and activity is abnormal 
(Berkovic et al, 2008).  Fibroblasts from these patients have reduced GCase protein levels and 
enzyme activity with evidence that GCase is aberrantly targeted for extracellular secretion rather 
than to the lysosome (Blanz et al, 2010).  SCARB2 polymorphisms have also been associated 
with sporadic PD (Michelakakis et al, 2012).
Recently, the phosphatidylinositol kinase pathway has also been demonstrated to be important in 
targeting GCase to the lysosome (Jovic et al, 2012).     Phosphatidylinositol kinase-III beta has 
been shown to regulate passage of GCase out of the golgi body while Phosphatidylinositol 
kinase-II alpha was shown to regulate traffic of GCase from endosome to lysosome. 
Phosphatidylinositol kinase-II alpha inhibition also caused missorting of GCase into the cell 
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culture medium.  Once in the lysosome GCase interacts with its co-factor Saposin-C, which 
enhances GCase enzyme activity (reviewed in Tamargo et al, 2012).  The importance of Saposin-
C to GCase function is emphasised by the fact that recessive mutations which affect Saposin-C 
cause a severe form of GD which has reduced GCase enzyme activity (reviewed in Tamargo et  
al, 2012).  Clearly the GCase enzyme must interact with a variety of chaperones and cellular 
compartments for it to be correctly targeted to the lysosome and thus there are several steps at 
which GBA mutations could disrupt GCase enzyme function.  
In addition to the lysosomal GCase (also termed GCase-1), 2 additional isoforms of the enzyme 
exist: GCase-2 and GCase-3 (Aureli et al, 2012).   GCase-2 is located chiefly in the plasma 
membrane (Aureli et al, 2012) and GCase-3 in the cytoplasm (Dekker et al, 2011).  GCase-2 can 
metabolise GCase-1 substrates (e.g. glucosylceramide) while GaCse-3 cannot (Dekker et al, 
2011).  GCase-3 activity is not detectable in fibroblasts and this enzyme will not be considered 
further here (Aureli et al, 2012). GCase-2 activity is assayed by measuring total cellular GCase 
activity and subtracting the value for GCase activity measured in the presence of adamantane-
pentyl-dNM;N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin (DNJ), which is a 
specific inhibitor of GCase-2 (Aureli et al, 2012).  Aureli et al (2012) demonstrated increased 
GCase-2 activity in fibroblasts from GD patients; with greater elevation of activity in GD Type 1 
and 2 than in GD Type 3.     This was associated with elevation of GCase-2 transcript levels 
suggesting that gene induction was responsible for the increased activity of GCase-2 (Aureli et  
al, 2012).  The authors postulate that increased GCase-2 activity is a protective response to 
compensate for loss of GCase-1 and minimise substrate accumulation.  In this thesis GCase is 
used to mean GCase-1 and the term GCase-2 will be used specifically to refer to this isoform of 
the enzyme.       
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The spectrum of GBA mutations and their functional consequences
The GBA mutation spectrum was comprehensively reviewed by Hruska et al (2008).  At that 
time around 250 mutations had been described.   Including 203 missense, 18 nonsense, 36 small 
inserions or deletions, 14 splice site mutations and 15 complex mutations (recombinant 
mutations or alleles with 2 or more point mutations in cis).  Since then several dozen more GBA 
mutations have been reported in GD, but missense changes remain the most common.  A 
selection of these recently reported mutations will be described here but a more comprehensive 
list of GBA mutations (>350) can be found at  http://www.hgmd.cf.ac.uk/ac/index.php.  
Park et al (2012) report neonatal lethal GD (hydrops, hepatosplenomegaly, skin lesions) in a 
korean family due to novel deletion mutation at cDNA nucleotide position 630 resulting in the 
frameshift (Pro171fsX21) in exon 6 and a G>A transition mutation at cDNA nucleotide position 
887 (Arg257Gln) in exon 7.  Baris et al (2012) report a novel F331S (c.1109 TNC) GBA 
mutation causing non-perinatal-lethal Type 2 GD in a Palestinian family, this mutation was 
predicted to affect the catalytic site of the enzyme and to disrupt protein stability.  El-Morsy et al 
(2011) identified the novel M450L (g.7336A>C)  GBA mutation in an Egyptian child with GD. 
Jeong et al (2011) identified a novel recombinant allele using long range PCR (Rec 8a: GBAP 
pseudogene sequence from intron 5 to exon 11 is substituted for the GBA gene).  Balwani et al 
(2011) describe a novel GBA allele consisting of N370S and L444P on the background of a 
RecNcil allele.  This is important to recognise as the asymptomatic carrier was initially 
diagnosed as have bi-allelic GBA mutations.  Lavaut et al (2011) identified a novel I403T 
mutaion in a Cuban Type I GD patient.  Jeong et al (2011) comprehensively screened Korean 
GD patients and identified novel mutations in GBA: P201H, a complex allele with F347L and 
L444P in cis and a small deletion c.630delC.  Tajima et al (2010) report a novel G199D missense 
mutation in a patient with myoclonic epilepsy in GD.  Yassin et al (2008) describe a novel 
L371V mutation in trans to RecNcil with a paediatric, severe Type I GD phenotype.  In Turkish 
GD patients novel missense mutations S356F and L296V along with 303-305delCAC were 
reported (Emre et al, 2008).  
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Clearly all reported GBA mutations act by reducing GCase activity.   There are several different 
predicted/proven mechanisms of action for the different GBA mutations.   Many of the missense 
mutations are predicted to cause GBA misfolding and subsequent endoplasmic reticulum 
retention (Ron and Horowitz, 2005).  Several missense mutations also affect the active site of 
GCase and we identified a novel mutation predicted to disrupt the interaction between GCase 
and saposin-C (Duran et al, 2012).  Nonsense mutations in GBA are much less frequent and 
result in a truncated non-functional GCase or unstable mRNA.  Most of the recombinant alleles 
are effectively null alleles (Hruska et al, 2008) producing no or unstable mRNA.   
Genotype-phenotype correlations in GD are not absolute.  But in general GD patients with at 
least one N370S allele have non-neuronopathic disease and those with other combinations of 
GBA mutations develop Type II or Type III GD.  The L444P mutation is generally described as a 
more severe mutation than N370S since L444P is more commonly associated with neuronopathic 
GD.  Perinatal lethal GD is associated with bi-allelic null alleles, such as recombinant alleles or 
less commonly a recombinant mutation in heterozygosity with a severe point mutation (Hruska 
et al, 2008).    
Even more controversial is the role of the E326K and T369M GBA variants.  Both have been 
found to occur more frequently in PD cases than in controls (Lesage et al, 2011; Pankratz et al, 
2012).  But whether E326K should be considered a benign polymorphism, a disease modifier or 
a disease causing mutation in GD is not completely resolved.      
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Evidence for endoplasmic reticulum associated degradation of mutant glucosylceramidase
As discussed above the majority of GBA mutations are missense changes which are predicted to 
disrupt protein structure (Ron and Horowitz, 2005).  Such mutations are known to cause protein 
misfolding and trigger the ER protein folding quality control mechanism. The ER quality control 
mechanisms prevent accumulation of misfolded proteins, either by refolding them through the 
action of molecular chaperones or by directing them to the proteasome for degradation, so 
preventing the Unfolded Protein Response (UPR) and ultimately cell death by apoptosis 
(reviewed in Benbrook and Long, 2012).  Soluble proteins synthesised on ER bound ribosomes 
initially bind to chaperones in the ER lumen to aid correct folding.  Heat shock protein (HSP) 40 
family members, especially BiP/Grp78, HSP 70 and Protein disulfide isomerase play crucial 
roles in binding unfolded proteins to maintain solubility and permit correct folding (Benbrook 
and Long, 2012).  Nearly all secretory proteins synthesised in the ER undergo N-linked 
glycosylation, two of the three glucose residues in the protein are trimmed by glucosidase I and 
II, creating a binding site for the lectins calnexin and calreticulin (Hetz, 2012).  These catalyse 
correct protein folding.  The final glucose residue is then removed by glucosidase II, which 
releases the protein from the lectins. If the protein is still misfolded, it is recognized by the 
glucosyl transferase (GT), which preferentially recognizes unfolded or molten globule species 
and reglucosylates the polypeptide (Hetz, 2012). This permits lectin rebinding and prevents the 
misfolded protein from leaving the ER.  If the protein still does not fold correctly then in 
subsequent cycles of lectin binding and cleavage of glucose residues the binding of 
calnexin/calreticulin becomes less efficient and the protein is passed to another lectin binding 
protein: ER degradation enhancing α-mannosidase-like protein.  This protein then processes the 
misfolded protein for retrotranslocation into the cytoplasm (Hetz, 2012).  In the cytoplasm the 
misfolded protein undergoes sequential ubiquitination by E1, E2 and then E3 ubiquitin ligases. 
The ubiquitinated protein is then delivered to the 26S proteasome for degradation.  
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GD fibroblasts have been shown to have reduced GCase protein levels (Ron and Horowitz, 2005; 
Lu et al, 2011) In pulse-chase radiolabelling experiments in transfected HeLa cells Lu et al  
(2011) demonstrated that initial levels of GCase protein coded for by N370S or L444P GBA 
mutations are the same as wild type but that there is a rapid decrease in cellular GCase protein 
levels. Ron and Horowitz (2005) demonstrated that ERAD is responsible for the loss of GCase 
protein in GD. Using immunofluorescence they demonstrated loss of lysosomal GCase staining 
and co-localisation of GCase with ER markers in fibroblasts from Type I, II and III GD patients. 
They also demonstrated increased endo-H sensitivity of the mutant glucosylceramidase in GD 
cells; suggesting that this endo-H sensitive fraction of GCase had not reached the mid-golgi and 
was ER retained.  These authors correlated higher levels of the endo-H sensitive fraction of 
GCase with the severity of the GD phenotype.  They went on to demonstrate using co-
immunoprecipitation that mutant GCase interacts with the ER chaperone calnexin, suggesting a 
physiological attempt to chaperone/fold the misfolded GCase.  Treatment of the cell lines with 
proteasomal inhibitors resulted in an increase in GCase protein levels, suggesting the proteasome 
was responsible for degrading mutant GCase.  In pulse chase experiments the same authors 
treated L444P/L444P fibroblasts with cyclohexamide (to stop protein synthesis) and a 
proteasome inhibitor and demonstrated that in the presence of a proteasome inhibitor the half life 
of mutant GCase is prolonged.  Despite the detailed characterisation perfomed by these authors it 
is worth noting that there was no detailed clinical phenotyping of the patients whom fibroblasts 
were generated from and in 3 of the fibroblast cell lines the genotype was unknown.  Also there 
have been no modern PCR based studies of the effects of GBA mutations on mRNA stability. 
Further study of the role of ERAD in fibroblasts from well phenotyped and genotyped GD 
patients, and, in particular, heterozygous carriers of GBA mutations with and without PD, will 
provide further valuable information on the cellular processing of mutant GCase protein.           
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The  role of Ubiquitin ligases and Parkin protein in glucosylceramidase metabolism 
Given the evidence that the proteasome plays a key role in degrading mutant GCase it is clear 
that the ubiquitin ligase system, which targets proteins to the proteasome, will play a role in GD 
pathogenesis.  By studying fibroblasts derived from L444P/L444P GD patients Ron and 
Horowitz (2011) demonstrated that after proteasomal inhibition, immunoprecipitated GCase was 
found to be ubiquitinated.  This provides evidence that the ubiquitin ligase system plays a role in 
the degradation of mutant GCase.  Ron et al (2010) investigated whether Parkin protein acts as 
an E3 ubiquitin ligase of mutant GCase.  They demonstrated that in HEK293 cells over 
expressing the N370S mutant GCase that Parkin and the mutant, but not wild type, GCase 
protein co-immunoprecipitated.  This suggests that Parkin can recognise and bind mutant, 
misfolded GCase.  When increasing amounts of wild type Parkin were transfected into SH-SY5Y 
cells expressing the N370S GCase mutant it was found that GCase was degraded in a dose 
dependent manner.  Parkin did not degrade wild type GCase.  Wild type Parkin was also shown 
to mediate K48 polyubiquitination of mutant GCase, thus targeting it to the proteasome. The 
P437L RING finger Parkin mutant was not able to mediate degradation of mutant GCase.
  
Further evidence of the importance of ubiquitin ligases and the proteasome in GD comes from 
the study of Lu et al (2010).  In cultured fibroblasts from Type I, II and III GD patients they 
show that GCase enzyme activity is proportional to the amount of GCase protein in the cells and 
that proteasomal inhibition with lactacystin increases both GCase protein levels and enzyme 
activity.  In a crucial experiment they immunoprecipitate N370S and L444P GCase from GD 
fibroblasts and show that the GCase has almost normal enzymatic function.  Taken with the work 
of Ron (2005, 2011) this suggests that reduced GCase activity in GD predominantly reflects 
proteasomal degradation of the protein rather than mutations directly influencing GCase activity 
by altering the structure of its catalytic site.   In addition, Lu et al (2010) show that c-Cbl (an E3 
ubiquitin ligase) co-immunoprecipitates with mutant GCase, and that siRNA knockdown of c-
Cbl resulted in up regulation of GCase protein expression and enzyme activity in GD fibroblasts. 
This suggests that c-Cbl plays a role targeting mutant GCase to the proteasome.   The ubiquitin-
proteasome system thus plays a key role in degrading mutant, misfolded GCase.        
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Endoplasmic reticulum stress responses in Gaucher disease
When the rate of accumulation of misfolded proteins overwhelms the ability of basal levels of 
chaperones to correctly fold them the Unfolded Protein Response (UPR) is induced (Hetz, 2012). 
The UPR consists of 3 elements (Benbrook and Long, 2012): 1. Inhibition of protein synthesis, 
2. Induction of chaperone expression and 3. Upregulation of ERAD activity.  Upon accumulation 
of unfolded proteins in the ER BiP/Grp 78 dissociates from the ER stress transducers PKR-like 
endoplasmic reticulum kinase (PERK), inositol-requiring enzyme 1 (IRE1), and activating 
transcription factor 6 (ATF6).  BiP/Grp78 then binds to unfolded and misfolded proteins. Upon 
activation, IRE1 splices the mRNA of XBP1, and produces an active transcription factor named 
spliced XBP1 (XBP1-S), which upregulates ER chaperones and proteins implicated in ERAD 
(Benbrook and Long, 2012). In addition, IRE1 recruits TRAF2 and ASK1, resulting in JNK 
activation. The activation of PERK increases phosphorylation of eIF2α, leading to a global 
reduction of protein synthesis and a concomitant increase in ATF4 translation. In turn, ATF4 
induces CHOP, a proapoptotic transcription factor. After the dissociation of Bip, ATF6 
translocates to Golgi apparatus, where it is activated by proteolysis. Activated ATF6 
transcriptionally induces ERAD genes and upregulates CHOP expression (Hetz, 2012). 
If there is ongoing accumulation of misfolded proteins then the UPR may be overwhelmed 
leading to activation of apoptotic pathways and cell death (Benbrook and Long, 2012).  The 
major pathway of UPR induced apoptosis is CHOP and IRE1 acting directly and indirectly to 
reduce expression of anti-apoptotic factors such as BCL and upregulating pro-apoptotic factors 
such as BAX (Hetz, 2012).  ER resident caspase-12 can also trigger apopototic pathways in 
response to ER stress (Benbrook and Long, 2012).   Given the evidence of ER retention of 
mutant GCase proteins in GD the ER stress response may play a role in cell death in GD. 
However, there are few studies of ER stress markers in GD and none provide convincing 
evidence of ER stress induction.
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Cha et al (2011) describe reduced expression of the ER stress marker BiP/Grp78 following 
treatment of fibroblasts from Type II GD patients with erythropoietin.  They interpret this as 
evidence of ER stress in Type II GD.  However, they did not compare BiP/Grp78 expression 
levels between GD and control fibroblasts and so this does not provide evidence of increased ER 
stress in GD compared to controls.  The same group (Lee et al, 2011) report that catechin reduces 
ER stress in Type I GD fibroblasts.  They propose that catechin reduces oxidative stress thereby 
increasing protein folding.  They demonstrate that catechin reduces BiP/Grp78 protein levels on 
Western blot and immunofluorescence in Type I GD fibroblasts; however they did not 
demonstrate increased BiP/Grp78 expression in Type I GD fibroblasts compared to cell lines 
generated from healthy individuals.  These studies can therefore not be taken as evidence of  ER 
stress in GD as there was no adequate comparison with controls.  
Wei et al (2007) demonstrated increased expression of mRNA and protein for the ER stress 
markers calnexin, XBP1 and BiP/Grp78 in GD.  However, they studied just a single Type I GD 
and a single Type II GD fibroblast line.  Given the intrinsic variability of both fibroblast cell 
lines and the GD phenotype this paper cannot be taken as definitive proof of ER stress in Type I 
GD.  In contrast Farfel-Becker et al (2009) did not find any evidence of ER stress in various 
models of neuronopathic GD.  Treatment of cultured neuronal and astrocytic cell lines with the 
GCase inhibitor CBE did not result in upregulation of ER stress markers (XBP1, BiP/Grp78, 
CHOP) nor was there evidence of ER stress marker upregulation in the brain tissue of GBA null 
mice.  This is probably explained by the fact that there is no misfolded/mutated GCase in these 
models present to induce ER stress. However, the same authors went on to demonstrate that there 
was no evidence of ER stress  marker upregulation (BiP/Grp78, CHOP, XBP1) in brain tissue of 
aged (3 months old) L444P/L444P mice or cultured embryonic neurons from these mice.  Thus 
the evidence for ER stress induction in Type I GD is not convincing and further studies are 
required.  Given the consistent evidence of proteasomal degradation of mutant GCase in GD 
cells it could be argued that this removes misfolded GCase protein and protects against ER stress 
in this disease.
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Agents which can increase glucosylceramidase protein levels and activity in GD
Based upon our understanding of the mechanisms by which GBA mutations lead to GCase 
protein depletion and dysfunction several agents have been studied for their ability to improve 
GCase activity in cell culture models.  These include anti-oxidants, pharmacological chaperones 
and histone-deacetylase inhibitors.  The questionable value of erythropoeitin and catechin has 
been discussed above and will not be covered further here.
Lu et al (2011) studied the effects of the histone deacetylase inhibitor (HDACi) suberoylanilide 
hydroxamic acid (vorinostat) on L444P/L444P and N370S/N370S fibroblasts and demonstrated 
that it enhances both GCase protein levels and enzyme activity.  They also demonstrate that 
mutant GCase has reduced binding to HSP70 and TCP1 (which are chaperones which promote 
normal protein folding) and is more likely to be bound to HSP90 and ubiquitinated for 
degradation.  Treatment with the HDACi was shown to increase binding to HSP70 and thus 
facilitate normal GCase folding, consistent with this the HDACi resulted in reduced GCase 
ubiquitination. Importantly the HDACi improved protein levels and activity for both N370S and 
L444P mutant GCase.    
Maegawa et al (2009) identified ambroxol hydrochloride, an expectorant, as an agent which 
enhances the enzymatic activity of GCase by acting as a pharmacological chaperone by 
screening the National Institutes of Health (NINDS) drug repurposing library of 1 040 drugs 
previously used in routine clinical practice in man.  The initial screen sought to identify 
compounds which stabilised GCase against thermal denaturation and ambroxol was one of the 
agents identified in this initial screen. The authors subsequently show that ambroxol increased 
both the GCase protein levels and enzymatic activity in fibroblasts from patients with genotypes 
N370S/N370S and F213I/L444P  but not L444P/L444P.  After removal of ambroxol from culture 
media, the enhanced GCase activity returned to baseline at 6 days. Lysosomal fractions from 
treated cells were shown to be specifically enriched in GCase protein levels and activity after 
ambroxol treatment.  This thorough characterisation of ambroxol provides strong evidence that it 
stabilises GCase protein and enhaces its delivery to the lysosome and its enzymatic activity.    
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Other groups have confirmed the value of  ambroxol in improving cellular GCase function.  Ron 
and Horowitz (2011) demonstrated that ambroxol can reduce the endo-H sensitive fraction of 
GCase and increase its enzymatic activity in fibroblasts from Type II GD.  Luan et al (2012) 
confirm that ambroxol can increase GCase enzymatic activity in GD fibroblasts with a range of 
genotypes and showed that ambroxol given orally to mice in water is non-toxic, enters the brain 
and improves cerebellar GCase enzyme activity.  In general these studies demonstrate that 
ambroxol is not effective at enhancing GCase activity in L444P/L444P GD, which is a major 
drawback to the potential clinical use of this agent.  There are still several unanswered questions 
relating to ambroxol's activity: it needs to be determined if ambroxol induces GCase 
transcription, what the effects of ambroxol on other lysosomal enzymes is and if ambroxol might 
show some efficacy in heterozygous cell lines. Investigating these issues were thus major goals 
of our cell biology study of patient derived fibroblasts.  
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Studies of autophagy markers in Gaucher disease
The cell physiology of autophagy is discussed in the general introduction, here, papers 
describing autophagy in GD are discussed.  There are no systematic studies of autophagy in Type 
I GD due to GBA mutations.  However, Vaccaro et al (2010) studied autophagy in fibroblasts 
from GD patients with bi-allelic saposin-C mutations.  In these cells GCase protein levels are 
comparable to that of control fibroblasts, but the protein is mislocalised with less of it reaching 
the lysosome and causing a reduced level of GCase activity.  These cells had evidence of 
glucosylceramide and lipid storage in lysosomes.  This group found evidence of enhanced 
autophagy in Saposin C mutation associated GD: levels of LC3-II (a marker of mature 
autophagosome) rose to greater levels in disease cells than control cells after starvation 
suggesting enhanced induction of autophagy.  Increased formation of autophagic vesicles upon 
starvation was confirmed with electron micropscopy.  This same group subsequently found that 
decreased degradation of autophagosomes was responsbile for increased autophagosome 
accumulation (Tatti et al, 2012) in these cells.  In the same paper Tatti et al (2012) demonstrate 
normal macroautophagy in 4 GD fibroblast lines.  Pacheco et al (2007) describe normal 
autophagic function in a single fibroblast cell line from a Type I GD patient. Sun et al (2010) 
utilised immunohistochemistry to describe p62 accumulation in neurons and glia in a mouse 
model of neuronopathic GD, and suggested this might reflect impaired autophagy.  However, this 
mouse was a cross between a saposin C null mouse and a V394L/V394L homozygous mouse. 
This is a distinct molecular mechanism from human GD and so the relevance of this result to 
human pathology is debatable.  Of course the different results in fibroblasts and mouse brain 
tissue could reflect a cell specific effect on autophagy of GBA mutations.   
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Alterations in Lysosomal biochemistry described in Gaucher disease fibroblasts. 
Several studies of tissue from GD patients indicate that in addition to deficient GCase activity 
there is secondary alteration of other lysosomal enzyme activity and that this pattern differs 
between brain and peripheral tissue (Moffitt et al, 1978).  In spleen from both non-neuronopathic 
and neuronopathic GD, activities of most lysosomal enzymes are not altered (Glucuronidase, 
sphingomyelinase, arylsulphatase A, beta-galactosidase) while total-beta-hexosaminidase activity 
was elevated 5 fold and galactocerebrosidase 10 fold (Moffitt et al, 1978).  This same study 
found a different pattern in neuronopathic GD brain in which galactocerebrosidase activity was 
twice the control value and total-hexosaminidase was only slightly elevated (around 30%) 
(Moffitt et al, 1978).  Natowicz et al (1991) demonstrated a doubling of tota-betahexosaminidase 
activity in serum from adult GD patients.  Other groups report similar findings in Type II GD 
(Chidayat et al, 1987).  Recently a large increase in beta-hexosamindase activity localised to the 
plasma membrane of GD fibroblasts has been described accompanied by increased GCas-2 
activity (Aureli et al, 2012). 
The cause and consequences of the secondary alterations in lysosomal hydrolases in GD are 
unclear.  It is plausible that they are compensatory mechanisms.  For example elevation of 
galactocerebrosidase could result in increased metabolism of galactosylceramide to ceramide, to 
compensate for reduced conversion of glucosylceramide to glucose and ceramide.  It is likely 
that increased activity of beta-hexosamindase, which produces GM3-ganglioside, will account, at 
least partly, for the elevated levels of GM3 in GD brain and peripheral tissues (Moffit et al, 
1978).  Increased GCase-2 activity is likely to be a compensatory mechanism since GCase-2 can 
metabolise GCase-1 substrates (Aureli et al, 2012).    
Fibroblasts from GD with bi-allelic GBA mutations store no or minimal glucosylceramide, in 
contrast to fibroblasts from GD patients with homozygous saposin-C mutations (see below). 
Saito and Rosenberg (1984) demonstrated that Type II GD fibroblasts accumulate GM3-
ganglioside (around 30% elevation) but not glucosylceramide (Saito and Rosenberg, 1984). 
However with long term culture the elevation of GM3-ganglioside disappeared.   Studying 
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fibroblasts is therefore unlikely to give insight into the pathophysiological consequences of 
substrate accumulation.          
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IIIb. Materials and methods
Generation of patient derived fibroblast cell lines
Skin biopsy was performed after informed written consent was obtained.  Biopsy was performed 
on the non-dominant forearm.  Local anaesthesia with lignocaine and an aseptic technique was 
used.  A 6mm Stiefel biopsy punch was used in all cases with wound closure with steristrips. 
The subcutaneous fat and skin layer were then dissected apart and cultured separately in standard 
fibroblast growth media (DMEM with 4.5 g/L glucose and Glutamax I, Penicillin and 
Streptomycin, 10% Fetal calf serum and 1mM of pyruvate).  Fibroblasts were grown in 5cm 
plates until confluent, trypsinized and split.  At an appropriate passage fibroblasts were harvested 
and frozen in liquid nitrogen in media containing 10% DMSO.
Details of alpha-synuclein over expressing cell lines
SH-SY5Y  cells  (neuroblastoma  cells)  contain  endogenous  alpha-synuclein  levels  that  are 
essentially undetectable by western blot (Alvarez-Erviti  et al., 2010). Therefore, to investigate 
factors modulating cellular alpha-synuclein levels, an SH-SY5Y stable cell line expressing high 
levels of exogenous wild-type alpha-synuclein were used (gift of Dr J Cooper, Department of 
Clinical Neurosciences). The alpha-synuclein protein levels in these lines were approximately 
10-fold higher than wild type SH-SY5Y lines (Alvarez-Erviti et al., 2010). Alpha-synuclein was 
cloned in to pcDNA3.1, transfected in to SH-SY5Y cells, and positive clones selected using the 
antibiotic G418 (20 ug/ml). Exogenously expressed alpha-synuclein contains a hemagglutinin 
tag  (HA)  at  the  C-terminal.  All  SH-SY5Y  cell  lines  were  cultured  in  1:1  DMEM/F12 
(Invitrogen) supplemented with 10% FCS, non essential amino acids, 1 mM sodium pyruvate 
and penicillin-streptomycin. 
Extraction of DNA and GBA sequencing 
DNA was extracted from cultured fibroblasts using the standard QiaAMP DNA mini-kit 
(www.qiagen.com). Briefly, fibroblasts were trypsinized and re-suspended in PBS then treated 
with proteinase K and extraction buffer.  DNA was then precipitated with ethanol and purified 
through a column based system.  The extracted DNA was then used in the sequencing reaction 
described above in Chapter 1 to confirm presence of the GBA mutation detected in the patient’s 
leukocytes in the patient’s fibroblasts.   
153
Determination of glucocerebrosidase enzyme activity levels 
The enzymatic assay was performed on fibroblasts harvested from a confluent 10cm plate of 
fibroblasts using a fluorometric assay with the widely used synthetic substrate 
4-methylumbelliferyl-β-D-glucopyranoside.  Cells were trypsinized, resuspended in media and 
then washed in PBS.  This assay was developed and validated by Dr Matthew Gegg, Department 
of Clinical Neurosciences UCL Institute of Neurology.
The cell pellet was then resuspended in dH2O and sonicated for 1 minute.  Enzyme activity was 
measured in duplicate under 3 conditions: 1. With McIilvaine citrate-phosphate ph 5.4, 2. With 
McIilvaine citrate-phosphate pH 5.4 and sodum taurocholate (149mM, to inhibit GCase-2) and 3. 
With McIilvaine citrate-phosphate pH 5.4 and DNJ (to inhibit GCase-2).  Ten µL of cell sonicate 
was then added to 40µL of solution 1, 2 and 3. Ten µL of dH2O was added to 40µL of 1, 2 and 3 
to make blanks.  Fifty µL of substrate solution (10mM 4-methylumbelliferyl-β-D-
glucopyranoside) was added to each tube at timed intervals and the tubes incubated at 370C for 
60 minutes.  At timed intervals the reaction was then stopped with 0.25M glycine buffer at 
pH10.4.  Fluorescence was then read with excitation of 365nm and emission 450nm.  All 
enzymatic assays were quantified on a Bio Tek Synergy HT plate reader.  
GCase-2 activity was determined from the formula: GCase-2 activity=total GCase activity – 
Gcase activity measured in the presence of DNJ.   An initial control reaction was performed with 
conduritol-b-epoxide (a selective GCase-1 inhibitor) to ensure that the measured activity was 
indeed GCase-1. The GCase-1 activity quoted in this study was that measured in the presence of 
sodium taurocholate, since this activates wild type GCase-1 and inhibits mutant GCase-1, 
permitting distinction of wild type and pathogenic enzyme activity.  
Assay of total-beta hexosaminidase and  beta-galactosidase enzymatic activity
Total-beta hexosaminidase and beta-galactosidase activity levels were measured on fibroblasts 
harvested from a single well of a 6 well plate.  For total-beta hexosaminidase fibroblasts were 
lysed in dH2O and 10 uL of 0.2mg/mL cell lysate was used for the reaction.  Each sample was 
assayed in triplicate in a 96 well format.  Each reaction was started by adding 30 uL of reaction 
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mix to 10 uL of cell lysate per well. The reaction mix was 20uL of buffer (MVA citrate buffer at 
pH 4.2: citrate 0.1M and Na2HPO42H2O 0.2M) and 10 uL of 8mM substrate solution (2.71 mg 
of 4-methylumbelliferyl-2-acetoamido-2-deoxy-6-sulfo-b-D-glucopyransoside/1 mL dH2O). 
The reaction was incubated at 37oC for 30 minutes and stopped by adding 200uL of 0.2M gly-
cine buffer (pH 10.4).  Blanks were reaction mix plus water and the standard was 200 uL of the 
glucosylceramidase standard plus 1mL of stop buffer.  Fluorescence was then read with excita-
tion of 365nm and emission 450nm
Beta-galactosidase was assayed in a 96 well format.  Fibroblasts were resuspended in dH2O and 
sonicated for 1 minute.  Ten microlitres of lysate was added to a 96 well plate in triplicate for 
each cell line and the reaction started by adding 30uL of reaction buffer.  The reaction was incub-
ated for 30 minutes at 37oC and stopped by adding 200uL of 0.2M glycine stop buffer.  Reaction 
mix consisted of 1 mg of substrate (4-methylumbelliferyl-B-D-galactopyranoside) dissolved in 
3mL of assay buffer (MVA citrate buffer at pH 4.2: citrate 0.1M and Na2HPO42H2O 0.2M). 
Blanks were reaction mix plus water and the standard was 200 uL of the glucosylceramidase 
standard plus 1mL of stop buffer.  Fluorescence was then read with excitation of 365nm and 
emission 450nm.  Protein in each sample was measured using the BCA kit described above and 
enzyme activity normalised to protein concentration in each sample.
Western blot analysis of glucocerebrosidase protein levels
Fibroblasts were trypsinised and re-suspended in 1 mL PBS.  Each sample was then treated with 
100 µL lysis buffer  with protease inhibitors (1% Triton X-100 with 1/1000 leupeptin, PMSF, 
pepstatin, NaV) and left on ice for 15 minutes.  Cell lysates were then centrifuged at full speed 
for 10 minutes and the supernatant transferred to fresh tubes.  Protein levels in the lysates were 
assayed with a BCA kit (Pierce product number 23228). 
Lysates were diluted so each lane was loaded with 30ug of protein.  Lysates were mixed with 
loading dye and reducing agents and heated at 70 degrees for 10 minutes.  Lysates were then 
electrophoresed at 200V for 35 minutes on a NuPage gel.  Proteins were transferred to a PVDF 
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membrane, blocked in non-fat milk (5%), treated with primary antibody for 1 hour, washed and 
incubated with HRP labelled secondary antibody.  Antibody binding was then detected using an 
ECL Chemiluminescence kit (Pierce ECL Western blot substrate, product number 32106). 
Primary antibodies used are described in table 10.
Band intensity was quantified using Image-J (National Institutes of  Health, Bethesda, 
http://rsbweb.nih.gov/ij/).  The intensity of the band for the protein of interest for each cell line 
was divided by the intensity of the band for actin (loading control) in the same lane to quantify 
the amount of the protein of interest in that cell line.  
Table 11. Primary antibodies used for Western blotting
Antigen Company Dilution, incubation
Glucocerebrosidase Abcam, ab55080, mouse 1: 1000, 1 hour
Cathepsin D Abcam, ab40697, mouse 1: 1000, 1 hour
Actin Abcam, AC15, mouse 1: 50 000, 1 hour 
BiP/Grp78 Abcam, ab21685, rabbit 1: 1000, 1 hour
Calnexin Abcam, ab22595, rabbit 1: 1000, 1 hour
LIMP-2 Abcam, ab106519, rabbit 1: 1000, 1 hour
P62 Abcam, ab56416, mouse 1: 1000, overnight
LC3 Cell signalling, rabbit 1: 1000, overnight 
LAMP1 Abcam, mouse 1: 1000, overnight
Anti-haemagluttin Covance, HA.11, mouse 1: 5000, 1 hour
Endoglycosidase- H assay for endoplasmic reticulum retention of GCase
To determine endoglycosidase-H sensitivity of GCase 20 ug of protein was mixed with a 1:10 
dilution of glycoprotein denaturing buffer (New England Biolabs P0702S kit) and heated at 100 
0C for 10 minutes.  For each cell line a positive sample and a negative reaction mix was made; in 
the positive reaction mix there was endoglycosidase-H enzyme (2 uL of 500 000 U/mL enzyme 
stock with 2 uL of reaction buffer and 6 uL of dH2O) while the negative reaction mix had dH2O 
instead of endoglycosidase-H.  Both reaction mixtures were incubated at 370C for 12 hours and 
the reaction terminated by adding 6 uL SDS sample buffer and 1 uL of reducing agent.  Western 
blotting using the anti-GCase antibody was then performed using the protocol above.  The endo-
glycosidase-H sensitive fraction (representing the ER retained fraction) of GCase was calculated 
by dividing the intensity of the endo-glycosidase-H sensitive GCase band (the band of lowest 
156
molecular weight which was not seen in untreated lanes, figure 11a) on Western blotting by the 
intensity of all the detected GCase in the lane.  
Proteasomal inhibition
Proteasome inhibition was performed using a published protocol (Ron et al, 2005).  Ten 
centimetre petri dishes of control and disease fibroblasts were incubated with ALLN (26 mM) 
and MG132 (15 uM) for 20 hours.  For each cell line a petri dish treated with MG132 and ALLN 
was compared to a control petri dish treated with DMSO only.  
Immunofluorescence localisation of glucocerebrosidase protein in fibroblasts 
The subcellular localisation of the glucocerebrosidase protein in fibroblasts was studied using 
antibodies raised against human glucocerebrosidase (Abcam, ab55080, 1:50) and calnexin (an 
endoplasmic reticulum marker, Abcam, ab22595, 1:500).  Fibroblasts were grown on 22mm 
coverslips overnight, fixed in 4% paraformaldehyde for 20 minutes and permeablised in ice cold 
methanol for 15 minutes.  Non-specific staining was blocked with 5% goat serum.  Fibroblasts 
were then incubated with the primary antibody for 1 hour at room temperature and washed 
before incubation with secondary antibody (Alexafluor-488 rabbit anti-mouse or Alexafluor-568 
goat anti-rabbit, 1:500) and counterstained with DAPI.  Antibodies were made up in PBS.  Cells 
were photographed using  a fluorescence microscope equipped with an ApoTome and 
AxioVision software (all Zeiss, Jena, Germany).  
       
Quantitative PCR
RNA was  extracted  from   cultured  cells  (<  106  cells)  using  the  RNeasy  kit  (Qiagen)  and 
converted to cDNA with QuantiTect reverse transcription kit (Qiagen). Relative expression of 
GCase,  TFEB  and  β-actin  mRNA  was  measured  with  Power  SYBRgreen  kit  (Applied 
Biosystems) using a STEP One PCR machine (Applied Biosystems). β-actin mRNA levels were 
used to normalise data. Primers are listed in Supplementary Table 1. Relative expression was 
calculated using the ΔCT method.
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Table 12.  Primer targets and sequences for quantitative PCR. 
Target Sequence
Annealing Temp 
(°C)
β-actin
5’-TCT ACA ATG AGC TGC GTG TG-3’
5’-GGT GAG GAT CTT CAT GAG GT-3’
58
TFEB
5’- CCAGAAGCGAGAGCTCACAGAT-3’
5’-TGTGATTGTCTTTCTTCTGCCG-3’
58
GCase
5’-TGC TGC TCT CAA CAT CCT TGC C-3’
5’-TAG GTG CGG ATG GAG AAG TCA A-3’
58
Treatment of fibroblasts with ambroxol hydrochloride
A titration was performed to determine the optimum concentration of ambroxol hydrochloride to
treat fibroblasts with. A single control line and a single GD fibroblast cell line were treated with
10uM, 30uM and 60uM of ambroxol dissolved in DMSO (final concentration of DMSO 60 uL in 
10 mL culture media) for 5 days.”Fibroblasts were grown on 10 cm petri dishes and treated with 
60uM of ambroxol hydrochloride dissolved in DMSO and then harvested for assessment of 
GCase protein and activity levels after treatment.  For each line fibroblasts harvested from a 10 
cm plate of untreated cells was used as a negative control and treated with DMSO only.  
Cholesterol assay
Total cholesterol was measured with the Amplex red cholesterol kit (www.invitrogen.com). 
Fibroblasts were lysed in sucrose buffer (100uL).  Twenty microlitres of cell lysate was added to 
30uL of reaction buffer (supplied in kit).  Cell lysates were assayed in duplicate and in the 
presence of cholesterol esterase in order to calculate total cholesterol.  Fifty microlitres of 
reaction mix was added to each well to start the reaction and the reaction mixture was incubated 
for 15 minutes at 37oC protected from light.  The reaction mixture for one plate of 16 wells (ie 8 
samples done in duplicate) consisted of 15 uL of amplex red reagent, 10 uL of horse radish 
peroxidise, 10 uL of cholesterol oxidase and 1 ul of cholesterol esterase made up to final volume 
with 960uL of reaction buffer (supplied in kit).  After 15 minutes the reaction was quantified on a 
Bio Tek Synergy HT plate reader with excitation 570 and emission 585 nm. 
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Statistical analysis
All analysis was performed using PASW version 20.1 (IBM).  Non-parametric variables (i.e. 
percentages) were compared with a Mann-Whitney U-test.  Parametric variables (i.e. rates of 
enzyme activity) were compared with a t-test.  
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IIIc. Results
Details of patient derived fibroblast cell lines
Table 12 summarises the details of the patient derived fibroblast cell lines.  The 2 carriers who 
underwent skin biopsy were specially selected to have no clinical markers of prodromal PD, no 
family history of PD and to be of advanced age so as to minimise the chances that they would 
develop PD in future (i.e. that they are truly non-manifesting carriers, NMC).  DNA was 
extracted from each cell line and carriage of GBA mutations confirmed by direct sequencing of 
the entire GBA  gene (performed by Dr R Duran, Department of Molecular Neuroscience).  The 
mean age of the disease group (GD, PD and NMC combined) did not differ from that of the 
control group (55.9 years versus 69, p=0.13).  They were also matched for sex (disease group 
8/12 male versus control group 2/3 male, p=0.14).  Fibroblast lines from 3 GBA mutation 
negative PD cases were used as a disease control (2/3 female, mean age 77+/-4 4 years).   In 
addition 4 fibroblast lines from patients with recessive early onset PD with bi-allelic Parkin 
mutations were provided by Dr J Taanman (Department of Clinical Neurosciences, UCL Institute 
of Neurology).  The Parkin cells had the following mutations: 1.  exon 3 deletion/exon 3 
duplication, 2. exon 2-3 deletion/exon 2-3 deletion, 3. exon 3 deletion/P275W, 4. exon 4-5 
deletion/exon 4-5 deletion.  
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Table 13. Clinical and demographic characteristics of patients fibroblast cell lines were 
generated from 
Patient identifier Genotype Prodromal markers of PD
Gaucher disease
GD01, M/50 N370S/c1263del55 Nil
GD02, M/70 N370S/N370S Nil
GD03, M/40 N370S/L444P Nil
GD04, M/61 N370S/203insC Hyposmia, MoCA score 18/30
GD05, M/40 N370S/L444P Isolated motor sign
Carrier
C39, F/80 N370S/Wt Nil
C41, M/62 L444P/Wt Nil
PD-GBA
PD01, F/53 N370S/Wt Clinical PD
PD02, M/45 N370S/Wt Clinical PD
PD03, M/72 L444P/Wt Clinical PD
PD04, F/61 RecNcil/Wt Clinical PD
PD05, E326K/E326K E326K/E326k Clinical PD, no overt GD
Control
CN01, M/78 Wt/Wt Nil
CN02, M/81 Wt/Wt Nil
CN03, F/50 Wt/Wt Nil
GCase protein levels are reduced in GD, PD-GBA, carrier and control fibroblast lines
Western blotting revealed a significant reduction in GCase protein levels in all GD (median 
GCase levels 48 % [IQR 25-55%] of control, P<0.001), PD-GBA (median 60 % [IQR 55-79%] 
of control p<0.001), E326K/E326K [median 80% of control [IQR 75-80%], p=0.003) and NMC 
cell lines (median 85 % of control [IQR 80-100%], p=0.043). 
GCase enzyme activity in GD, PD-GBA, carrier and control fibroblast lines
GCase activity (measured in the presence of sodium taurocholate) was reduced  by 99% 
compared to untreated cells in control fibroblasts treated with the GCase-1 inhibitor conduritol-
b-epoxide (40uM for 12 hours), confirming that the activity we were measuring is that of GCase-
1.  Results of GCase Western blotting and activity are summarised in figure 10. GCase activity 
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(measured in the presence of sodium taurocholate) in GD fibroblasts was significantly lower than 
controls (mean 15 +/- 14 nmol/hour/mg protein compared to 300 +/- 100 nmol/hour/mg protein, 
p<0.001).   The GCase activity of the GD group was  4% (IQR 2-5.6%) of the control group. 
GCase activity in PD-GBA (246 +/- 173 compared to 300+/-100, p=0.49) and NMC (300+/-121, 
p=0.99) was not significantly lower than controls.  GCase activity in fibroblasts from the E326K 
homozygous PD case was significantly reduced (mean activity 99+/-8 nmol/hour/mg protein, 
p=0.001) compared to control, but to a lesser degree than seen in GD.  GCase activity was not 
deficient in fibroblasts from GBA mutation negative PD (mean 250 nmol/hour/mg protein, 
p=0.5).
Correlation between GCase protein levels and GCase enzyme activity
When GCase protein levels and enzyme activity were correlated a significant, positive 
correlation was observed (Spearmans rho=0.79, p=0.001) such that increasing levels of GCase 
protein measured on Western blot were associated with increasing levels of GCase enzyme 
activity.  This suggests that there is a relative loss and not an absolute deficiency of GCase 
activity in PD-GBA and NMC with loss of enzyme activity in proportion to reduction of GCase 
protein levels. 
Assessment of LIMP-2 protein levels in patient derived fibroblasts
To ensure that GCase depletion was not secondary to loss of LIMP-2 expression Western blot 
measurement of LIMP-2 levels was performed.  LIMP-2 levels did not differ from controls in 
either GD (median 93 % of control [IQR 90-105%], p=0.33), PD-GBA (median 93% of control 
[IQR 90-100%], p=0.12) or NMC (median 95% [IQR 90-105%], p=0.1) fibroblasts.
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Assessment of GBA mRNA levels
Figure 11. Assesment of GCase protein and activity levels.
11a. Western blot of GCase protein levels.  Note reduction of GCase protein levels in GD, PD-GBA and NMC 
compared to control lines. G= GBA, A = actin. 
11b. Graph summarising GCase protein levels quantified from Western blot in GD, PD-GBA, E326K/E326K 
and NMC compared to control lines. Results are mean of 3 experiments +/-1 standard deviation.
11c. Graph summarising GCase activity levels in GD, PD-GBA, E326K/E326K and NMC compared to 
control lines. Results are ean of 3 experiments for each cell line in each group +/- standard deviation. 
11d. Graph summarising GCase mRNA levels in GD and PD-GBA cell lines.  There was no reduction of 
transcript levels in N370S/N370S, E326K/E326K or N370S/Wt fibroblasts.
A B
C
D
      Controls     GD1    GD3    GD2     GD4    GD5
     Cont.   PD3      PD1    PD2   Cont.  NMC2 NMC1
  GBA
  GBA
  Actin
163
qPCR assessment of GCase mRNA levels in GD and PD-GBA
GBA transcript levels were reduced in GD lines with N370S/recombinant mutation or 
N370S/L444P and in PD-GBA with L444P or RecNcil mutations, but not in N370S homozygous 
GD, E326K homozygous or PD-GBA fibroblasts with N370S alleles (figure 10d). 
Immunofluorescence of GCase localisation in patient derived fibroblasts
Indirect immunofluorescence using antibodies to GCase protein demonstrated that in control 
cells GCase accumulated in punctate vesicular structures at the cell periphery, in a pattern 
resembling that of LAMP1 immunostaining (figure 11d).  In PD-GBA and NMC cells the pattern 
of GCase staining resembled control.  However, in GD lines there was a severe reduction in 
GCase staining, with few or no punctate vesicular structures seen.   This suggests that even 
though total cellular GCase (assessed by Western blotting) was reduced in PD-GBA and NMC, 
cellular compensatory mechanisms exist to increase lysosomal delivery of GCase and preserve 
enzyme activity.   
Assessing evidence of ER retention of GCase: Endoglycosidase-H digestion of GCase 
ER retained forms of GCase carry carbohydrates which are sensitive to cleavage by 
endoglycosidase-H (figure 11a, 11b). The endoglycosidase-H sensitive fraction of GCase was 
significantly higher in GD fibroblasts  (mean 12.2% +/- 4 compared to mean 0.76 %, p<0.001), 
E326K/E326K (mean 15% +/-5%, p<0.001), and PD-GBA fibroblasts (mean 3.5 +/- 3.5%, 
p=0.026), indicating ER retention (figure 11b).  As expected, cell line PD4 did not show an 
elevated endoglycosidase-H sensitive fraction, in keeping with its mutant allele being a 
recombinant allele and producing no/very truncated protein.  
Assessing evidence of ER retention of GCase: calnexin immunofluorescence
To confirm ER retention of GCase indirect immunofluorescence using antibodies to GCase and 
calnexin (an ER marker) was performed.  In GD lines there was evidence of co-localisation of 
GCase and calnexin in the peri-nuclear region where the ER is located (figure 11d).  Clear 
evidence of ER retention in the PD-GBA lines could not be demonstrated.  This is likely due to 
rapid degradation of the ER retained mutant GCase in these lines resulting in quantities of ER 
retained GCase too small to be detected by immunofluorescence.  
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Figure 12. Evidence of endoplasmic reticulum retention in Gaucher disease.
12a.  Representative western blots of cell lysate treated with endoglycosidase-H for 12 hours.  Note 
appearance of low molecular weight band in GD samples (arrow), which represents endoplasmic 
reticulum retained GCase protein.   “+” lanes were treated with endoglycosidase-H.  
12b.  Bar chart summarising percentage of endoglysosidase-H sensitive GCase in GD, PD-GBA and 
NMC compared to controls.  Results are mean of 3 experiments. 
12c.  Top panel: representative western blot of BiP expression.  Bottom panel: representative 
western blot of calnexin expression.  
2d.  Top panel: immunofluorescence of control cells showing vesicular staining of GCase (green) at 
the periphery of the cell and perinuclear, reticular staining of calnexin (red, ER marker).  Bottom 
panel: colocalisation of GCase and calnexin represented by yellow perinuclear staining with 
minimal green vesicular staining pattern in 2 GD cell lines. 1
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Effect of proteasomal inhibition on GCase metabolism in GD and PD-GBA
Given the reduced GCase protein levels and evidence of ER retention of GCase in the disease 
fibroblasts we hypothesized that reduced GCase levels may result from proteasomal degradation. 
Disease and control fibroblasts were treated with MG132 and ALLN for 20 hours and then 
harvested.  Proteasome inhibition resulted in elevated GCase protein levels, as assessed by 
Western blotting, within GD fibroblasts (mean 49 +/- 43% increase, p=0.029) and PD-GBA 
fibroblasts (mean  increase 21 +/- 17 %, p=0.043) to a greater degree than in controls (mean 2% 
increase).  As expected, cell line PD4 did not show an elevated GCase protein level after 
proteasome inhibition, in keeping with its mutant allele being a recombinant allele and producing 
no/very truncated protein. . 
Assessment of ER stress markers in GD and PD-GBA
Given the evidence of ER retention of GCase we assessed the cell lines for evidence of ER stress 
by Western blotting (figure 11c).  There was  BiP/Grp78 elevation on Western blotting of GD 
(median 60%  increase compared to controls [IQR 20-100% increase], p=0.0016) and PD-GBA 
cells (median 15% increase [IQR 0-50%] , p= 0.0023).    Calnexin levels were significantly 
elevated in GD fibroblasts (median 50 % increase [IQR 50-100%], p=0.003) and PD-GBA 
fibroblasts (median 32 % increase [IQR 12-50%], p=0.019).   It should be noted that ER stress 
markers were not elevated in PD04 (RecNcil/Wt).
Assessment of GCase metabolism in fibroblasts with bi-allelic Parkin mutations
Parkin protein may act as a ubiquitin ligase to facilitate degradation of mutant GCase.  We 
therefore examined metabolism of GCase in fibroblasts from 4 patients with bi-allelic Parkin 
mutations.  There was no alteration in GCase protein levels as assessed by Western blotting 
(Parkin median 102% [IQR 90-110%] of control mean, p=0.69), nor was there alteration in the 
endoglycosidase-H sensitive fraction of GCase (no endoglycosidase-H sensitive GCase is present 
in Parkin cells). To simulate the effects of protein misfolding induced by GCase mutations, we 
treated Parkin and control fibroblasts with tunicamycin (5 µg/mL of media for 24 hours), which 
inhibits glycosylation and proper protein folding. Induction of the unfolded protein response was 
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confirmed by elevation of Bip/Grp78 on Western blotting (greater than 2-fold increase in 
Bip/Grp78 levels in treated compared to untreated cells, data not shown).  After treatment with 
tunicamycin the levels of GCase within Parkin and control cells decreased by a similar amount 
(control medan reduction 32 % [IQR 25-35%] vs disease median  reduction 28.7% [IQR 25-
30%], p =0.58), presumably reflecting degradation of abnormally folded protein.  This does not 
support the contention that Parkin protein is an E3-ubiquitin ligase for GCase.          
Assessment of lysosomal mass in GD, PD-GBA, carrier and control fibroblast lines
To ensure that the reduction in GCase protein levels in the fibroblast lines was not due to 
generalised depletion of lysosomes a study of other lysosomal markers was performed.  LAMP-1 
Western blotting demonstrated no difference in the levels of this endo-lysosomal marker between 
GD (median 95 % of control [IQR 90-105%], p>0.05) and PD-GBA (median 98% of control 
[IQR 95-110%]) or control (figure 12c).  In keeping with this, activity levels of beta-
galactosidase did not differ between GD (mean 600 +/-153 nmol/hour/mg, p=0.3), PD-GBA 
(mean 549 +/200 nmol/hour/mg,  p=0.9) and controls (mean 563+/-119 nmol/hour/mg).  On 
Western blotting, the amount of Cathepsin D was significantly increased in GD (median 55% 
increase [IQR 32-100%], p<0.0001), PD-GBA (median 33% increase [IQR 20-40%],  p=0.002) 
and NMC (median 27% increase [IQR 20-40%],  p=0.003) fibroblasts (figure 11c).  Total beta-
hexosaminidase activity was elevated in GD (mean 12 800+/-3 200 nmol/min/mg, p=0.008), PD-
GBA (12 400+/-5 700 nmol/min/mg, p=0.004)  and NMC (mean 12 750 +/-1800 nmol/min/mg, 
p=0.001) compared to controls (mean 5200+/-1000 nmol/min/mg).  Enzymatic activity of 
GCase-2 (defined as total GCase activity – GCase activity measured in the presence of DNJ [a 
specific inhibitor of Gcase-2]) was significantly higher in GD (mean 7.5+/-3.9 nmol/hour/mg, 
p<0.001), PD-GBA (mean 6.3+/-3.1 nmol/hour/mg, p=0.008) and NMC than controls (mean 
7.3+/-0.9 nmol/hour/mg, p=0.023).  Taken together, these data suggest that there are secondary 
changes in Cathepsin D, GCase-2 and total beta-hexosaminidase metabolism which are not due 
to an overall expansion or contraction of  the lysosomal compartment in GD, PD-GBA and 
NMC.     
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Macroautophagy is normal in GD and PD-GBA fibroblasts 
Given the evidence of subtle lysosomal dysfunction we investigated macroautophagy and 
cholesterol metabolism.  At baseline (i.e. without starvation) there was no elevation of p62 in GD 
(median 101%  [IQR 90-110%] of control, p=0.9),  PD-GBA fibroblasts (median 100 % [IQR 
95-105%] of control, p=0.8) or NMC (median 99% of control, p=0.8)(figure 12a).  At baseline 
(i.e. without starvation) there was no alteration of  LC3-II in GD (median 82% [IQR 75-100%] 
of control, p=0.062) or PD-GBA (median 88% [IQR 80-100%] of control, p=0.13) or NMC 
(median 99% of control)(figure 12a).   Starvation increased LC3-II expression in control (median 
increase 20% [IQR 10-20%]) and GD (median increase 100% [IQR 40-200%], p=0.95) 
indicating intact induction of autophagy.  This suggests that macroautophagy is not abnormal. 
Total cholesterol levels were not altered in GD fibroblasts (mean 142+/-9.7 ug cholesterol/mg 
protein, p=0.096) or PD-GBA  (mean 147+/-27 ug cholesterol/mg protein, p=0.238) compared to 
controls (mean 178+/-17 ug cholesterol/mg protein).  
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Figure 13. Assessment of autophagy and  lysosomal metabolism in GD and PD-GBA.
13a.  Western blots of LC3 and p62.  There is no alteration in levels of LC3-II or p62 in GD or PD-GBA 
compared to control cell lines.
13b.  Graph of total beta-hexosaminidase activity in GD , PD-GBA and NMC compared to control.  Results 
are mean of 3 experiments for each cell line in each group +/- 1 standard deviation. 
13c. Western blot demonstrating increased cathepsin D (CTSD) levels in GD and PD-GBA compared to 
control (top panel), and unaltered LAMP1 levels in GD and PD-GBA (bottom panel) with large increases in 
expression of LAMP1 after ambroxol treatment (lanes marked +).
13d.  Graph summarising densitometric analysis of cathepsin D levels in GD and PD-GBA. 
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Effect of ambroxol hydrochloride on GCase metabolism
To determine the optimal dose of ambroxol hydrochloride, a titration of 10uM, 30uM and 60uM 
treatment was performed.  The titration was performed in a single GD cell line compared to 
control.  As assessed by Western blotting an increase of 100%, 100% and  400% was noted with 
10uM, 30uM and 60uM of ambroxol respectively in the GD cell line and 5%, 15% and 20% in 
the control line.  Treatment at 60uM produced the greatest increase in GCase protein expression, 
it was therefore decided to use this dose to evaluate the effects of ambroxol.  
Ambroxol treatment resulted in a significant elevation of GCase protein levels in GD (median 
increase 100% of untreated cells [IQR 87-200% increase], p=0.004) and PD-GBA (median 
increase 50 % of untreated cells value [IQR 50-130%], p=0.04) compared to control fibroblasts 
(median 10 % increase of untreated [IQR 10-20%], p>0.05) on Western blotting (figure13a). 
Ambroxol treatment also resulted in a significant elevation of GCase activity levels (figure 13c). 
In GD fibroblasts there was a median 400%  increase (IQR 300-500%, p=0.004) in GCase 
activity (measured in the presence of sodium taurocholate) compared to untreated cells.  After 
ambroxol treatment the GCase activity of GD fibroblasts remained significantly below mean 
control cell activity (median 13.7%  [IQR 7.1-18%] of control group activity, p<0.001). In PD-
GBA fibroblasts there was a median 375% (IQR 275-500%) increase in enzyme activity 
(p=0.009). In control cells GCase activity increased a median of 40% (IQR 30-40%).  Enzyme 
activity in PD04 increased by a median of 30 %, being no different from controls (p>0.05). 
Treatment with ambroxol resulted in a complete disappearance of the endoglycosidase-H 
sensitive fraction from both GD and PD-GBA fibroblasts (figure 14b). This suggests a reduction 
in the proportion of GCase retained in the endoplasmic reticulum after ambroxol treatment.
Ambroxol hydrochloride induces GBA gene transcription
GBA mRNA levels increased significantly in GD (median 100% increase [IQR 87-150%], 
p<0.05), PD-GBA (median 200% [IQR 150-200%], p<0.05) and control cell lines (median 100% 
[IQR 100-150%], p<0.05):  suggesting induction of transcription (figure 13d).  This was 
associated with upregulation of TFEB transcript levels in GD (median 152% [IQR 100-150%], 
p<0.05), PD-GBA (median 25% [IQR 15-25%], p<0.05) and control (median 100% increase, 
p<0.05).   
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Effect of ambroxol hydrochloride on lysosomal metabolism
Ambroxol treatment resulted in elevation of LAMP-1 protein levels, total cholesterol and beta-
galactosidase activity accompanied by significant reductions in cathepsin D levels and total beta-
hexosaminidase activity.  LAMP-1 protein levels increased by a median of 100% (IQR 100-
200%) in GD, 100% (IQR 100-200%) in PD-GBA and 100% (IQR 100-200%) in controls. Total 
cholesterol increased by a median of 200% (IQR  100-600%) in GD, 300% (IQR 150-650%) in 
PD-GBA and 300% (IQR 100-300%) in controls. Beta-galactosidase activity increased to the 
same extent in GD (median 50% increase, IQR 45-100%, p=0.54),  PD-GBA (median 70%, IQR 
36-100%, p=0.90) and control (median 60%, IQR 50-60%).    In GD fibroblasts Cathepsin D 
levels  were reduced by a median of 35 % [IQR 25-50%] compare to untreated cell lines 
(p<0.001).  In PD-GBA cell lines Cathepsin D levels were reduced by a median of 22% [IQR 15-
40%] compared to untreated cells (p=0.0002). Cathepsin D levels did not change in ambroxol 
treated controls. Total beta-hexosaminidase activity fell by a median of 36.5% (IQR 26.2-50% 
fall, p=0.012) in GD and 30% (IQR 20-50%, p=0.019) in PD-GBA with a median increase in 
activity of 8% in controls.  GCase-2 activity was significantly reduced in both GD (mean 1.6+/-
0.3 after treatment compared to mean 7.5+/-3.9 nmol/hour/mg before, p=0.012) and PD-GBA 
(mean  0.5+/-0.3 after treatment compared to mean 6.3+/-3.1 nmol/hour/mg before, p=0.001) 
after ambroxol treatment, but there was no change in control cell GCase-2 activity (figure 14a). 
This suggests an increase in lysosomal mass with reduction in cathepsin D and beta-
hexosaminidase in response to restored GCase activity in GD and PD-GBA.      
Ambroxol hydrochloride treatment increases ER stress markers but not cell death 
After ambroxol treatment BiP levels rose in GD (median 33% increase [IQR 24-40%], p=0.001) 
but not PD-GBA (median increase 1%, IQR -3% to +4%, p=0.3).  Calnexin increased in GD 
(median 52% increase, IQR 33-100%, p<0.001) but not PD-GBA (median increase 3%, IQR 0-
9%, p=0.065).  There was no evidence of cell death after ambroxol treatment of control or GD 
fibroblasts (median decrease of 15%  fluorescent units/5 000 cells treated for GD cells versus 
median decrease of 11% of FU/5 000 cells for control treated, p=0.96).   
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Figure 14. Effect of ambroxol treatment on GCase  in GD and PD-GBA fibroblasts.
14a.  Western blot demonstrating significant increase in GCase protein levels (top row) after 
ambroxol treatment of GD and PD-GBA fibroblasts. Middle row shows decrease in 
cathepsin D after ambroxol treatment.  Lanes marked (+) were treated with ambroxol.   
14b.   Graph summarising results of densitometry of  GCase protein levels on Western blot 
after ambroxol treatment demonstrating significant increase in GD and PD-GBA  cell lines. 
Results are mean of 3 experiments +/- 1 standard deviation.    
14c.  Graph demonstrating absolute increase in GCase activity after ambroxol treatment. 
Results are mean of 3 experiments +/- 1 standard deviation. Even though there was a 
significant increase in activity after ambroxol treatment, activity in GD cells did not 
approach the GCase activity range of control fibroblasts. 
14d.   Graph demonstrating the increase in GCase transcript levels, expressed as a 
percentage of untreated controls.  Results are mean of 3 experiments +/- 1 standard 
deviation. 
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Figure 15.   Effect of ambroxol treatment on lysosomal markers.
15a.  Graph demonstrating a significant decrease in absolute GCase-2 activity levels after 
ambroxol treatment.  Results represent mean of 3 experiments +/- 1 standard error.  Control 
represents 3 control lines measured in triplicate.  
15b.  Western blot demonstrating a decrease in the endo-glycosidase H sensitive fraction of 
GCase in ambroxol treated GD cells.  This implies a reduction in endoplasmic reticulum trapping 
of GCase.  Lanes marked “-“ are without ambroxol treatment and “+” are after ambroxol 
treatment.  All lanes were treated with endo-glycosidase H.   Arrows point to endo-H sensitive 
band (ie lowest weight band). 
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Ambroxol hydrochloride decreases alpha-synuclein levels in alpha-synuclein over 
expressing neuroblastoma cell lines
After 5 days of ambroxol hydrochloride treatment (60 uM) levels of  HA-tagged alpha- synuclein 
in the over expressing neuroblastoma cell line decreased significantly (median fall 15% [IQR 15-
25%], p=0.0034)(figure 15a-c).  This was accompanied by an increase in GCase (median 30% 
increase [IQR 15-40%], p=0.011) and LAMP-1 protein levels (median 140% increase [IQR 125-
155%], p=0.031).  This suggests that ambroxol is acting to increase lysosomal mass and thus 
degrade alpha-synuclein.  
Figure 16.  Effect of ambroxol treatment on alpha-synuclein over expressing neuroblastoma 
cells.
16a. LAMP-1 Western blot demonstrating increased LAMP-1 expression after ambroxol 
treatment. 
16b. GCase Western blot demonstrating increased GCase expression after ambroxol 
treatment.
16c. Western blot demonstrating decreased HA tagged alpha-synuclein in ambroxol treated 
neuroblastoma cells.  
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IIId. Discussion.  
Mechanisms by which GBA mutations cause loss of GCase activity 
Here we report a detailed characterisation of the cellular processing of mutant GCase protein in a 
panel of fibroblasts from GD patients (n=5), PD-GBA patients (n=5) and non-manifesting 
carriers (n=2).  The GD fibroblasts express a reduced amount of GCase protein when compared 
to control fibroblasts (median GCase levels 48 % [IQR 25-55%] of control, P<0.001).  This is 
entirely in keeping with the results of Ron et al (2005) who demonstrated GCase levels of 30-
70% of normal in Type I GD fibroblasts.  The GCase protein levels in PD-GBA (median 60 % 
[IQR 55-79%] of control p<0.001), p=0.003) and NMC cell lines (median 85 % of control [IQR 
80-100%], p=0.043) were reduced compared to control fibroblasts but not to the same extent as 
in Type I GD fibroblasts.  This is in keeping with the results of Gegg et al (2012) who 
demonstrated  reduced GCase protein levels on Western  blotting of substantia nigra from PD 
brain from patients with heterozygous GBA  mutations.  These results clearly reflect  the 
presence of 1 wild type allele in the heterozygous fibroblasts.  
The mean GCase activity level for the Type I GD cells as a group was 5% of control values. 
This is similar to the values reported by Ron et al (2005) for Type I GD.  The GCase activity 
levels of the PD-GBA and NMC fibroblasts were not significantly lower than that of the control 
cells.  However, when the GCase protein levels for each cell line were correlated with the GCase 
enzyme activity was proportional to the amount of GCase protein.  Thus while there was not an 
absolute deficiency of GCase activity in the heterozygous cells there was evidence of a relative  
reduction of GCase activity in proportion to GCase protein depletion.  This is in keeping with the 
work of Lu et al (2011) who demonstrated that N370S or L444P mutant GCase extracted from 
GD fibroblasts had near normal enzymatic activity and that it was the reduction in GCase protein 
levels in these cells which accounted for depletion of GCase activity.   
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In the cell lines studied here fibroblasts carrying  N370S and  E326K mutations had normal 
levels of GBA transcripts. The L444P, recombinant (RecNcil, Rec[c.1263del55] (Sarria et al, 
1999)  and 203insC mutations (which is predicted to cause a frameshift and premature stop 
codon, with a truncated transcript that is likely to decay (Frischmeyer and Dietz, 1999)) were 
associated with reduced mRNA levels.   Previous studies had demonstrated normal levels of 
L444P and N370S mRNA  with reductions of A120G and P415R mutation bearing mRNA 
(Ohashi et al, 1990) in transfected NIH 3T3 cells.  Tayebi et al (1998) demonstrated reduced 
mRNA levels for a patient with homozygous GBA null mutations .  However, the mRNA in these 
studies was quantified with Northern blotting, which is less sensitive for detection of mRNA 
levels than the qPCR technique utilised in the current study.   Thus the reduction in transcript 
levels for certain GBA mutations we identified is likely to reflect the greater sensitivity of our 
technique.  Moreover, Germain et al (2001) demonstrated severe reduction in GBA mRNA levels 
caused by the g.5255del T GBA mutation, predicted to cause a frameshift and stop codon.  This 
demonstrates that qPCR can detect reductions in GBA transcript levels due to GBA mutations.  It 
seems reasonable to suggest that the RecNcil and Rec[c.1263del55] mutations will produce an 
unstable mRNA or reduce transcription given the structural re-arrangement of the GBA gene on 
these alleles.  It is unclear why the L444P mutation should cause a reduction in GBA transcripts 
since the mutation is not predicted to cause mRNA instability (Hruska et al, 2008).   It might be 
that as the misfolded L444P protein induces the unfolded protein response there is a reduction in 
L444P transcription as part of this. Given that the N370S and E326K variants are broadly 
accepted as less severe mutations it might be that the unfolded protein response is induced to a 
lesser extent than for L444P with no accompanying reduction in GBA transcription.  Nonsense 
mediated decay is unlikely to play a role given that the L444P mutation is not predicted to form a 
premature stop codon (Hruska et al, 2008).   
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However, given that all cell lines had reduced GCase protein and activity levels a post-
translational process must also play a role in interefering with GCase activity in these cells. 
Previous work has demonstrated evidence of ER retention and proteasomal degradation in GD 
(Ron and Horowitz, 2005).  Here we confirm that this process occurs in fibroblasts from Type I 
GD patients and PD-GBA.  The endoglycosidase-H sensitive fraction of GCase was increased in 
all cells (apart from the PD line RecNcil/Wt), and in GD fibroblasts GCase protein and the ER 
marker calnexin co-localised on immunofluorescence.  Treatment with proteasome inhibitors 
increased GCase levels suggesting that ER retained GCase is degraded in the proteasome.  Thus 
GBA mutations reduce GCase activity by at least 2, non-mutually exclusive mechanisms:   1. 
reducing GBA translation or causing transcript instability and 2. triggering ER retention and 
proteasomal degradation.  Both of these processes represent valid therapeutic targets.  
Alternative explanations for the depletion of GCase from the fibroblasts include loss of a 
cofactor for GCase synthesis or a generalised loss of lysosomes.  As discussed in the introduction 
LIMP-2 is vital for GCase trafficking to the lysosome and genetic variation at SCARB-2, the 
LIMP-2 gene, is associated with sporadic PD (Michelakakis et al, 2012).  It was therefore 
conceivable that alterations in LIMP-2 expression might occur in response to decreased GCase 
activity (i.e. increased expression of LIMP-2 to compensate for reduced GCase expression) or 
that genetic variation in SCARB2 associated with PD might result in reduced LIMP-2 expression 
and secondary depletion of GCase.  Our Western blotting study clearly shows that LIMP-2 
protein levels are not depleted in GD or PD-GBA/NMC and thus this does not contribute to loss 
of cellular GCase in association with GBA mutations.  To assess for a generalised decrease in 
lysosomal mass in GD we performed Western blotting for LAMP1 expression, demonstrating no 
difference between disease and control cells, suggesting no general loss of lysosomes.   Likewise 
there is no evidence of loss of lysosomes in PD-GBA brain tissue (Gegg et al, 2012).   
We recently described loss of GCase protein and enzyme activity in the substantia nigra of PD-
GBA and PD without GBA mutations (Gegg et al, 2012), and cell biology studies suggest that 
alpha-synuclein accumulation depletes GCase (Mazzulli et al, 2011). The reduction in GCase 
activity and protein in heterozygous GBA mutation carriers, as evident in NMC fibroblasts, may 
thus predispose to age related loss of neuronal GCase activity secondary to age related alpha-
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synuclein accumulation.  Several studies indicate that alpha-synuclein accumulates in brain 
tissue from aged humans without PD providing support for this mechanism (Mazzulli et al, 
2011). Once this reduction in GCase activity crosses a hypothetical critical threshold it will result 
in a “feed-forward” mechanism as lysosomal dysfunction leads to alpha-synuclein accumulation, 
which in turn exacerbates loss of GCase. Since all GBA mutations are predicted (or proven) to 
cause ER retention or reduced GBA transcription/mRNA stability this hypothesis explains how 
both recombinant alleles and point mutations in the GBA gene can predispose to PD.
How alpha-synuclein inhibits GCase activity is unknown.  Alpha synuclein accumulation in cells 
has been shown to alter endoplasmic reticulum calcium efflux and enhance autophagic activity 
(Cali et al, 2012), this could in theory deplete cellular GCase and also cause endoplasmic 
reticulum retention of GCase as the protein requires calcium ions to aid folding.  Colla et al 
(2012) demonstrate that  alpha-synuclein oligomers accumulate in the endoplasmic reticulum. It 
has been shown that alpha-synuclein and GCase can physically interact, suggesting that alpha-
synuclein oligomers could physically trap GCase in the endoplasmic reticulum.  We could not 
examine the interaction between GCase activity and alpha-synuclein in our cell model since 
fibroblasts do not express alpha-synuclein. But clearly a cell with compromised GCase activity 
and upregulated unfolded protein response will be vulnerable to depletion of GCase secondary to 
alpha-synuclein accumulation.       
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The role of Parkin protein in GCase metabolism
There is evidence that Parkin protein acts as a ubiquitin ligase to facilitate the degradation of 
mutant GCase protein (Ron et al, 2010). However, this evidence comes from cell lines over 
expressing Parkin and GCase proteins.  Here we assessed the metabolism of GCase in fibroblasts 
from patients with bi-allelic Parkin mutations.  We hypothesised that mutant Parkin proteins 
would not be able to ubiquitinate GCase and target it for degradation.  Neither GCase protein 
levels, enzyme activity nor the endoglycosidase-H GCase sensitive fraction were altered in 
Parkin cells.  This is in keeping with the study of Ron et al (2010) which demonstrated that 
Parkin only bound to and ubiquitinated mutant, and presumably misfolded, GCase protein.  We 
then treated cell lines with tunicamycin, which inhibits protein glycosylation and induced the 
Unfolded Protein Response, in order to simulate GCase misfolding due to GBA mutations.  This 
caused degradation of GCase protein in both control cells and Parkin mutation carrying cells to 
the same degree.  Tunicamycin induces severe protein misfolding and triggers the Unfolded 
Protein Response, clearly causing degradation of GCase.  If Parkin protein played an important 
role in targeting mutant, misfolded GCase to the proteasome then GCase degradation should 
have been inhibited in these cell lines.  It might be that Parkin protein only plays a role in 
“neuronal” SHSY-5Y  cell lines utilised by Ron et al (2010) or that Parkin and GCase only 
interact when the proteins are over expressed and not at endogenous levels.  Clearly further 
studies into the interaction between Parkin and GCase are required to define the importance of 
Parkin as an E3 ubiquitin ligase for GCase.                                      
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The role of ER stress in GD and PD-GBA pathogenesis 
Induction of the Unfolded Protein Response and ER stress are well described in both PD and 
Lysosomal storage disorders.  Wei et al (2007) demonstrated upregulation of calnexin, Grp78 
and XBP1 in fibroblasts from a range of neuronopathic (neuronal ceroid lipofuscinosis) and non-
neuronopathic (Type I GD, GM1-gangliosidosis, Tay-Sachs disease) Lysosomal Storage 
Disorders.  Gegg et al (2012) showed upregulation of ER stress markers in substantia nigra from 
PD-GBA.  There are several post-mortem studies demonstrating increased expression of 
endoplasmic reticulum stress markers in PD brain (see general introduction).  Several cell 
biology studies indicate that alpha-synuclein accumulation can directly induce endoplasmic 
reticulum stress suggesting that this pathway is of central importance in dopaminergic cell death 
(Colla et al, 2012). The expression of  ER stress markers in Lysosomal Storage Disorders chiefly 
relates to ER retention of mutant lysosomal enzymes.  There is also evidence that lysosomal 
inhibition with ammonium chloride can induce ER stress, presumably secondary to inhibition of 
trafficking of proteins from ER to lysosome.  Both GD and PD-GBA fibroblasts had elevated 
BiP/Grp78 and calnexin levels, suggesting ER stress.  That ER stress markers are upregulated in 
fibroblasts from NMC suggests that ER stress is an important early mechanism in the 
pathogenesis of PD-GBA.  Moreover, as fibroblasts express only very low levels of SNCA  it is 
clear that ER stress is not related solely to Lewy body accumulation and is therefore an early 
process in PD-GBA.  
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Autophagy and lysosomal biochemistry in GD and PD-GBA
There were no gross alterations in lysosomal metabolism in the GD or PD-GBA fibroblasts. 
Lysosomal mass was not altered.  This is in keeping with data from GD fibroblasts, spleen, liver 
and bone marrow mesenchymal cells (Moffitt et al, 1978; Campeau et al, 2009). 
Macroautophagy was not altered in GD or PD-GBA fibroblasts. At baseline neither p62 nor LC3-
II levels were different to controls, and LC3-II was induced by starvation to a similar extent in 
GD and controls.    These results are similar to that of Tatti et al (2012) who demonstrated 
normal macroautophagy in N370S/N370S fibroblasts.  In contrast the same group report 
impaired autophagy in fibroblasts from homozygous saposin C mutation associated GD 
(discussed below).  Though there was no clear increase in lysosomal mass in GD or PD-GBA 
cathepsin D protein levels, GCase-2 activity and total-beta hexosaminidase activity were 
increased.   Cathepsin D mRNA levels have been reported to be elevated in brain tissue from a 
mouse model of neuronopathic GD (Vitner et al, 2010) and Cathepsin B, K and S activities are 
elevated in GD plasma (Moran et al, 2000).  Cathepsin D can proteolytically activate saposin C 
by cleaving it from pro-saposin and thus Cathepsin D upregulation may be a homeostatic 
response to decreased GCase activity in GD fibroblasts.  Multiple studies report elevation of 
total-beta-hexosaminidase activity in GD fibroblasts, spleen and blood with some also 
identifying elevated activity in the blood of carriers (Moffitt et al, 1978).   GCase-2 can 
metabolise GCase-1 substrates and clearly upregulation of GCase-2 could be a compensatory 
mechanism for reduction of GCase-1 activity (Aureli et al, 2012).  
 
It is noteworthy that several studies indicate that the alterations in lysosomal biochemistry in 
peripheral tissues and human brain differ; for example the elevation in beta-hexosaminidase 
activity is not reported in post-mortem brain from GD patients.  Thus the absence of defective 
macroautophagy in the fibroblasts studied here should not be taken as evidence that defective 
autophagy does not occur in the brain in patients with GBA mutations.  Studies of mouse models 
of neuronopathic GD have demonstrated accumulation of p62 histologically (Sun et al, 2010), 
suggesting that defective autophagy may occur in the central nervous system in GD.  This issue 
remains to be conclusively addressed in mouse models and neuronal culture systems.   
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It is interesting to contrast the reported alterations in macroautophagy in GD with homozygous 
saposin C mutations (Tatti et al, 2012) compared to our GD fibroblasts with GBA mutations.  In 
saposin C deficient cells there is failure of autophagosome degradation due to cathepsin B and D 
downregulation. Transfection of cathepsin B and D restored autophagy in these cells.  In GD 
there is no clear evidence of defective autophagy and cathepsin D levels are upregulated in 
fibroblasts and cathepsin B reported to be upregulated in blood (Moran et al, 2000).   In saposin 
C deficient cells GCase is potentially active (ie in vitro assays using synthetic substrates show 
normal activity) but in vivo  activity is severely deficient as GCase is not trafficked properly to 
the lysosome resulting in glucosylceramide and ceramide accumulation.  In contrast GD 
fibroblasts with GBA mutations have relatively more residual GCase activity and store little or no 
substrate.  It might be this substrate accumulation which alters autophagy in GD with saposin C 
mutations. Thus the organs which accumulate substrate in GD, such as the brain, may manifest 
altered autophagy.   
The mechanisms by which alpha-synuclein are degraded are thought to involve both the 
proteasome and the lysosome.  Some argue that proteasomal degradation is more important 
under physiological conditions and that lysosomal degradation via chaperone mediated 
autophagy (CMA) is more significant under pathological conditions.  Alvarez et al (2010) 
demonstrate that Hsc70 binds to alpha-synuclein and directs it to the lysosome by docking with 
LAMP2.  The identy of the proteases involved in alpha-synuclein degradation remain unclear. 
One candidate is cathepsin D, overexpression of this enzyme results in reduced cellular alpha-
synuclein levels and cathepsin D knock out mice have evidence of neuronal alpha-synuclein 
accumulation (Cullen et al, 2009).  The upregulation of cathepsin D reported by us and others, 
suggests that it is not alteration of this enzyme's activity which leads to alpha-synuclein 
accumulation in association with GBA mutations. Interestingly, depletion of GM1-ganglioside 
has been postulated to disrupt alpha-synuclein interactions with membranes and possibly lead to 
its pathological accumulation (Martinez et al, 2007).  Increased activity of beta-hexosaminidase 
could result in depletion of GM1-ganglioside and consequent perturbation of alpha-synuclein 
interactions with membranes.  The upregulation of beta-hexosaminidase activity is relevant in 
this regard as a possible mechanism by which secondary changes induced by GBA mutations 
could result in alpha-synuclein accumulation.  Against this is the fact that the product of this 
183
enzyme, GM3-ganglioside, has been shown to bind alpha-synuclein and inhibit aggregation (Di 
Pasquale et al, 2010).    An alternative mechanism is that altered lysosomal biochemistry in GD 
and PD-GBA may inhibit CMA.  This has been demonstrated in mucolipoidosis type IV 
fibroblasts (Venugopal et al, 2009) which displayed reduced degradation of CMA targets upon 
serum withdrawal.  However, in this disease the mutated protein TRPML1 directly interacts with 
Hsc 70 giving clearly explaining why CMA should be abnormal.  There is no rationale to support 
the hypothesis that CMA will be abnormal in GD and it seems less likely that this is the 
mechanism by which GBA mutations lead to alpha-synuclein accumulation.  However, given that 
alpha-synuclein is not expressed in fibroblasts, neuronal culture systems should be used to 
examine the mechanisms by which altered lysosomal biochemistry caused by GBA mutations 
leads to Lewy body formation.  
Reductions in total cholesterol including low density and high density lipoprotein have been 
consistently reported in blood from GD patients (Stein et al, 2011) and heterozygous carriers 
(Pocovi et al, 1998).  This abnormal lipid profile is reversed by enzyme replacement therapy and 
is attributed to increased catabolism of apolipoproteins B100 and A1.    We could not identify 
any alteration of total cholesterol levels in GD or PD-GBA fibroblasts. Some authors have 
reported that GD fibroblasts have elevated cholesterol levels (Salvioli et al, 2005).  However, 
this report used Filipin staining, which is not a quantitative technique.  Ron and Horowitz (2007) 
describe elevated intracellular cholesterol in dermal fibroblasts from a severely affected GD 
patient and postulate that elevated intracellular cholesterol is associated with more severe 
phenotypes in GD.  However,  this patient has been shown to carry a heterozygous SCARB2 
mutation, this gene has been implicated in cholesterol flux and this might explain why this cell 
line had elevated intracellular cholesterol (Velayati et al, 2011).  The role of alterations in 
intracellular cholesterol metabolism in GD remains unclear, but of potential relevance since 
lysosomal cholesterol can inhibit GCase (Salvioli et al, 2005)  and disruptions in membrane 
lipids could potentially result in alpha-synuclein accumulation.  
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The cellular pathophysiology of the E326K GBA mutation 
It is unclear if the E326K variant should be considered a benign polymorphism, a pathogenic 
mutation or a genetic modifier of GD (Horowitz et al, 2011).  In the context of PD it is clear 
thatE326K is found more frequently in PD than in controls (Lesange et al, 2011; Pankratz et al, 
2012; Ron and Horowitz, 2010), both  in the heterozygous and homozygous state, and can be 
considered a genetic risk factor for PD. No GD patients with homozygous E326K variants have 
been reported, but there is evidence that it acts as a genetic modifier since when it is present in 
GD patients with homozygous or compound heterozygous GBA mutations it is associated with a 
more severe phenotype (Horowitz et al, 2011).  However, given the high frequency of clinically 
silent GD with homozygous N370S mutations it is plausible that E326K homozygosity could 
cause very mild, subclinical GD which is not clinically recognised (Balwani et al, 2010). To 
resolve this issue will require comprehensive phenotyping of E326K homozygotes, for example 
with nuclear medicine bone scans and bone marrow histological examination.  
Thus, it is not clear if the E 326K homozygous PD patient should be classified as having PD as a 
clinical manifestation of GD or PD related to GBA mutations.   That the E326K fibroblasts had 
GCase protein levels and activity intermediate between controls and GD lines fits with reports of 
GCase activity in transfected cell systems where E326K activity was compared to that of  N370S 
and L444P (Horowitz et al, 2011).  Given the intrinsic variability of fibroblasts, the GCase 
activity obtained from a single cell line does not permit us to conclusively state that E326K 
homozygosity will not cause enzyme deficiency sufficient to cause GD.   However, it seems that 
the E326K variant has a less severe molecular and cellular effect on GCase than the GD 
associated mutations and this might explain its reduced pathogenicity.  
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Ambroxol hydrochloride as a possible enzyme enhancing strategy for GD and PD-GBA
There is strong evidence from several research groups that ambroxol hydrochloride improves 
GCase protein levels and enzymatic activity; probably by acting as a chaperone and increasing 
mutant GCase protein folding and lysosomal delivery (Maegawa et al, 2009; Luan et al, 2012). 
Here we confirm these  findings by demonstrating increased GCase protein levels, on Western 
blot, and increased enzymatic activity in fibroblasts from Type I GD patients treated with 
ambroxol hydrochloride.  We also show that ambroxol hydrochloride enhances the GCase 
protein levels and enzyme activity in PD-GBA fibroblasts.  In GD, PD-GBA and control 
fibroblasts treatment with ambroxol hydrochloride there was a robust  and significant elevation 
of GBA mRNA levels.  This suggests that ambroxol can induce GBA transcription.  Control, GD 
and PD-GBA fibroblasts treated with ambroxol demonstrated increased transcription factor EB 
(TFEB) mRNA levels.  This demonstrates that ambroxol upregulates GBA mRNA levels via a 
pathway involving TFEB.  However, the fact that ambroxol treatment caused a significant 
reduction in the endoglycosidase-H sensitive fraction of GCase (i.e. the endoplasmic reticulum 
retained portion of the protein, figure 14b) suggests that it also acts as a chaperone. 
Despite the significant increase in GCase protein levels and activity in GD fibroblasts treated 
with ambroxol, the absolute GCase activity in these cells remained very low compared to control 
fibroblasts (see figure 13c).  It is unclear if this increase in GCase enzyme activity would be 
clinically relevant.  However, the fact that it is associated with reductions in the elevation of 
cathepsin D and GCase-2 and tota-betahexosaminidase activity suggests that it is having some 
beneficial effect on cellular biochemistry.  Importantly, our study of ambroxol treatment of 
alpha-synuclein over expressing neuroblastoma cells demonstrated a reduction in alpha-synclein 
levels.  This was accompanied by increases in GCase and LAMP-1 protein.  Alpha-synuclein is 
degraded by both macroautophagy and chaperone mediated autophagy, which are dependent 
upon the lysosome (Alverez et al, 2010).  Thus it seems reasonable to suggest that increased 
lysosomal mass associated with TFEB induction by ambroxol treatment might result in increased 
alpha-synuclein turnover.  It is also possible that ambroxol treatment could result in decreased 
alpha-synuclein synthesis.  Whilst we cannot exclude this, it seems less likely given that TFEB 
induction has not been reported as a mechanism of transcriptional repression (Palmieri et al, 
2011).   It is also not clear from our study whether the increase in GCase activity would result in 
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reduction of substrate accumulation since fibroblasts accumulate minimal, if any, substrate in 
GD. 
In keeping with ambroxol hydrochloride inducing TFEB expression, there was a general increase 
in lysosomal mass in treated cells.  In control fibroblasts LAMP-1, beta-galactosidase and total 
cholesterol increase significantly with minor increases in cathepsin D and GCase protein levels 
and total-beta hexosaminidase activity.  The increase in cholesterol may reflect increased syn-
thesis of lysosomal membranes.  However, it has been reported that TFEB can induce PRKAG2, 
a member of the AMPK (MAP kinase) gamma subunit family which stimulates cholesterol bio-
synthesis, which may explain the large increase in total cholesterol after ambroxol treatment 
(Palmieri et al, 2011).  The pattern in GD and PD-GBA fibroblasts was similar but with signific-
ant decreases in cathepsin D protein levels, GCase-2 activity and total beta-hexosamindase activ-
ity.  This suggests that ambroxol is triggering a general increase in lysosomal mass by inducing 
TFEB, but that in GD and PD-GBA cells the accompanying improvement of GCase deficiency is 
reversing the postulated compensatory mechanisms of cathepsin D, GCase-2 and beta-hexosa-
minidase over expression.   In support of the contention that reduced cathepsin D expression re-
flects normalisation of lysosomal function is the observation that enzyme replacement therapy 
reduces cathepsin B, K and S activity in the plasma of GD patients (Moran et al, 2000).  
Transcription factor EB (TFEB), a member of the basic helix-loop-helix leucine-zipper family of 
transcription factors is a “master regulator” of lysosomal function (Palmieri et al, 2011).     TFEB 
induces lysosomal gene expression by binding to E-boxes in their promoters.  This genetic 
network has been collectively termed CLEAR (Coordinated Lysosomal Expression and 
Regulation) and consists of at least 471 target genes (Palmieri et al, 2011).  Cells overexpressing 
TFEB have increased lysosomal number/mass and increased ability to degrade lysosomal 
substrates.  Most TFEB targets are lysosomal proteins including enzymes (e.g. GCase, 
cathepsins, hexosaminidase), lysosomal membrane proteins (e.g. LAMP1), proteins essential for 
lysosomal acidification, lysosomal biogenesis and autophagy (e.g. beclin-1)(Palmieri et al, 
2011).  TFEB targets also include endosomal, mitochondrial and endoplasmic reticulum proteins. 
TFEB itself is induced by peroxisome proliferator-activated receptor gamma, coactivator 1 alpha 
(PPARGC1A)  binding to its promoter (Tsunemi et al, 2012).  An additional layer of regulation 
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comes from  mammalian target of rapamycin (mTOR) complex 1 (mTORC1), which controls 
phosphorylation and nuclear translocation of TFEB (Settembre et al, 2012).  
TFEB induction in a murine model of Huntington disease was associated with clearance of 
Huntington aggregates (Tsunemi et al, 2012).  Inhibition of glycogen synthase kinase 3  resulted 
in clearance of amyloid precursor protein in cultured neuronal cells via upregulation of TFEB 
and increased autophagy (Parr et al, 2012).  This suggests that TFEB upregulation represents a 
potential therapeutic target for a broad range of neurodegenerative diseases associated with 
protein aggregates, such as PD, and also for enzyme enhancement in lysosomal storage 
disorders.  Ambroxol hydrochloride is a small molecule which can cross the blood brain barrier 
and has been trialled successfully for non-neuropathic manifestations of Type I GD (Zimran et  
al, 2012).  Our cell biology study has shown that amboxol hydrochloride can upregulate GBA 
and normalise certain aspects of lysosomal biochemistry.  This suggests that ambroxol 
hydrochloride is an excellent candidate drug to trial as a neuroprotective agent both for carriers 
of heterozygous GBA mutations and GD patients.  
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Summary and concluding remarks 
Here we confirm that fibroblasts from GD patients are deficient in GCase activity and show that 
there is a relative reduction in GCase enzyme activity in fibroblasts from PD-GBA and NMC in 
proportion to the reduction in GCase protein levels in these cell lines.  This reduction in GCase 
levels was due to a combination of reduced GBA transcript levels - for RecNcil and L444P 
mutations - and endoplasmic reticulum retention of GCase protein.  Reduced GCase protein 
levels will clearly predispose to further loss of GCase activity triggered, for example, by age 
related alpha-synuclein accumulation (Gegg et al, 2012).   This mechanism explains why almost 
all GBA mutations associated with GD have been linked to increased PD risk, since all of them 
are predicted (or proven) to cause reduced transcript levels or cause protein misfolding and 
endoplasmic reticulum retention leading to reduced GCase protein levels.  
The reduction in GCase acvitivity did not induce defects in macroautophagy in any of the cell 
lines.  This likely reflects the fact that there is some residual GCase activity and no storage of 
substrate, in contrast to saposin C deficiency in which there is absolute loss of GCase activity 
and substrate accumulation.  However, elevated cathepsin D protein levels and GCase-2 and 
beta-hexosaminidase activity in GD and PD-GBA suggests subtle lysosomal dysfunction in these 
cell lines.  It is possible that autophagy is dysfunctional in neuronal lines, which accumulate 
substrate, and this is suggested by the accumulation of p62 in brain tissue from mouse models of 
GD.  
Ambroxol hydrochloride increases GCase protein levels and activity in both GD and PD-GBA 
cell lines via induction of TFEB and increased GBA transcription.  The reduction in the 
endoglycosidase-H sensitive (i.e. ER retained) fraction of GCase suggests that ambroxol has an 
additional activity as a pharmacological chaperone increasing GCase folding and delivery to the 
lysosome.  Ambroxol hydrochloride should be further investigated as an enzyme enhancing 
strategy for lysosomal storage disorders and PD-GBA. 
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CHAPTER IV.
ANALYSIS OF MITOCHONDRIAL FUNCTION AND MARKERS 
OF OXIDATIVE STRESS IN FIBROBLASTS FROM GAUCHER 
DISEASE PATIENTS AND PARKINSON’S DISEASE PATIENTS 
WITH HETEROZYGOUS GLUCOCEREBROSIDASE 
MUTATIONS
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IVa. Introduction
General aspects of mitochondrial physiology
Mitochondria are membrane enclosed organelles ranging from 0.5-1 uM in diameter (reviewed in 
Vafai and Mootha, 2012).  Mitochondria are the major source of cellular adenosine triphosphate 
(ATP).  Mitchondria are composed of an outer membrane, an inner membrane, the 
intermembrane space, cristae and the matrix (Otera et al, 2013).  
The outer membrane encloses the entire mitochondrion and contains large numbers of integral 
proteins called porins, which allow molecules of 5 000 Daltons or less to diffuse freely (Vafai 
and Mootha, 2012).  Larger proteins can enter the mitochondrion if they have a targeting 
sequence which binds to the mitochondrial translocase on the outer membrane (Fox, 2012).  The 
intermembrane space has the same ion concentration as the cytosol but the protein composition is 
different; for example cytochrome C is localised to the intermembrane space.  The mitochondrial 
inner membrane is impermeable, partly because of its high cardiolipin content (Yurkova et al, 
2011), and almost all molecules require special transport proteins to cross this membrane (e.g. 
proteins utilise the translocase of the inner membrane).  The inner membrane has a crucial 
physiological function as it contains the enzymes of the electron transport chain (Vafai and 
Mootha, 2012).  The inner membrane is folded into numerous cristae which increases its surface 
area considerably in order to maximise membrane area for ATP synthesis.  The matrix is the 
space enclosed by the inner membrane and contains the mitochondrial genome and enzymes of 
the citric acid cycle and enzymes for oxidation of pyruvate and fatty acids (Stobbe et al, 2012).  
Most ATP is generated by oxidative phosphorylation carried out by the electron transport chain 
(reviewed in Vafai and Mootha, 2012; Schapira, 2012).  At complex I electrons are passed to the 
electron transport chain from NADH, generated by the citric acid cycle, and at complex II 
electrons are donated from succinate.  Electrons flow down the electron transport chain from 
complex I-IV before being accepted by oxygen to form water. A small proportion of electrons 
escape and react directly with oxygen to form the reactive oxygen species superoxide.  Passage 
of electrons down the electron transport chain generates energy which pumps protons into the 
intermembrane space.  Complex I is the major site of electron leak and thus of superoxide 
production (Gandi and Abramov, 2012). Leakage of electrons can also occur from complex III 
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under conditions where there is a high mitochondrial membrane potential. Complexes I, II and 
III act as proton pumps to establish the proton gradient. Protons flow back across the inner 
mitochondrial membrane through the Fo subunit of Complex V (ATP synthase) releasing energy 
for the F1 subunit to phosphorylate ADP to ATP (Abramov et al, 2012).  Coupling of 
establishment of a proton gradient across the inner mitochondrial membrane with transfer of 
electrons down the electron transport chain to synthesis of ATP is vital.  However, the energy 
created by the proton gradient can be “uncoupled” from ATP synthesis by Uncoupling Proteins 
(UCPs) which offer an alternate route for protons to cross the inner mitochondrial membrane and 
enter the matrix (Divakaruni and Brand, 2011).  Energy dissipated in this way generates heat in 
brown adipose tissue (Divakaruni and Brand, 2011).  
The components of mitochondria are encoded in both the nuclear and mitochondrial genome 
(mtDNA)(reviewed in Vafai and Mootha, 2012).  The mitochondrial DNA encodes 13 peptides 
which contribute to the following components of the respiratory chain: Complex I (NADH 
dehydrogenase), Complex III (coenzyme Q-cytochrome c reducatase), Complex IV (cytochrome 
c oxidase) and Complex V (ATP synthase).  Mitochondrial rRNA and tRNA are also encoded in 
the mtDNA.  Forty-five genes encode the subunits of Complex I, only 7 of which are 
mitochondrial with the rest being encoded by nuclear DNA.  Complex II (succinate 
dehydrogenase) is entirely encoded by nuclear genes. Complex III-V are encoded by a mixture of 
nuclear and mitochondrial genes.  A complete list of genes encoding the mitochondrial 
respiratory chains can be found at the HUGO Gene Nomenclature Committee website 
(http://www.genenames.org/genefamilies/mitocomplex). 
Thus mutations in both nuclear and mitochondrial DNA can give rise to mitochondrial DNA 
diseases (reviewed in Schapira, 2012).  For example, mutations in the nuclear or mitochondrial 
components of Complex I or II can cause Leigh’s syndrome (infancy/childhood onset dystonia 
and seizures with basal ganglia cavitation on brain imaging).  While mutation of the 
mitochondrial components of Complex I cause Leber’s hereditary optic neuropathy (LHON). 
Some mitochondrial disorders are due to deletions of mtDNA resulting from faulty repair and 
replication – for example polymerase gamma mutations.  
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Figure 17. Schematic representation of electron transport chain. 
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The role of mitochondrial dysfunction in Parkinson’s disease
The role of mitochondrial dysfunction in PD is discussed in more detail in Chapter I: General 
Introduction.  Multiple studies have demonstrated the importance of mitochondrial dysfunction 
in PD.  Loss of mitochondrial complex I subunits has been demonstrated by 
immunhistochemistry in substantia nigra from PD patients (reviewed in Schapira, 2012), and 
reduced complex I activity demonstrated in PD brain tissue (substantia nigra and frontal cortex) 
(Schapira et al, 1990), PD platelets (Krige et al, 1992) and fibroblasts (Grunewald et al, 2010). 
Moreover, primary mitochondrial disorders can present with parkinsonism, especially 
Polymerase-gamma (POLG) mutations (Davidzon et al, 2006).  The cause of mitochondrial 
dysfunction in sporadic PD is unclear.  However, studies of substantia nigra from aged brain and 
PD brain demonstrated clonally expanded mitochondrial DNA  (mtDNA) deletions, with 
associated loss of respiratory chain subunits and mitochondrial dysfunction (Reeve et al, 2008). 
Mitochondrial dysfunction has also been reported in several types of monogenetic PD. 
Fibroblasts from LRRK2 G2019S mutation associated PD demonstrate reduced ATP synthesis 
and increased mitochondrial proton leak due to altered expression of uncoupling proteins 
(Papkovskaia et al, 2012).  Both fibroblasts carrying bi-allelic ATP13A2 mutations and neuronal 
cell lines with ATP13A2 knock down demonstrate altered mitochondrial physiology compatible 
with defective mitophagy, such as increased maximal oxygen consumption rate after treatment 
with mitochondrial depolariser and altered mitochondrial morphology (Grunewald et al, 2012). 
It is postulated that loss of ATP13A2 function causes lysosomal dysfunction and accumulation of 
dysfunctional mitochondria (Grunewald et al, 2012).  Mitochondrial dysfunction has also been 
reported in models of Parkin and PINK1 associated PD.   Grunewald et al (2010) demonstrated 
reduced ATP synthesis and increased mitochondrial mass in fibroblasts from PD patients with bi-
allelic Parkin mutations.    Abramov et al (2012) demonstrate a number of mitochondrial 
abnormalities in fibroblasts from PINK1 patients including reduced mitochondrial membrane 
potential with the mitochondria consuming ATP via the F1F0-ATPase in order to maintain 
mitochondrial membrane potential.  Thus mitochondrial dysfunction plays a role in the 
pathogenesis of both sporadic and monogenetic PD.  
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The role of mitochondrial dysfunction in lysosomal storage disorders
Though there is no primary defect of mitochondrial function in lysosomal storage disorders, 
several studies point to a secondary accumulation of defective mitochondria due to altered 
mitophagy.  In muscle from Pompe disease patients there is evidence of accumulation of 
enlarged, morphologically abnormal mitochondria (Raben et al, 2012). Similar findings were 
observed in a mouse model of Multiple Sulfatase deficiency (a recessive lysosomal storage 
disorder caused by mutations in the sulfatase modifying factor 1 gene) (de Pablo-Latorre et al, 
2012).  Mitochondria from livers of these mice displayed reduced membrane potential and ATP 
content.  These mitochondrial changes were associated with release of cytochrome-C and cell 
death.  This was associated with impaired Parkin mediated ubiquitination of mitochondria and 
defective mitophagy.  Other lysosomal storage disorders show similar defects.  In fibroblasts 
from mucolipidosis type II and III there is impaired degradation of autophagosomes and 
mitochondrial fragmentation with impaired mitochondrial function (Otomo et al, 2009). 
Takamura et al (2008) demonstrated enhanced autophagy in a knock-out mouse model of GM1-
gangliosidosis (recessive mutations of beta-galactosidase) accompanied by evidence of 
mitochondrial fragmentation and reduced mitochondrial membrane potential.  In contrast 
Sansanwal et al (2010) demonstrated increased mitophagy associated with impaired 
mitochondrial function in nephropathic cystinosis.  Accumulation of defective mitochondria, 
secondary to impairment of mitophagy, may be a common pathological mechanism in many 
types of lysosomal storage disorders. 
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Evidence of mitochondrial dysfunction in Gaucher disease
There are no studies reporting on mitochondrial function in GD models, either cellular or animal. 
Cleeter et al (2012) demonstrated a reduction of ADP phosphorylation and a reduction in 
mitochondrial membrane potential in neuroblastoma cell lines treated with the GCase inhibitor 
conduritol-b-epoxide.  However, this results in a very severe inhibition (99%) of GCase activity 
which is much greater than that seen in humans with bi-allelic GBA mutations.  They excluded a 
non-specific toxic effect of conduritol-b-epoxide by recapitulating the findings of mitochondrial 
abnormalities in GCase knock downs in neuroblastoma lines.  Functional imaging (31-P 
magnetic resonanse spectroscopy) studies of PD patients with heterozygous GBA mutations did 
not demonstrate any evidence of mitochondrial dysfunction (Brockmann et al, 2012).   However, 
clearly functional neuroimaging may not detect subtle mitochondrial dysfunction and 
biochemical studies of fibroblasts from PD-GBA patients are required to address the issue of 
mitochondrial function as a predisposing factor to the development of PD in GBA mutation 
carriers.  
  
Reactive oxygen species and antioxidant defences
Reactive oxygen species are chemically reactive molecules containing oxygen.  Atomic oxygen 
has two unpaired electrons in separate orbits in its outer electron shell, and is thus susceptible to 
free radical formation (Gandi and Abramov, 2012).  Sequential reduction of oxygen by addition 
of electrons leads to the  formation of several ROS: superoxide, hydrogen peroxide, hydroxyl 
radical, hydroxyl ion and nitric oxide. There are several sources of intracellular reactive oxygen 
species generation, as discussed in Chapter I General Introduction, but of particular importance 
is incomplete reduction of oxygen by the mitochondrial electron transport chain.   The constant 
generation of reactive oxygen species by aerobic cells means that cells must possess a robust 
antioxidant defence system to prevent damage.  When this defence system is overwhelmed by 
increased production of reactive oxygen species oxidative damage to proteins, lipids and DNA 
occurs.  
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Antioxidants are species which can donate electrons to molecular centres which are vulnerable to 
loss of electrons and therefore to generation of free radicals and initiation of oxidative chain 
reactions (reviewed in Dinkova-Kostova and Talalay, 2008).  The antioxidant defence system of 
cells consists of a range of enzymes (e.g. superoxide dismutase, catalase) which play a role in 
defences against free radical mediated damage.  Superoxide dismutase (SOD) catalyzes the 
conversion of two superoxide anions into a molecule of hydrogen peroxide (H2O2) and oxygen 
(O2). In  peroxisomes, the enzyme catalase converts H2O2 to water and oxygen, and thus 
completes the detoxification initiated by superoxide dismutase. In addition there are 2 types of 
small molecule antioxidant:  1. direct antioxidants (such as glutathione, ascorbic acid, vitamin K) 
which scavenge oxidation products directly and 2. indirect antioxidants which are substances 
which can induce the so called phase 2 cytoprotective response to oxidative stress by 
upregulating a variety of antioxidant genes.  The genes induced by the indirect antioxidants 
include antioxidant enzymes (e.g. Superoxide dismutase, catalase), enzymes which synthesise 
glutathione, direct antioxidants such as bilirubin and enzymes that detoxify electrophiles such 
NAD(P)H:(quinone acceptor)oxidoreductase 1(NQO1).  Many of these are regulated by the 
KEAP1-NRF2 pathway (reviewed in Dinkova-Kostova and Talalay, 2010).  
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Evidence of oxidative stress in Parkinson’s disease
Several post-mortem studies of PD brain have demonstrated accumulation of products of 
oxidative damage to membranes (reduced polyunsaturated fatty acid levels, elevated 4-hydroxy 
nonenal) (Cheng et al, 2011), proteins (protein carbonyls) and DNA (8-hydroxy guanine)(Alzam 
et al, 1997) in the neurons of the substantia nigra along with loss of the antioxidant reduced 
glutatione.  A high prevalence of mitochondrial DNA deletions in substantia nigra neurons has 
also been described – which is thought to be due to oxidative damage (Bender et al, 2006). 
Elevated levels of oxidative stress markers have also been found in blood (8-OHG) and 
cerebrospinal fluid (4-HNE, 8-OHG) samples from PD patients (Abe et al, 2003).   There are 
several possible sources for ROS production in PD.  Complex I inhibition with MPTP or 
rotenone is associated with increased superoxide radical formation (Smith and Bennett, 1997). 
Mutations in a number of PD genes cause mitochondrial dysfunction associated with oxidative 
stress.  The cellular pathophysiology of these genes is discussed  in Chapter I: General 
Introduction. Alpha-synuclein can also interact with mitochondria and induce oxidative stress in 
some models (Gandi and Abramov, 2012).  Increased ROS production by NADPH oxidase 
occurs in microglia in rotenone and MPTP treatment models (Gao et al, 2003), while PINK1 
deficiency results in NADPH activation and ROS production (Gandhi et al, 2009). 
Dopaminergic neurons are also exposed to additional oxidative stress produced by the 
metabolism of dopamine by monoamine oxidase (which generates hydrogen peroxide) and the 
auto-oxidation of dopamine (which generates superoxide).  This may partly explain the selective 
vulnerability of dopaminergic substantia nigra neurons (Gandhi and Abramov, 2012). Thus there 
is much evidence that oxidative stress is a key mediator of neuronal injury and death in PD.  
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Evidence of oxidative stress in lysosomal storage disease
There is strong evidence of oxidative stress in the majority of lysosomal storage disorders 
studied.  In brain tissue from a mouse model of Niemann-Pick Type C disease there was 
elevation of nitrosylated proteins.  Vazquez et al (2011) reported elevation of transcript levels for 
antioxidant enzymes (e.g. hem-oxygenase 1) in cerebella from NPC null mice, consistent with 
oxidative stress.  Fu et al (2010) studied serum from 37 Niemann-Pick Type C patients, 
demonstrating a significant reduction in coenzyme Q10 (CoQ10) and trolox equivalent 
antioxidant capacity (TEAC), consistent with oxidative stress.  Reddy et al (2006) demonstrated 
upregulation of multiple genes involved in regulating oxidative stress in fibroblasts derived from 
Niemann-Pick Type C patients.  Accumulation of dysfunctional mitochodria has been suggested 
as a cause of oxidative stress in this disorder (reviewed in Vazquez et al, 2011).  An alternative 
mechanism is loss of activity of peroxisomal catalase, which may relate to c-able/p73 being 
translocated to the nucleus as part of an apoptotic programme and not phosphorylating catalase, 
thus leading to degradation of catalase (reviewed in Vazquez et al, 2011).  
Fabry disease is an X-linked lysosomal storage disorder due to mutations of α-galactosidase, 
leading to accumulation of globotriaosylceramide (Gb3).   Biancini et al (2012) demonstrated 
markers of lipid oxidation (malondialdehyde) in blood from Fabry patients, indicating oxidative 
damage.  Shen et al (2008) show that adding Gb3 to cultured Fabry disease vascular endothelial 
cells results in increased intracellular generation of free radicals, suggesting that Gb3 
accumulation could trigger oxidative stress.  
There is strong evidence of oxidative stress in Batten disease (neuronal ceroid lipofuscinosis). 
Wei et al (2008) studied fibroblasts from NCL Types 1, 3, 6 and 8 demonstrating upregulation of 
oxidative stress genes catalase and superoxide dismutase-2.  In 2007 Benedict et al reported 
accumulation of carbonylated proteins and upregulation of superoxide dismutase-2 in brain 
tissue from CLN3 null mice.  Histopathological studies of brain tissue from patients with late 
infantile neuronal ceroid lipofuscinosis demonstrated 4-hydroxynonenal in neurons and 
upregulation of pro-apoptotic proteins (Hachiya et al, 2006).  
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Filippon et al (2011) demonstrate  increased malondialdehyde levels and carbonylated protein 
levels in blood from patients with mucopolysaccharidosis type II (MPS II ), indicative of 
oxidative stress.  Arifi et al (2011) demonstrated upregulation of transcript levels for several 
antioxidant genes in the brain of a mouse model of Sanfilippo disease (MPS IIIA).   In a mouse 
model of MPS Type II (Hunter syndrome) there was evidence of upregulated superoxide 
dismutase and catalase activity, suggestive of oxidative stress (Reolon et al, 2009).  Pereira et al 
(2008) demonstrated reduced catalase and upregulated superoxide dismutase activity in blood 
from MPS Type I patients, taken as evidence of oxidative stress and providing evidence of the 
clinical relevance of these findings.  The cause of oxidative stress in the MPS is unclear.  In one 
study of an MPS III mouse, upregulation of phagocyte NAD(P)H oxidase mRNA was found, 
implication inflammatory mechanisms, at least in part, in oxidative stress in this group of 
lysosomal storage disorders (Reolon et al, 2009).  
There is also evidence of oxidative stress in GM1-gangliosidosis.  There was upregulation of 
transcripts for catalase and superoxide dismutase-2 in fibroblasts from a GM1-gangliosidosis 
patient (Wei et al, 2008).   Takamura et al (2008) demonstrated increased sensitivity of neurons 
from a beta-galactosidase knockout mouse model to oxidative stress, possibly related to 
abnormal mitochondrial function.  
It is clear that oxidative stress represents a pathologenic mechanism which is likely to be 
common to many, if not all, of the lysosomal storage disorders.  Given the diverse range of genes 
involved in this group of diseases it is unlikely that a single mechanism accounts for oxidative 
stress in all of them.  Possible mechanisms of oxidative stress include generation of free radicals 
by dysfunctional mitochodria, which accumulate secondary to defective mitophagy, as discussed 
above.  Alternatively the toxic substrates which accumulate in lysosomal storage disorders may 
generate oxidative stress by activating enzymes which generate free radicals.  It is also possible 
that defects in autophagy may impinge upon the cell's antioxidant defences.  For example, 
defective lysosomal degradation of KEAP1 could inhibit the NRF2 antioxidant pathway and 
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render cells vulnerable to oxidative damage (Dinkova-Kostova and Talalay, 2010).  Iron 
accumulation has been reported in some lysosomal storage disorders, and it is possible that 
accumulating unchelated iron could participate in Fenton reactions (Fe2+ + H2O2 → Fe3+ + OH·+ 
OH− or Fe3+ + H2O2 → Fe2+ + OOH· + H+) and generate oxidative stress (Stein et al, 2010). 
Evidence of oxidative stress in Gauchers disease 
Several studies, both in patient derived blood samples and in cell models point to an important 
role for oxidative stress in Gaucher disease.  Roversi et al (2006) reported elevated catalase 
activity and reduced superoxide dismutase activity in blood samples from Gaucher disease 
patients, with an increase in total glutathione levels after infusion of enzyme replacement 
therapy.  They argue this is consistent with enzyme replacement ameliorating oxidative stress 
levels.  Moraitou  et al (2008) report reduced plasmalogen levels in red blood cells from Gaucher 
patients (peroxisomal activities were otherwise normal), which they interpret as being secondary 
to oxidative stress.  In a neuroblastoma cell line treated with the GCase inhibitor conduritol-b-
epoxide Cleeter et al (2012) report that dihydroethidium oxidation rates are increased and that 
aconitase activity is decreased, consistent with oxidative stress.  Degunato et al (2007) report 
elevated rates of dihydroethidium oxidation in fibroblasts from Type II Gaucher disease patients 
along with elevated protein carbonyl levels.  Thus there is much evidence that oxidative stress is 
an important pathogenic factor in lysosomal storage disorders and Gaucher disease.  Because of 
this, it is a major goal of this study to characterise oxidative stress and its mechanisms in Type I 
Gaucher disease fibroblasts, and investigate the potential role of oxidative damage as a 
pathogenic factor in PD-GBA fibroblasts.  
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IVb. Methods
Assessment of mitochondrial function in patient derived fibroblasts
ADP phosphorylation assay
Fibroblasts harvested from 1 subconfluent 10cm plate was used for assay of ADP 
phosphorylation rate in each cell line; each cell line was assayed in biological triplicate.  Before 
assaying ADP phosphorylation in patient cells a titration was performed to determine the optimal 
volume of 1mg/mL digitonin solution to use with human fibroblasts; 2 uL, 4 uL, 8 uL and 16 uL 
were used in titration reaction.  With 4uL of digitonin the rate of ATP synthesis measured reached 
a peak and plateaud with 8 – 16 uL of digitonin. Therefore 4uL of digitonin was selected for use 
in the reaction mixture.   Cells were trypsinised, pelleted and washed 3 times in ice cold PBS (5 
minutes, 2500 rpm, 4 degrees centigrade).  Prior to the last spin cells were counted in a 
haemocytometer.  After washing cells were re-suspended in incubation medium (25mM Tris, 
150mM Kcl, 2mM K-EDTA, 10mM K2HPO4 at pH 7.4) to give a concentration of 2.5 x 10^5 
cells.  Substrate mixes were then prepared immediately before use:
Glutamate/malate (I, III, IV):  20 uL 0.5M glutatmate
                                               20 uL 0.5M malate
                                                 20 uL 50mg/mL bovine serum albumin
                                                 40 uL 25mM ADP
                                                 4 uL 10mg/ml digitonin in EtOH
Succinate (II, III, IV):             20 uL 0.5M succinate
                                                10 uL 4mg/10mL rotenone
                                                20 uL 50mg/mL BSA
                                                40 uL 25mM ADP
                                                4 uL 10mg/ml digitionin in EtOH
Ascorbate (IV):                      10 uL 0.2M ascorbate
                                                5 uL 10 mM N, N, N, N-tetramethyl-p-phenylenediamine
                                                20 uL 50mg/mL BSA
                                                40 uL 25mM ADP
                                                4 uL 10mg/ml digitionin in EtOH
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Each substrate solution was made up to 1mL with incubation buffer.  Two control reactions were 
also set up: A. cells + substrates + acid (acid kills the cells therefore this measures the amount of 
ATP present in the cells before the reaction and controls for any contamination of the ADP with 
ATP) and B. cells + BSA (calculates background rate of ATP synthesis when no ATP present). 
Each cell line was measured in duplicate for each substrate and both disease cells and control 
cells were measured in the same experiment.  One hundred uL of substrate or control mix was 
added to a 1.5mL eppendorf, at timed intervals 100 uL of cell suspension was added to the tubes. 
The tubes were placed in a rotating incubator for 30 minutes (37 degrees centigrade, 120 rpm). 
A final cell count for each cell suspension was then made (mean of 3 measurements).  At timed 
intervals the reaction was stopped by adding 11.5 uL of 70 % perchloric acid to each tube. 
Mixes were then incubated on ice for 30 minutes, centrifuged at 13 000 rpm for 10 minutes and 
the supernatants aliquoted into fresh tubes.  Each reaction mix was then neutralised with 20 uL of 
neutralisation buffer (3M K2CO3 in 0.5M triethanolamine), pH was checked with pH paper. 
Samples were incubated on ice for 20 minutes and then centrifuged at 13 000 rpm for 10 
minutes.  Supernatants were then aliquoted into fresh eppendorfs.  
ATP concentration was assayed with the ATP bioluminescence kit from Roche (High sensitivity 
II kit).  Glutamate/malate and succinate/rotenone reactions were diluted 1/50 in PBS, ascorbate 
samples diluted 1/5 in PBS.  Fifty microlitres of sample were diluted with 50uL of dilution buffer 
(from Roche kit) then 100uL of luciferase added.  Luminescence was measured immediately on a 
luminometer.  For each experiment an ATP luminescence standard curve was drawn by 
measuring luminescence of ATP standards.  
The rate of ATP synthesis was calculated as follows.  The ATP standard curve was used to 
convert the sample luminescence to moles of ATP.  This figure was multiplied by 50 as the 
sample was diluted 1/50 or by 5 if the sample was diluted 1/5.  This figure was then multiplied 
by 4 as only 50 uL of a reaction volume of 200 uL was used.  This figure was then normalised to 
a cell count of 2.5 x 10^4.  The result was then divided by 30 to give moles ATP/min/2.5 x 10^4 
cells. This figure was multiplied by 4 to give ATP/min/10^5 cells.  The value for the 2 controls 
was then subtracted from the result for the respective substrates.  The mean ATP synthesis rate 
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for each cell line, taken from 3 repeat experiments, was compared to control cell lines using 
students t-test with statistical significance at the 5 % level
Seahorse XF-24 bioanalyser
The Seahorse XF-24 analyses mitochodrial and non-mitochondrial energy metabolism in live 
cells in a multiwell format in real-time.  Oxygen consumption rate is measured in pmol of 
oxygen consumed per minute and is proportional to ATP synthesis rate in untreated cells (i.e. 
basal conditions).  Measurement of oxygen consumption rate after treatment with uncoupler 
provides a measure of maximal oxygen consumption, which is proportional to total 
mitochondrial mass.  Proton leak can be assessed by measuring oxygen consumption rate after 
treatment with oligomycin. Non-mitochondrial respiration is studied by measuring oxygen 
consumption rate after treatment with an inhibitor of the electron transport chain such as 
Antimycin A.   Validation for this methodology is provided by the manufacturer on their website 
http://seahorsebio.com/products/instruments/analyzers.php. 
Each well of the multiwell plate (24 wells) is an individual reaction chamber, there is an oxygen
consumption electrode (containing an oxygen sensitive fluorophore) for each well on the plate on
the seahorse bioanalyser. This electrode forms a transient microchamber over the monolayer of 
cells in each well when it is inserted into the well at 2-5 minute intervals to assay metabolites. 
Oxygen consumption by the cells is measured in real time by the electrode in each well which 
assays removal of oxygen from the cell culture media kinetically to generate an oxygen 
consumption rate for the cell line. The Seahorse XF-24 has several ports which permit sequential 
injection of drugs to assay aspects of mitochondrial physiology.
Fibroblasts used in this assay were grown on 10 cm plates.  These cells were not allowed to reach 
confluence for at least 3 passages prior to the assay as confluence could in theory affect 
mitochondrial metabolism.  Cells were then trypsinised and resuspended in culture media, cells 
were then counted and diluted in 300uL of media per well so that the desired density of cells per 
well was obtained.  An initial optimisation was performed to determine which density of cells 
should be used for the experiments.  Optimisation of oligomycin, FCCP and Actimycin A dose is 
described in the results section.  Before the cells were analysed in the Seahorse XF-24 the culture 
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media was aspirated off and phenol red free assay media added to each well.  The Seahorse XF-
24 analysis was performedby George Chennell (UCL Scientific Support Services).  The data 
from each experimental run was analysed by Alisdair McNeill with advice from George 
Chennell.
      
 
Figure 18. Example of Seahorse “mito stress test profile” from Seahorse XF-24 provided 
bySeahorse bioscience.
Basal respiration (blue portion of profile) is proportional to ATP synthesis rate. The 
addition of oligomycin inhibits ATP synthase and OCR measured after this treatment gives 
the rate of activity of this enzyme and can be used to calculate proton leak. FCCP dissipates 
the mitochondrial membrane potential (ie uncouples mitochondria) and the OCR with this
treatment gives a measure of maximal respiratory capacity of the cells. Antimycin D and
rotenone are added to inhibit the respiratory chain, which can give a measure of spare
respiratory capacity and non-mitochondrial respiration.
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Citrate Synthase activity assay 
Fibroblasts were grown to subconfluence on 10cm plates, trypsinised, washed once in PBS and 
made into a pellet.  Cells were then lysed with 50 uL of 0.25% Triton X 100, kept on ice for 15 
minutes and then centrifuged at 15 000 xg for 10 minutes.  The supernatant was then aliquoted. 
For the assay 10 uL of cell supernatant was mixed with 20 uL of oxaloacetic acid and 970 uL of 
reaction mix (2.25 mL Tris buffer, 90uL of acetyl coenzyme A, 90 uL of DTNB, 45 uL of 10% 
triton X 100, 1.89 mL dH2O).  This assay has been validated by Dr David Chau, UCL 
Department of Clinical Neurosciences. 
The assay was performed on a 96 well plate using a Bio Tek Synergy HT plate reader.  The plate 
reader was preheated to 30 degrees centigrade.  Two hundred and fifty microlitres of the reaction 
mixture was added to each well, with each cell being assayed in triplicate.  Blanks consisting of 
reaction mix without cell lysates were also assayed in triplicate.  The protein concentration for 
each cell line was measured using the BCA kit described in the methods section of Chapter III. 
Citrate synthase activity was calculated as nmol fluorescent product/mg protein/minute.  
Single cell analysis of dihydroethidium and monochlorobimane 
Cytosolic ROS production was monitored by single cell analysis of dihydroethidium (DHE) 
oxidation rate.   For each cell line fibroblasts were imaged with 2 uM of DHE in HBSS (Hepes 
buffered salt solution, 156 NaCl, 3 KCl, 2 MgSO4, 1.25 KH2PO4, 2 CaCl2, 10 glucose, and 10 
HEPES, pH adjusted to 7.35 with NaOH). No preincubation (“loading”) was performed to 
minimise intracellular accumulation of the oxidised product.  Fluorescence measurements were 
obtained using a Nikon (Tokyo, Japan) epifluorescence inverted microscope equipped with a 
cooled CCD camera.  DHE was excited at 490nm and images were collected at intervals of 10 s, 
digitized, and stored for off-line analysis using software from Andor (Belfast, UK).  Each cell 
line was imaged in biological triplicate.  The rate of DHE oxidation and the rate of change of the 
ratio of oxidised to non-oxidised DHE was calculated. Fibroblast lines were assayed in triplicate 
with 3 control lines compared to 4 GD, 4 PD-GBA and 2 NMC fibroblast lines.   
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Cellular glutathione levels were assayed with monochlorobimane (MCB) dye.  MCB fluoresces 
after being conjugated to glutathione by glutathione s-transferase, and so its
fluorescence is proportional to cellular glutathione content.”.  Fibroblasts were grown on 
coverslips and incubated with MCB dissolved in HBSS for 30 minutes before imaging.    MCB 
was imaged with excitation of 394nm and emission of 490 nm.  Fibroblast lines were assayed in 
triplicate with 3 control, 3 GD and 2 PD-GBA lines compared.  
Assessment of mitochondrial form factor
Mitochodria were immunostained using an antibody to TOM20 (Santa-Cruz Biotechnology, 
FL145, 1: 250, incubated for 1 hour) on fixed cells, using the technique outlined in Chapter III. 
Cells were photographed using  a fluorescence microscope equipped with an ApoTome and 
AxioVision software (all Zeiss, Jena, Germany).  Mitochondrial morphology was assessed using 
the Form Factor (FF).  By means of ImageJ (NIH, Bethesda), raw images were binarized, 
mitochondrion area and outline were measured and the form factor was calculated (defined as 
[Pm2]/[4πAm]), where Pm is the length of the mitochondrial outline and Am is the area of the 
mitochondrion.  
OxyBlot Kit (western blot quantification of protein carbonyl levels)
Oxidative  damage to proteins introduces carbonyl groups (aldehydes and ketones) at lysine, 
arginine, proline or threonine residues.  The OxyBlot kit (Chemicon International) utilises an 
immunoblotting technique to detect carbonylated proteins at contentrations as low as 5 
femtomoles.  The kit is based on the principle that carbonylated residues in proteins react with 
2,4-dinitrophenylhydrazine (DNPH) to form 2,4-dinitrophenylhydrazone (DNP-hydrazone), 
which can be detected with an antibody in an immunoblot.   Cell lysates are made with 50mM 
DTT added to the lysis solution to prevent protein oxidation being induced by cell lysis. For each 
cell line five microlitres of lysate was then denatured by addition of 5 microlitres of 12% SDS 
(giving a final concentration of 6% SDS), with a duplicate made for each sample to act as a 
negative control.  Ten microlitres of 2,4-dinitrophenylhydrazine (DNPH) was then added to each 
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sample and 10 microlitres of control solution (provided in the kit) to the respective negative 
controls.  DNPH reacts with carbonylated residues to form 2,4-dinitrophenylhydrazone (DNP-
hydrazone).  After 15 minutes incubation 7.5 microlitres of neutralization buffer (provided in the 
kit) was added to each sample. Lysates were then loaded onto a 4-12% NuPage gel and 
electrophoresed at 200v before transfer to a PVDF membrane.  Membranes were blocked in 1% 
bovine serum albumin in PBS-T, then incubated with the kit’s primary antibody to DNP. 
Membranes were then incubated with the kit’s secondary antibody and developed with ECL 
chemiluminescence solution.  An antibody to beta-actin was used as a loading control and band 
intensity quantified with Image-J. All cell lines were assayed in triplicate.
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IVc. Results
Patients and fibroblast lines studied
Fibroblasts were generated from skin biopsies from 5 Type I GD patients, 4 heterozygous 
carriers with PD (PD-GBA), 1 PD patient with homozygous E326K GBA mutations and 2 
carriers without PD (non-manifesting carriers, NMC).  For comparison fibroblasts were 
generated from 3 PD patients without GBA mutations and 3 controls without neurological disease 
or GBA mutations.  The clinical characteristics and mutation spectrum of the patient cohort are 
given in Table x.   Details of the general cell culture conditions are given in Chapter III.  
Table. Characteristics of patient derived fibroblasts
Gaucher disease Genotype Prodromal markers of PD
GD01, M/50 N370S/c1263del55 Nil
GD02, M/70 N370S/N370S Nil
GD03, M/40 N370S/L444P Nil
GD04, M/61 N370S/203insC Hyposmia, cognitive impairment
GD05, M/40 N370S/L444P Isolated rest tremor
NMC
C01, F/80 N370S/Wt Nil
C02, M/62 L444P/Wt Nil
PD-GBA
PD01, F/53 N370S/Wt Clinical PD
PD02, M/45 N370S/Wt Clinical PD
PD03, M/72 L444P/Wt Clinical PD
PD04, F/61 RecNcil/Wt Clinical PD
PD05, M/50 E326K/E326K Clinical PD, no overt GD
Control
CN01, M/78 Wt/Wt Nil
CN02, M/81 Wt/Wt Nil
CN03, F/50 Wt/Wt Nil
Optimisation of ADP phosphorylation assay
Before assaying ADP phosphorylation in patient cells a titration was performed to determine the 
optimal volume of 1mg/mL digitonin solution to use with human fibroblasts; 2 uL, 4 uL, 8 uL 
and 16 uL were used in a titration reaction.  With 4uL of digitonin the rate of ATP synthesis 
measured reached a peak and plateaud with 8 – 16 uL of digitonin. Therefore 4uL of digitonin 
solution (1mg/mL) was selected for use in the reaction mixture.
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Optimisation of Seahorse XF-24
The number of fibroblasts to use per well was optimised on a single plate with 10 000, 20 000, 
30 000 and 50 000 cells per well in each row.  The cell number giving the greatest oxygen 
consumption rate was selected. Fifty thousand cells per well gave the greatest oxygen 
consumption rate and this was selected as the concentration of cells to use per well for the 
experiments.  A titration of FCCP (p-trifluoromethoxy carbonyl cyanide phenyl hydrazone) was 
performed using 250 nM, 500nM, 750 nM and 1 000nM; 750nM gave the greatest increase in 
oxygen consumption rate with a plateau reached at higher concentrations.  This was therefore 
selected as the concentration of FCCP to use to assay maximal oxygen consumption rate.  The 
dosage of oligomycin (2 uM) and antimycin A (3 uM) were selected according to standard 
Seahorse protocols for working with human dermal fibroblasts.  
No alteration of ADP-phosphorylation rate or oxygen consumption rate in Gaucher disease 
or PD-GBA
There was no significant difference in ADP phosphorylation rates for complex I-IV between 
Gaucher disease (550+/-190 pmolesATP/min/105 cells, p=0.5) and control cell lines (600+/-150 
pmolesATP/min/105 cells).  There was no difference for complex II-IV between Gaucher disease 
(360+/-170  pmolesATP/min/105 cells, p=0.5) and control cell lines (420+/-160 
pmolesATP/min/105 cells), or complex IV GD (65+/-20  pmolesATP/min/105 cells, p=0.5) and 
control cell lines (60 +/-30  pmolesATP/min/105 cells).  There were no differences between 
oxygen consumption rates (OCR) as assessed by the Seahorse XF-24 between Gaucher disease 
(143+/-25 pmol O2/ug/min, p=0.7), PD-GBA (135 +/- 40 pmol O2/ug/min, p=0.5) and control 
lines (137+/30 pmol o2/ug/min).  
After treatment with the uncoupling agent oligomycin there was no difference in oxygen 
consumption rates between control (13+/-5 pmol O2/min/mg) and Gaucher disease (20.9 +/-8 
pmol O2/min/mg, p=0.185) or control (19+/-2 pmol O2/min/mg) and PD-GBA (28+/-7 pmol 
O2/min/mg, p=0.1).  Thus there is no evidence for increased mitochondrial proton leak 
(mitochondrial uncoupling) in Gaucher disease or PD-GBA.  Proton leak was calculated as 
oxygen consumption rate after oligomycin treatment – oxygen consumption rate after antimycin 
A treatment.  
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There was no difference in non-mitochondrial respiration rate between control (mean 40+/-5 
pmol O2/min/mg) and Gaucher disease (mean 32 +/- pmol O2/min/mg, p=0.17) or control (mean 
34 +/- 10 pmol O2/min/mg) and PD-GBA (mean 36+/-9 pmol O2/min/mg, p=0.79).  Non-
mitochondrial respiration was measured from the oxygen consumption rate after treatment with 
Antimycin A.  
No alteration in mitochondrial mass in Gaucher disease or PD-GBA
After treatment with FCCP the maximal OCRs did not differ between Gaucher disease (341+/-89 
pmol O2/ug/min, p=0.5), PD-GBA (395+/-143 pmol O2/ug/min, p=0.92) and control lines 
(365+/-54 pmol o2/ug/min).  Enzymatic activity of citrate synthase did not differ between control 
(mean 191+/-21 nmol/min/mg), Gaucher disease (mean activity rate 183+/30 nmol/min/mg, 
p=0.63) or PD-GBA (mean 196+/-56 nmol/min/mg, p=0.80).  This suggests there is no 
difference in mitochondrial mass and implies that mitophagy is not deficient.  
No alteration in mitochondrial morphology in Gaucher disease or PD-GBA
The value for form factor obtained by analysing 6 cells each from 2 control lines stained with 
TOM20 antibody was set at 100% as the reference value, and the form factors of the Gaucher 
disease and PD-GBA fibroblasts were expressed as a percentage of this. There was no difference 
in mitochondrial morphology (form factor) between GD (p=0.4), PD-GBA (p=0.5) and control 
cells.    This provides further evidence that mitophagy is not abnormal since defective mitophagy 
would be associated with accumulation of dysmorphic mitochondria.  
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Figure 19. Analysis of mitochondrial function.  
19a.  Basal oxygen consumption rate (pmol o2/min/mg) does not differ between GD, PD-GBA or controls.
19b.  Maximal oxygent consumption rate (pmol o2/min/mg) after FCCP treatment (0.75 uM) does not 
differ between GD, PD-GBA and controls.
19c. Form factor does not differ between GD, PD-GBA and controls (results are normalised to controls 
which have form factor set to 100).
19d. Immunofluorescent staining of mitochondrial network with Tom20 for calculation of form factor. 
Top panel: representative control cells, bottom panel: representative GD cells.
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The rate of DHE oxidation is elevated in GD and PD-GBA fibroblasts 
The rate of DHE oxidation was significantly elevated in Gaucher Disease (median 40 % 
increase, IQR 15-70%, p<0.001), PD-GBA (median 55% increase, IQR 45-70%, p<0.001), NMC 
(median 70% increase, IQR 65-75%, p=0.002) and the E326K homozygous (median 50% 
increase, IQR 10-60%, p=0.012) fibroblast lines.   
Elevated levels of carbonylated proteins occur in Gaucher disease and PD-GBA
In addition there were elevated  levels of carbonylated proteins in Gaucher disease (median 50% 
increase, IQR 25-75%, p<0.001) and PD-GBA cell lines (median 0% increase, IQR 0-75%, 
p=0.03).  It should be noted that the increase in carbonylated proteins in PD-GBA was entirely 
due to line PD03 (L444P/Wt).       
Reduction of glutathione levels in Gaucher disease and PD-GBA fibroblasts
The intensity of staining of Gaucher disease (median 77 % of control values [IQR 50-90%], 
p=0.001) and PD-GBA fibroblasts (median 72% [IQR 50-92%] of control, p=0.001) with MCB 
was significantly less than that of control fibroblasts. This suggests a reduction in cellular 
glutathione levels, possibly due to depletion due to oxidative stress. 
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Figure 20.  Oxidative stress assays in Gaucher and Parkinson's disease fibroblasts.
20a.  Graph summarising significant increases in rates of DHE oxidation for GD, PD-GBA and NMC 
compared to control cells.  
20b  Representative oxyblots demonstrating increased carbonylated proteins in GD and increased 
carbonylated proteins in PD03 line only.
   Control
  Control
   GD01      GD02        GD03
      PD01     PD02  PD03
a
b
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IVd. Discussion
Mitochodrial function is not altered in Gaucher disease and PD-GBA fibroblasts
None of the mitochondrial biochemical parameters examined were altered in Gaucher disease or 
PD-GBA fibroblasts compared to control cell lines.  ADP-phosphorylation rate and basal oxygen 
consumption rate, which is proportional to ATP synthesis rate, did not differ in Gaucher disease 
or PD-GBA fibroblasts compared to control cells.   This suggests that there is no defect of 
mitochondrial ATP synthesis such as occurs with mutations of the respiratory chain complex 
enzymes.  Thus there is no evidence from the study of Gaucher disease and PD-GBA fibroblasts 
that a deficiency of Complex I activity, which commonly occurs in PD (Schapira, 2012), plays a 
role in the mechanisms by which GBA mutations predispose to PD.  Moreover, there was no 
alteration in oxygen consumption rates in Gaucher disease fibroblasts or PD-GBA fibroblasts 
compared to control fibroblasts after treatment with Antimycin A.  This demonstrates that there is 
no difference in non-mitochondrial respiration between Gaucher disease and PD-GBA fibroblasts 
and control fibroblasts.  If there was mitochondrial impairment then a compensatory increase in 
non-mitochondrial respiration would be expected to occur.  Oxidative damage usually causes 
some degree of mitochondrial dysfunction (Gandhi and Abramov, 2012), and it is somewhat 
unexpected that the cell lines used in this study had oxidative stress with normal mitochondrial 
function.  It is possible that subtle mitochondrial dysfunction is present, but which would only be 
detected by alterations in mitochondrial membrane potential..  But, due to time constraints it was 
not possible to perform single cell analysis of mitochondrial membrane potential with dyes such 
as Tetramethylrhodamine (TMRM) so we cannot exclude this possibility.  Alternatively it might 
be that the oxidative stress in the fibroblasts is of a relatively low severity and that antioxidant 
defences are buffering the free radical production, manifested by depletion of glutathione in the 
cells, and protecting the mitochondria.  
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No evidence for mitochodrial uncoupling in Gaucher disease or PD-GBA fibroblasts 
The oxygen consumption rate after treatment with oligomycin was not different in Gaucher 
disease or PD-GBA fibroblasts compared with control fibroblast lines.  This suggests that there is 
no increased proton leak across the mitochondrial membrane.  Basal proton leak is unregulated 
(i.e. occurs directly through the phospholipid inner mitochondral membrane) and relates to 
metabolic rate, while induced proton leak is controlled by the adenine nucleotide translocase 
(ANT) and the uncoupling proteins (UCP)(Divakaruni and Brand, 2011).  The physiological role 
of mitochondrial uncoupling, associated with activation of uncoupling protein-1, is to generate 
heat in brown fat (Divakaruni and Brand, 2011).  Increased proton leak has been demonstrated in 
fibroblasts from PD patients carrying the LRRK2 G2019S mutations (Papkovskaia et al, 2012), 
associated with increased basal oxygen consumption rate and reduced ADP-phosphorylation and 
mitochondrial membrane potential.  This mechanism clearly does not operate in Gaucher disease 
or PD-GBA since basal oxygen consumption was not altered and there was no difference 
compared to controls in oxygen consumption rate after oligomycin treatment.  This suggests that 
the mechanisms by which GBA and LRRK2 G2019S mutations cause PD are different. 
No evidence for defective mitophagy in Gaucher disease or PD-GBA fibroblasts
Cellular mitochondrial quality control is an important process to prevent accumulation of 
dysfunctional mitochondria and cellular toxicity.  Two mitochodrial quality control mechanisms 
exist: 1. fusion of mitochodrial and 2. mitophagy (degradation of dysfunctional mitochondria by 
the lysosome)(Sun et al, 2012).  As discussed above altered mitophagy has been reported in 
several lysosomal storage disorders, and is associated with decreased Parkin mediated 
ubiquitination of mitochondria in multiple-sulfatase deficiency.  In mitophagy Parkin protein is 
thought to be recruited to damaged mitochondria, which have reduced membrane potential,  by 
PINK1 protein, though the mechanism by which PINK1 translocates Parkin from the cytoplasm 
to mitochondria is unknown (Sun et al, 2012).  Parkin docks with damaged mitochondria by 
interacting with voltage dependent anion channels (VDACs 1, 2 and 3) on the mitochondrial 
membrane (Sun et al, 2012).  Parkin ubiquitinates mitochondrial membrane proteins such as 
mitofusin-2 and miro to target the mitochondria for degradation in the lysosome.  Ubiquitinated 
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mitochondria are then recognised by p62 protein and targeted to the lysosome (Huang et al, 
2011).  
The fact that maximum oxygen consumption rate after treatment with FCCP did not differ 
between Gaucher disease, PD-GBA and control fibroblasts suggests that mitophagy is not 
altered.  Treatment with FCCP is known to dissipate the mitochondrial membrane potential and 
induce uncoupling so that the oxygen consumption rate becomes proportional to the 
mitochondrial mass.  This also induces mitophagy.  If mitophagy was defective in Gaucher 
disease or PD-GBA fibroblasts then the maximum oxygen consumption rate would be expected 
to be signficantly higher than in control fibroblasts.  The fact that it was not suggests that 
mitophagy is intact.  
Further evidence for intact mitophagy comes from the fact that citrate synthase activity was not 
altered in Gaucher disease fibroblasts or PD-GBA fibroblasts compared to control cells.  Citrate 
synthase activity is proportional to mitochondrial mass (Grunewald et al, 2010).  If there was a 
significant impairment of mitophagy it would be expected that the Gaucher disease cells would 
have an increased mitochondrial mass.  The fact that this was not the case is evidence that 
mitophagy is not defective. 
Analysis of mitochondrial morphology using immunofluorescent analysis of fixed fibroblasts 
stained with anti-TOM20 antibody did not demonstrate any differences between Gaucher 
disease, PD-GBA and controls.  In cell lines with damaged mitochondria and impairment of 
mitophagy there is accumulation of mitochodria with abnormal morphology.  For example, 
Grunewald et al (2010) describe reduced branching of mitochondria and increased fragmentation 
, which manifests as decreased form factor, in fibroblasts from PD patients with bi-allelic Parkin 
mutations.  The morphology of mitochondria in Gaucher disease, PD-GBA and control 
fibroblasts was not distinguishable and the form factor did not differ significantly.  This suggests 
that mitochondrial morphology is normal in Gaucher disease and PD-GBA, providing more 
evidence that the mitophagy pathway is likely to be intact.  
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Why is mitophagy not defective in Gaucher disease?
As discussed in the introduction there is evidence that the majority of lysosomal storage 
disorders are associated with impaired mitophagy.  Here we demonstrate that mitophagy appears 
to be intact in fibroblasts from Gaucher disease patients and PD patients with heterozgyous GBA 
mutations.  
Why is there this difference between Gaucher disease and other lysosomal storage disorders? 
One explanation might be the degree of severity of autophagic dysfunction. For example, in 
multiple-sulfatase deficiency there is dysfunctional mitophagy along with clear evidence of 
defective macroautophagy (electron microscopy demonstrates accumulation of autophagocytic 
vesicles with impaired fusion with lysosomes)(de Pablo-Lattore et al, 2012).  The same is true in 
Kufor-Rakeb syndrome (ATP13A2 mutations), in which fibroblasts have increased mitochondrial 
mass, associated with reductions in mitochondrial ATP production, consistent with defective 
mitophagy and also clear evidence of defective lysosomal physiology in general (e.g. defective 
lysosomal acidification and degradation of mitochondria)(Dehay et al, 2012).  
Thus the fact that mitophagy is not altered in Gaucher disease or PD-GBA may reflect the intact 
macroautophagy system in these cell lines.  In Chapter III we report that there is no elevation of 
p62 or alteration of LC3-II levels in Gaucher disease or PD-GBA fibroblasts and describe intact 
induction of autophagy by starvation.  Thus it seems that for mitophagy to be deficient there 
needs to be a relatively severe impairment of the lysosome associated with defective 
macroautophagy.  
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Oxidative stress plays a role in the pathogenesis of Gaucher disease 
The rate of dihydroethidium oxidation was significantly elevated in Gaucher disease fibroblasts. 
This was accompanied by evidence of elevated accumulation of protein carbonyls as measured 
by the Oxyblot technique.  Similar results were reported by Degunato et al  (2007) in fibroblasts 
from patients with Type II Gaucher Disease.  The results of our study of oxidative stress markers 
in Type I Gaucher disease fibroblasts are also in keeping with work by several groups reporting 
evidence of elevated oxidative stress markers in blood from Gaucher disease patients (Moraitou 
et al, 2008).   The current study thus demonstrates that oxidative stress operates in both adult 
non-neuronopathic (Type I) Gaucher disease as well as paediatric neuronopathic (Type II) 
Gaucher disease.  
As noted in the introduction to this chapter there is evidence of oxidative stress in many of the 
lysosomal storage disorders.  In contrast, the genes involved, and substrates which accumulate, 
differ widely across the spectrum of the 50 or so lysosomal storage disorders.  Moreover, 
disruption of macroautophagy and mitophagy are described in many, but not all, lysosomal 
storage disorders. A case in point being the normal autophagy and mitophagy pathways in the 
Gaucher disease and PD-GBA fibroblasts in the current study.  It seems reasonable to postulate 
that oxidative stress may represent a common pathogenetic mechanism in all lysosomal storage 
disorders.    Because of its potential role across the spectrum of lysosomal storage disroders it is 
clearly an important therapeutic target.  
Oxidative stress could potentially contribute to several of the clinical manifestations of Gaucher 
disease.  Oxidative damage to bone marrow stem cells could contribute to the aetiology of 
myeloma in Type I Gaucher disease by causing DNA damage (Walters et al, 2011).  Oxidative 
damage could obviously also contribute to mutations underlying other malignancies associated 
with Type I Gaucher disease such as melanoma, and melanocytes have been shown to be 
sensitive to oxidative stress induced DNA damage (Ibarrola-Villava et al, 2011). Indeed, 
oxidative stress is associated with secretion of soluble factors by myofibroblasts which promote 
melanoma invasiveness (Comito et al, 2012).  There is also some data associating bone disease 
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with oxidative stress.  Spinal bone mineral density was negatively correlated with rising markers 
of lipid peroxidation in serum in post-menopausal women (Cervellati et al, 2012) and oxidative 
stress has also been shown to induce apoptosis of osteoblasts (Li et al, 2012).  As discussed in 
the introduction there is much evidence that oxidative stress plays a major role in PD 
pathogenesis, and the potential role for oxidative stress in PD-GBA is discussed later in this 
section.  
Oxidative stress plays a role in the pathogenesis of PD-GBA
The rate of dihydroethidium oxdiation was significantly elevated in PD-GBA fibroblasts 
compared to control fibroblasts.  This was accompanied by evidence of elevated protein 
carbonyls in the fibroblast line with the L444P/Wt genotype.  Evidence of oxidative stress has 
been reported in studies of fibroblasts from several different genetic subtypes of PD, including 
Parkin (Grunewald et al, 2010) and Pink1 mutation associated PD (Gegg et al, 2009).  It seems 
probable that oxidative stress will be present, to a greater or lesser degree, in every cell of the 
body in patients with heterozgyous GBA mutations.  It is well documented that neurons are 
especially vulnerable to damage  by free radicals, due to their high oxygen consumption (10 fold 
greater than other cell types) and the prominent role of nitric oxide as a neurotransmiter (nitric 
oxide can form damaging reactive peroxynitrite species)(Gandhi and Abramov, 2012).  Thus it
seems reasonable to propose that neurons in individuals with heterozygous GBA mutations will
manifest oxidative damage though this remains to be examined experimentally.  
Based on the evidence from this study, it is logical to suggest that oxidative stress is an early 
event in the pathogenesis of PD-GBA.  This is because oxidative stress is present in fibroblasts 
from non-manifesting carriers (elevated dihydroethidium oxidation rate) and thus is occurring 
before the onset of clinical PD.  There are several mechanisms by which oxidative stress could 
predispose to PD.  Oxidative damage to mitochondrial membranes could result in age related 
mitochondrial dysfunction in brain; examination of mitochodrial function in fibroblasts cannot 
exclude this.  Ongoing oxidative damage could damage lysosomal membranes and potentially 
interefere with lysosomal function, while oxidative damage to proteins could also increase the 
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propensity of GCase protein to misfold and be retained in the endoplasmic reticulum.  Perhaps 
most significantly oxidative damage to alpha-synuclein can predispose to aggregation and Lewy 
body formation (Giasson et al, 2000).  Thus, oxidative stress is a common pathological 
mechanisms across multiple different lysosomal storage disorders and is also a strong candidate 
as an important mechanism by which GBA mutations predispose to PD.  
Oxidative stress occurs in E326K homozygous fibroblasts from a patient with PD
As discussed in Chapter III it is unclear if the E326K GBA variant is a disease causing mutation, 
a disease modifying allele or a benign polymorphisms (Horowitz et al, 2011).  Here we describe 
evidence of oxidative stress in an E326K/E326K fibroblast line from a PD patient who did not 
have overt evidence of Gaucher disease.  No Gaucher disease patients with E326K/E326K 
genotype have been reported, but in Gaucher disease patients who have E326K on the same 
allele as a confirmed GBA mutation tend to have a more severe phenotype (Horowitz et al, 
2011).  The E326K GBA variant is more frequent in sporadic PD cases than in controls (Lesage 
et al, 2011).  It seems more likely that the PD patient with homozygous E326K mutations has PD 
related to GBA mutations rather than PD as part of Gaucher disease due to E326K/E326K 
genotype.   In the E326K/E326K homozygous fibroblast line it is clear that oxidative stress 
occurs and likely contributes to the pathogenesis of PD.   
Mechanisms of oxidative stress in Gaucher disease and PD-GBA
The mechanisms causing oxidative stress in GD and PD-GBA are unclear.  In other lysosomal 
storage disorders, for example Niemann-Pick Type C, accumulation of damaged mitochondria, 
which have increased production of reactive oxygen species, has been proposed to cause 
oxidative stress (reviewed in Vazquez et al, 2012).  Dysunfunctional mitochondria seem less 
likely to play a role in causing oxidative stress in Gaucher disease or PD-GBA given that 
mitochodrial biochemistry is normal and that there is no evidence of defective mitophagy. 
Degunato et al  (2007) provide data suggesting that NADPH oxidase is activated by substrate 
accumulation in Type II GD fibroblasts, but this seems less likely to explain why heterozygous 
cells have oxidative stress since they are not be expected to accumulate metabolites. Moreover, 
studies suggest that little, if any, glucosylceramide accumulates in Gaucher disease fibroblasts 
(Saito and Rosenberg, 1985).  
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There are several alternative mechanisms to explain why oxidative stress occurs in Gaucher 
disease and PD-GBA.  Upregulation of beta-hexosaminidase in Gaucher Disease and PD-GBA 
may predispose to oxidative stress, since this enzyme produces GM3 ganglioside, which can 
prime cells to produce large amounts of reactive oxygen species in response to glutamate toxicity 
(Sohn et al, 2006).  Dysregulation of the KEAP1-NRF2 pathway could also predispose cells to 
oxidative stress.    NRF2 translocates to the nucleus to upregulate antioxidant genes after 
oxidative stress causes KEAP1 to dissociated from NRF2, KEAP1 is then directed to the 
lysosome or proteasome for degradation (Dinkova-Kostova and Talalay, 2010).  There is 
evidence that p62 plays a role in KEAP1 degradation and that lysosomal dysfunction may 
interefere with KEAP1 degradation.  If KEAP1 degradation by the lysosome were dysregulated 
then it is possible that upregulation of antioxidant pathways could be impaired resulting in 
vulnerability to oxidative stress.  Altered calcium metabolism has been reported in Gaucher 
disease.  Glucosylceramide accumulation enhances calcium release from intracellular stores by 
increasing the sensitivity of the ryanodine receptor to agonists (Pelled et al, 2005).  This could in 
theory result in elevated cytosolic calcium levels which activate enzymes such as NADPH 
oxidase to cause oxidative stress.
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Summary and concluding remarks
Here we studied fibroblasts from Gaucher disease and PD-GBA patients and demonstrated that 
mitochondrial biochemistry is not altered.  There is no evidence of defective ATP synthesis, nor 
is there evidence of mitochondrial uncoupling or elevated non-mitochondrial respiration.  After 
treatment with FCCP cellular oxygen consumption rates did not differ between Gaucher disease, 
PD-GBA and control cell lines.   This suggests that mitophagy is not defective in these cell lines. 
In support of this is the fact that mitochondrial branching was not reduced in Gaucher disease or 
PD-GBA fibroblasts, since if mitophagy were defective, and abnormal mitochondria were 
accumulating, one would expect mitochondrial morphology to be altered. 
There is evidence of oxidative stress in Gaucher disease and PD-GBA fibroblasts.  Oxidative 
stress may be a common pathogenic mechanism occurring in most or all types of lysosomal 
storage disorders.  Oxidative stress was also present in fibroblasts from non-manifesting carriers 
of GBA mutations.  This suggests that oxidative stress is an early event in PD-GBA pathogenesis 
and not a secondary consequence of metabolic derangements occurring later in the disease 
course.  Thus oxidative stress may be a major mechanism by which GBA mutations predispose to 
the development of PD.  
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CHAPTER V.
CONCLUDING REMARKS:  A LOSS OF FUNCTION MODEL TO EXPLAIN 
HOW GLUCOCEREBROSIDASE MUTATIONS MAY PREDISPOSE TO 
PARKINSON'S DISEASE 
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There is much evidence that patients with GD and their heterozgyous GBA mutation carrier 
relatives have a significantly increased risk of developing PD (Bultron et al, 2010; Sidransky et al, 
2009; McNeill et al, 2012b). One study estimated the lifetime risk of PD in GD patients as being 21 
fold greater than that of controls  (Bultron et al, 2010) and heterozgyous GBA mutation carriers 
(parents of Gaucher disease patients) have a 10-15 % risk of developing PD by age 80 years 
(McNeill et al, 2012).   Clearly GD patients and carriers are a group at substantially increased risk 
of developing PD.  We hypothesised that by studying them clinically for markers of prodromal PD 
we could efficiently identify a cohort of subjects in the prodromal or early stages of PD.   To do this 
we recruited GD patients and their obligate carrier relatives from the NSCAG funded Lysosomal 
storage disorder clinics at the Royal Free Hospital (London) and the Addenbrookes Hospital 
(Cambridge).  We studied them for prodromal markers of PD such as hyposmia by using validated 
clinical ratings scales and generated fibroblast cell lines from a selection of study participants.   
We can identify GD patients and heterozygous GBA mutation carriers with prodromal signs 
of PD
As detailed in Chapter II a cohort of 75 Type I GD patients and 41 of their heterozgyous GBA 
mutation carrier relatives underwent clinical phenotyping.  As a group, the median Smell 
Identification Test and Montreal Cognitive Assesment scores were signficantly lower in GD patients 
and heterozygous GBA mutation carriers than in matched controls.  In Addition parkinsonian motor 
signs were more common in GD patients and carriers. Clearly there are multiple possible causes for 
these prodromal markers.  Hyposmia could be related to disease of the nose or sinuses or to 
smoking (Doty, 2012).  We minimised this confounder by excluding participants from the smell test 
if they had an upper respiratory tract infection/pathology or who were current smokers.  We also 
could not exclude other aetiologies for cognitive impairment such as vascular dementia or 
Alzheimer's disease.  The limitations of the motor examination in detecting motor signs of 
parkinsonism are discussed in chapter 2.  To gather more evidence that the prodromal markers we 
identified in these individuals reflect underlying neurodegeneration we performed optic coherence 
tomography on a subset of GD patients – demonstrating an association of retinal thinning with 
prodromal markers in these patients (as described and discussed in chapter 2).  This part of our 
study provides evidence in support of the argument that some of the GD patients and heterozgyous 
mutation carriers expressing prodromal markers such as hyposmia will be in the early stages of PD.
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Fibroblasts from participants with prodromal markers are a model to study how GBA 
mutations predispose to PD
Our clinical study provided evidence that we could identify individuals in the early or prodromal 
stages of PD using clinical markers such as hyposmia.  We thus hypothesised that fibroblasts 
generated from this cohort could be studied to help us understand both the cellular biology of GD 
(i.e. glucocerebrosidase deficiency) and the mechanisms by which heterozgyous carriage of GBA 
mutations predisposes to PD.  Fibroblast lines were generated from partial thickness skin biopsies 
taken from 5 Gaucher disease patients, 2 carriers without PD and 4 carriers with PD.    
Fibroblasts from GD patients had a severe deficiency of GCase protein levels and activity, while 
PD-GBA and NMC fibroblasts had a less marked reduction in GCase protein levels and a decline in 
enzyme activity proportional to the loss of GCase protein.  Loss of GCase protein was due to 
endoplasmic reticulum retention and proteasomal degradation of GCase protein.  This was 
accompanied by elevation of endoplasmic reticulum stress markers calnexin and BiP/Grp78.  Thus 
these fibroblasts can be used to model the effect of loss of GCase activity and endoplasmic 
reticulum stress induced by mutant, misfolded GCase.  
GBA mutations are associated with oxidative stress but not dysfunctional autophagy in 
fibroblasts
None of the disease fibroblast cell lines assessed had evidence of abnormal autophagy as neither 
p62 nor LC3-II protein levels were altered (as described in detail in chapter 3).  In keeping with this 
there was no evidence of defective mitophagy, as mitochodrial mass was not greater in the Gaucher 
disease fibroblasts and maximum oxygen consumption rate after FCCP treatment was not greater in 
GD or PD-GBA fibroblasts than control lines.  Defective mitophagy has been reported in several 
lysosomal storage disorders (see references from chapter 4).  The absence of this mechanism in GD 
fibroblasts may reflect the relatively mild storage phenotype of GD fibroblasts which accumulate 
little, if any, substrate and have normal macroautophagy.  We did however demonstrate elevation of 
cathepsin D protein levels, GCase-2 activity and total-beta-hexosaminidase enzyme activity in GD 
and PD-GBA fibroblasts.  This may reflect compensatory lysosomal mechanisms in response to 
reduction of GCase activity.  
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There was evidence of oxidative stress in GD, PD-GBA and NMC fibroblasts with elevation of 
dihydroethidium oxidation rates and accumulation of carbonylated proteins.  The mechanism of 
oxidative stress is unclear; but it seems unlikely to be related to mitochodrial generation of free 
radicals given the normal mitochondrial functional assays.  Oxidative stress is likely to be an early 
event in the pathogenesis of PD-GBA given that there was evidence of increased free radical 
production in fibroblasts from NMC.  Oxidative stress is well recognised as an important 
pathogenic process in both lysosomal storage disorders and PD (Schapira & Tolosa, 2010), and 
could contribute to predisposition to PD in many ways, not least by increasing alpha-synuclein 
aggregation.  
A loss of function model explaining why GBA mutations predispose to PD
Recent work from our group (Gegg et al, 2012), and others (Mazulli et al, 2011), has demonstrated 
that loss of GCase protein and enzyme activity occurs in the substantia nigra of PD patients with 
and without GBA mutations.  This suggests that loss of neuronal GCase activity is a key, nodal point 
in the  pathogenesis of both PD-GBA and sporadic PD.  
The current study helps elucidate the mechanisms by which GBA mutations lead to loss of cellular 
GCase activity.    In fibroblasts, the L444P and recombinant mutations result in reduction of GBA 
transcript levels (described in detail in chapter 3).   This clearly has the potential to contribute to 
reduced GCase protein expression.  In addition, there is evidence of endoplasmic reticulum 
retention and degradation of GCase protein in GD and PD-GBA fibroblasts.  Thus GBA mutations 
can reduced GBA transcript levels and trigger endoplasmic reticulum retention of GCase protein.    
In fibroblasts with heterozgyous GBA mutations there is a reduction in GCase protein levels and 
enzyme activity.  Given the results of the study by Gegg et al (2012), it is highly probable that 
neurons in the substantia nigra of these individuals will manifest the same enzymatic phenotype.  It 
is logical to suggest that cells with a reduction in GCase protein levels and activity will be 
vulnerable to further depletion of GCase activity by putative environmental interactions.   The only 
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“environmental” factor currently described which can be associated with reduced GCase expression 
is elevation of alpha-synuclein levels (Mazulli et al, 2011).  In cell lines overexpressing alpha-
synuclein there is reduction of GCase protein and activity (Gegg et al, 2012).  The mechanisms by 
which alpha-synuclein inhibits GCase is unknown, and possible pathways are discussed in detail in 
the introduction to chapter 3.   The mechanism accounting for loss of GCase activity in substantia  
nigra from sporadic PD cases is unclear.  It is possible that unrecognised mutations in GBA may 
play a role – but this seems unlikely to account for the results from 3 separate research groups 
(Gegg et al, 2012; Mazulli et al, 2011; Kurzawa-Akanbi et al, 2012).  It is also plausible that age 
related accumulation of alpha-synuclein in the substantia nigra may result in secondary depletion of 
GCase protein and activity.  
It seems reasonable to hypothesise that depletion of GCase activity in substantia nigra neurons 
below a putative critical threshold could then lead to dysfunction of the lysosome or autophagy 
pathways.  This could result in an exacerbation of alpha-synuclein accumulation.  In support of this, 
work in our lab (Cleeter et al, 2012) has demonstrated that inhibition of GCase with conduritol-b-
epoxide results in accumulation of alpha-synuclein. We could not examine this hypothesis directly 
in fibroblasts as they do not express alpha-synuclein.  
Oxidative and endoplasmic reticulum stress are alternative pathways by which GBA mutations 
could contribute to increased risk of PD.  As discussed in chapter 4, oxidative stress has a number of 
damaging effects on the cell.  In the context of PD chronic low level oxidative stress in the 
substantia nigra could constribute to aggregation of alpha-synuclein and Lewy body formation. 
Endoplasmic reticulum stress can lead to activation of apoptotic pathways and predispose to loss of 
dopaminergic neurons.   
This loss of function hypothesis can explain why both  heterozygous GBA mutation carriers and 
Gaucher disease patients have an increased risk of developing PD.  Under this hypothesis it is 
neuronal loss of GCase activity which is a key nodal point in the development of PD in these 
patients.  Several pathways could lead to this loss of activity; heterozgyous or bi-allelic GBA 
mutations, genetic variation in pathways which interact with GCase (e.g. LIMP-1/SCARB2) or 
depletion of GCase protein by interaction with an “environmental factor” such as alpha-synuclein. 
This also explains how such a wide spectrum of GBA mutations - including missense, nonsense and 
recombinant alleles – can predispose to PD since  all of these can reduce GCase expression by 
translational and/or post-translational mechanisms.  Under this model oxidative and endoplasmic 
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reticulum stress are contributory factors which act as mechanisms of neuronal injury triggered by 
GBA mutations.  
A major problem with this hypothesis is that the age related risks of PD in GD and heterozygous 
GBA mutation carriers are very similar.  If loss/reduction of neuronal GCase activity is the nodal 
point in PD pathogenesis in these individuals, then one would expect PD risk to be much higher in 
GD patients than in heterozygous GBA mutation carriers.  This is because neuronal GCase activity 
will be much lower in GD patients, and so pathogenic processes leading to neurodegeneration 
should theoretically be triggered much earlier than in carriers, in whom a lag time in which 
neuronal GCase activity is depleted must occur before PD pathogenesis is triggered. A potential 
explanation to account for this is that only relatively minor reductions in GCase activity, as seen in 
fibroblast cell lines with heterozygous GBA mutations, are sufficient to predispose to alpha-
synuclein accumulation.  Under this model, any further reductions in GCase activity below this 
putative threshold will not further increase PD risk but lead to lysosomal storage of substrate (i.e. 
GD).  In support of this is the observation that the E326K/E326K genotype is associated with PD, 
without apparent evidence of GD, and that the E326K/E326K fibroblasts display a partial 
deficiency of GCase activity compared to GD fibroblasts.  Flowchart 1, on the next page, 
summarises this hypothesis. 
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Figure 21. Mechanism by which GBA mutations lead to increased Parkinson's disease risk
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Limitations of current study and suggestions for future research 
The clinical component of this study is limited by the non-specificity of the prodromal markers of 
PD studied.  As noted previously there are many non-neurological causes of hyposmia and many 
neurological causes other than PD for hyposmia and cognitive impairment (Doty, 2012).  Retinal 
thinning, as revealed by optical coherence tomography, is also not specific for PD (Hajee et al, 
2009).  Thus future work needs to examine whether these prodromal markers identified do in fact 
predict future development of PD.  One approach to this is to perform repeated tests of olfaction and 
cognition and an examination for parkinsonian signs at a period of 12 months or more after the 
initial examination.  This is currently being performed by Dr Michelle Beavan (Clinical Research 
Associate, UCL Institute of Neurology).  An alternative approach is to correlate the clinical markers 
of prodromal PD with an objective biomarker of PD.  This could be achieved by undertaking 
dopamine transporter imaging in a selection of GD patients and heterozygous GBA mutation 
carriers with and without prodromal markers of PD. This would however be limited by the fact that 
dopamine transporter imaging as limited sensitivity in detecting dopaminergic neuronal loss in the 
earliest stages of PD.  
The cell biology arm of the project was limited chiefly by the fact that we were examining a non-
neuronal cell line.  There are differences in both lysosomal and mitochodrial physiology between 
fibroblasts and neurons.  Thus it is possible that the absence of mitochondrial dysfunction and 
defective autophagy might reflect cell specific effects rather than a true absence of  a role for these 
mechanisms in the pathogenesis of PD-GBA.  Fibroblasts do not express alpha-synuclein, this was a 
major limitation since it meant we could not assess the impact of GBA mutations on alpha-synuclein 
metabolism.  A further limitation of the cell biology project was that the fibroblasts had a diversity 
of mutations – despite coming from GD patients with a Type I phenotype – which will account for 
some of the variability in the variables studied between cell lines.  Some of these limitations can be 
addressed by generating dopaminergic neurons from induced pluripotent stem cells generated from 
patient derived fibroblasts.  These cells will be neuronal and express alpha-synuclein, permitting us 
to address the crucial question of how GBA mutations influence alpha-synuclein metabolism.  I 
have been awarded an MRC Centenary Award 1 year extension to my Research Training Fellowship 
in order to begin generating dopaminergic neurons from my panel of patient derived fibroblasts.  
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Concluding remarks 
Heterozygous GBA mutations are numerically the most important risk factor for developing PD. For 
example, GBA mutations are of far greater prevalence in PD than mutations in other genes such as 
LRRK2, PINK1 and Parkin.   Moreover, the contribution of GBA mutations to PD pathogenesis 
eclipses the relatively small increased risk conferred by environmental factors such as being a non-
smoker.  It should be remembered that the role of GBA mutations in PD pathogenesis was 
discovered by careful clinical observation and simple family history studies of GD families and not 
through expensive genetic techniques.  The story of how the aetiological role of GBA mutations in 
PD was discovered is a classic example of how studying rare disease can illuminate the pathogeneis 
of a common disorder.  
The high prevalence of GBA mutations in sporadic PD cohorts and the reduction of GCase enzyme 
activity in post-mortem substantia nigra from PD brain gives important clues as to the pathogeneis 
of sporadic PD.  There are several studies showing alteration of autophagy markers in post-mortem 
PD brain and the lysosome is a major site for alpha-synuclein degradation.  The evidence 
implicating reduction of GCase activity in PD thus corroborates and confirms the potential 
importance of autophagy in PD pathogenesis.   However, perhaps most importantly, reduction of 
neuronal GCase activity in sporadic PD represents a novel, tractable therapeutic target for this 
common neurodegenerative disease.  There are a number of small molecules which can enhance 
GCase enzyme activity and cross the blood brain barrier (e.g. isofagamine, ambroxol), these 
represent excellent candidates for future drug trials in PD and may pave the way for new classes of 
disease modifying drug.        
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